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7Introduction and Outline
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8Introduction
The main physiological role of the kidney is to maintain homeostasis of extracellular 
fluid. To this end, the kidney produces hormones, regulates blood pressure by fluid 
retention, maintains a physiological pH, retains essential nutrients and eliminates 
endogenous waste compounds, potentially harmful metabolites and exogenous drugs 
and toxins[1, 2]. As a consequence, the kidney is also a target for drug-induced injury. 
The potential of novel chemical entities to induce renal adverse effects is therefore 
determined in preclinical studies, as part of drug development. Nevertheless, acute 
kidney injury (AKI) is observed during clinical studies, leading to withdrawal of these 
compounds at a late stage of development. Improving in vitro preclinical evaluation 
of the nephrotoxic potential of candidate drugs is, therefore, required. The use of 
human-derived renal cell models that demonstrate proximal tubule characteristics in 
drug screenings, can be a valid strategy to enhance the success rate of compounds 
and reduce nephrotoxicity-related drug attrition in late-stage pharmaceutical 
development. 
The clinical impact of drug-induced AKI
AKI is a major health issue with an increasing global incidence. An estimated 2% of 
hospitalized patients in the USA develop AKI, while the incidence rises to 5%-6% with a 
reported mortality rate of 15.2% in critically ill patients who require renal replacement 
therapy, as evaluated by a multinational study. Approximately 20% of hospital- and 
community acquired cases of AKI are induced by pharmaceutical compounds[3-5]. 
AKI is characterized by a sudden decline in kidney function and urine production[6]. 
Clinical diagnosis of AKI heavily depends on creatinine levels in serum to estimate the 
glomerular filtration rate (GFR). However, serum creatinine is a disputable marker for 
kidney function as it only changes when approximately 50% of GFR has been lost. In 
addition, it is dependent on other factors such as nutrition and muscle mass, making it 
unsuitable for early detection of renal damage[7]. Treatment of AKI is mainly supportive 
and aims to maintain fluid and electrolyte balance, using hemodialysis when required 
by severity of the illness[7]. While less severe AKI is reversible, 30% of patients acquire 
structural and functional renal aberrations with an increased risk of developing chronic 
kidney disease (CKD), underlining the importance of preventing renal injury[3]. 
AKI is most frequently caused by acute tubular necrosis, following ischemia or 
exposure to nephrotoxicants. Commonly used potentially nephrotoxic drugs include 
aminoglycoside and β-lactam antibiotics, nonsteroidal anti-inflammatory drugs, 
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angiotensin receptor blockers and chemotherapeutics. The susceptibility of the 
kidneys to drug-induced injury is high, since they receive 20% to 25% of cardiac output 
volume, causing a high delivery rate of potentially harmful substances by the blood[8]. 
Nephrotoxicity is further enhanced by the extensive concentrating ability of the renal 
tubules, increasing the exposure of (filtered) compounds in the tubule lumen. In 
addition, drug metabolism in the kidney by CYP450 and UDP-glucuronosyltransferase 
enzymes may result in production of toxic metabolites. Finally, extensive trafficking 
of compounds leading to a potential competition for apical secretory transporters, 
enhances drug accumulation and drug-induced toxicity, predominantly in the renal 
tubules. These transport processes are energy-dependent and particularly the 
proximal tubule is equipped with a high abundance of mitochondria to produce the 
required ATP by oxidative phosphorylation (OXPHOS). Hence, damage to the OXPHOS 
pathway increases drug-sensitivity of the renal tubules further[9]. 
The role of proximal tubules in renal clearance of 
therapeutic drugs 
Every healthy human kidney contains approximately 1 million filtration units, the 
nephrons (Figure 1.1A, B). The nephron is a complex 3D structure, encapsulated by 
extracellular matrix (ECM) and has an extensive vascular network. The glomerulus and 
renal tubules represent the functional units of the nephron, which facilitate filtration 
and both active and passive secretion and reabsorption of compounds, respectively. 
The section just downstream of the glomerulus, the proximal tubule, is lined with 
a tight monolayer of epithelial cells, which play a crucial role in renal excretion of 
drugs from plasma into urine (Figure 1.1C). The apical membrane, or brush border, of 
proximal tubule epithelial cells (PTEC) faces the tubular lumen, while the basolateral 
membrane is directed towards the interstitium and blood capillaries. The proximal 
tubule reabsorbs nutrients from the glomerular filtrate, which include water, glucose, 
amino acids and low-molecular weight proteins, and actively secretes protein-
bound waste metabolites, endogenous and exogenous toxins, including therapeutic 
drugs[1]. To this end, PTEC express dedicated membrane-spanning proteins termed 
drug transporters[2, 10]. Protein-bound waste metabolites and xenobiotics are actively 
taken up from the basolateral side by solute carrier (SLC) transporters, and transported 
into the tubule lumen by both SLC and ATP-binding cassette (ABC) transporters. SLC 
transporters are symporters, that derive the energy required to move a compound 
against an electrochemical gradient by coupling it to the movement of a second 
compound along its concentration gradient, or uniporters, that only facilitate 
transport along a concentration gradient; while ABC transporters hydrolyze ATP 
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to drive the cellular extrusion of compounds. Mediators of drug influx include the 
basolaterally expressed organic cation transporter 2 (OCT2/SLC22A2), organic anion 
transporter 1 (OAT1/SLC22A6) and 3 (OAT3/SLC22A8). Drugs are secreted into the 
proximal tubule lumen by apically located P-glycoprotein (Pgp/ABCB1), multidrug 
resistance protein 2 (MRP2/ABCC2) and 4 (MRP4/ABCC4), breast cancer resistance 
protein (BCRP/ABCG2), multidrug and toxin extrusion protein 1 (MATE1/SLC47A1) 
and 2-k (MATE2-k/SLC47A2). Organic cations are typically imported by OCT2, driven 
by the inward-directed negative membrane potential, followed by export mainly 
via MATE1 and MATE2-k, in exchange of H+ from the weakly acidic glomerular 
filtrate[11, 12]. Classic examples of drugs cleared by the organic cation pathway include 
the chemotherapeutic cisplatin[13], the antidiabetic metformin[14, 15] and the histamine 
receptor antagonist cimetidine[15, 16]. Organic anions are generally imported by OAT1 
and OAT3 in exchange of dicarboxylates, mainly α-ketoglutarate, before being 
secreted by MRP2, MRP4 or BCRP[17]. Typical examples of drugs cleared by the 
organic anion pathway include the chemotherapeutic methotrexate[18, 19]; the antiviral 
agents adefovir and tenofovir[20, 21]; the cholesterol-lowering drugs pitavastatin and 
rosuvastatin[22-25]; and probenecid for treatment of hyperuricemia and gout[26].
Regulatory pathways for drug transporters in the human renal proximal tubule have 
recently received increased attention, but knowledge is mostly limited to animal data. 
Examples include the glucocorticoid hormones, which induce Mrp2-mediated transport 
in killifish proximal tubules; and endothelin-1 which regulates Pgp- and MRP2-mediated 
transport in killifish and MDCK cells, in response to aminoglycoside antibiotics[27]. In 
addition, the nephroprotective Nrf2 pathway induced protein expression of Mrp2 and 
Mrp4 in rat PTEC, following exposure to cisplatin[28]. More recently, Nrf2 activation was 
demonstrated to reduce expression of OCT2 and increase expression of MATE1, in rat-
derived kidney slices and human-derived PTEC, respectively, leading in both cases to 
reduced cisplatin-induced nephrotoxicity[29, 30]. In a human-derived proximal tubule 
model, ciPTEC, the epidermal growth factor receptor (EGFR) recombinant antibody, 
cetuximab, downregulates OAT1 and BCRP while upregulating Pgp and MRP4 through 
the PI3K-AKT and MAPKK-ERK pathways[31]. In addition, microenvironmental cues affect 
drug transporter expression, as recently evidenced for flow-mediated regulation of 
MATE2-k via the Nrf2 pathway[32]. A thorough understanding of the regulatory pathways 
of drug transporters in the human proximal tubule is important to find new therapeutic 
avenues to modulate renal drug clearance and limit toxicity.
In addition to membrane transporters, receptor-mediated endocytosis is important 
in reabsorbing nutrients, peptides and proteins from the glomerular filtrate and drug 
exposure. PTEC express multi-ligand receptors megalin (LRP2) and cubilin (CUBN) at 
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Figure 1.1 Renal anatomy and xenobiotic handling. (A) Sagittal section of the kidney, demonstrating 
the medulla and the cortex. (B) The renal tubule system; the glomerulus and the proximal tubule 
are located in the cortex, while the remainder of the tubule is primarily located in the medulla. (C) 
Schematic overview of the proximal tubule cell, demonstrating trans-membrane transport proteins 
involved in xenobiotic handling. SLC transporters (light blue) located at the basolateral membrane 
mediate active influx of protein-bound drugs into the proximal tubule cell, shifting the equilibrium 
towards the freely available drug fraction, using transport of compounds (α-ketoglutarate) down 
their concentration gradient (OAT) or the membrane potential (OCT) as driving force. SLC transporters 
and ABC transporters (green) located on the apical membrane mediate active efflux of drugs into the 
tubule lumen, using transport of compounds (H+) down their concentration gradient or the hydrolysis 
of ATP into ADP as driving force, respectively. Low-molecular weight proteins are freely filtered by the 
glomerulus and subsequently reabsorbed into proximal tubule cell by multi-ligand receptor (megalin/
cubilin)-mediated endocytosis. Abbreviations: ABC, ATP-binding cassette; α-KG, α-ketoglutarate; BCRP, 
breast cancer resistance protein; OA-, organic anion; OAT, organic anion transporter; OC+, organic cation; 
OCT, organic cation transporter; Pgp, P-glycoprotein; MATE, multidrug and toxin extrusion transporter; 
MRP, multiresistance protein; SLC, solute carrier. Adapted from[83].
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the apical membrane, which bind low-molecular weight proteins from the glomerular 
filtrate, such as α1- and β2-microglobulin, followed by reabsorption via endocytosis and 
eventually lysosomal degradation. Drugs and toxins demonstrated to be internalized by 
receptor-mediated endocytosis include the aminoglycoside antibiotic gentamicin, the 
phytochemical aristolochic acid and heavy metal cadmium[33, 34].
Transport proteins, similar to drug-metabolizing enzymes, are well-described targets 
for drug-drug interactions (DDIs) that may affect the pharmacokinetic profile of a 
drug. DDIs in the kidney usually result in decreased renal clearance of the victim 
drug involved, hence increasing its plasma concentration and systemic exposure, or 
increasing the concentration in renal tubular cells. Widely studied renal interactions 
involve probenecid or cimetidine, interacting on OAT transporters; or on OCT and MATE 
transporters, respectively. A historical clinical application is the co-administration of 
penicillin and probenecid, reducing renal clearance and dosing requirements of 
penicillin[35]. Similarly, co-administration of the antiviral drug cidofovir and probenecid 
leads to reduced accumulation of cidofovir in the tubular cells and protects against 
drug-induced nephrotoxicity[36]. However, DDIs often lead to adverse effects, both 
systemic and renal. When cimetidine and metformin are co-administered, the resulting 
interaction on MATE efflux transporters leads to increased concentrations of metformin, 
in the kidney and blood circulation, causing an increased risk for developing systemic 
toxicity[37]. Similar observations have been made for cisplatin-induced nephrotoxicity in 
mice, which was enhanced by co-administration of the MATE-inhibitor pyrimethamine, 
suggesting a DDI on MATE1, causing increased proximal tubule accumulation of 
cisplatin[38]. As DDIs may influence plasma concentrations, renal clearance rates and 
adverse effects on the kidney, the regulatory agencies (EMA and FDA) require for the 
renal transporters Pgp, BCRP, OAT1/3, OCT2 and MATE1/2-k to evaluate potential DDIs 
during drug development[39, 40].
The current status of nephrotoxicity screening in 
drug development 
Over the past century, drug research has undisputedly contributed to the progress 
in medicine. Drug development has evolved from the isolation of morphine in 1815 
as a purely empirical endeavor, and the coincidental discovery of penicillin in 1929, 
to a mature science capable of systematically developing the first tyrosine-kinase 
inhibitor imatinib at the end of the 20th century, for which a complete understanding 
of the pathology-related molecular mechanism was required[41]. Therapeutic 
drugs are highly valued molecules and have become the cornerstone of modern 
13
1
healthcare. While the medical benefits are clear, the costs of successfully developing 
a therapeutic molecule have been rising for several years and are estimated to 
range from approximately 600 million to several billion US-dollars[42-44]. The number 
of new drug approvals, on the other hand, has only recently started to rise again 
after two decades of declining trends[45], likely explained by an enhanced standard 
care and increased complexity of diseases for which drugs are being developed. Even 
for compounds that have entered first-in-man clinical trials, the rate of successful 
registration is only 11%. Lack of efficacy and lack of safety are the main causes for 
clinical drug attrition, accounting for a substantial 30% each[46]. Cardiovascular and 
liver toxicity are the most common targets for drug-induced toxicity with 17-27% 
and 14%, respectively; while overall nephrotoxicity accounts for less than 10%[47, 48]. 
Adverse effects on the kidney, however, arise more often during the clinical phases 
of drug development, where it accounts for 9% of drug attrition[49]. This suggests that 
currently used preclinical models, both in vitro and in vivo, lack predictive value for 
clinically observed renal adverse effects. While in vivo animal models, mainly rodents, 
provide a physiological background, including drug disposition and metabolism, 
they demonstrate inherent interspecies differences and ethical opposition. Therefore, 
increasing attention has been generated for conducting research according to the 
3Rs, involving Refinement, Reduction and Replacement of animal models in research. 
In vitro models, on the other hand, often lack human- and tissue-relevant expression 
of transporters and metabolic enzymes, which are crucial for drug-induced toxicity 
evaluation. To overcome these issues and accurately predict nephrotoxicity in the 
early phases of drug development, inexpensive and robust in vitro cell culture models 
are being developed that reflect the differentiation status of human renal PTEC, 
which are compatible with high-throughput drug screening[50]. 
In vitro models used for drug-induced nephrotoxicity screening are mostly based 
on regular 2D culture systems. In the past, non-human derived cell lines were used 
extensively as models to predict nephrotoxicity, including Madin-Darby canine 
kidney (MDCKII) and proximal-like Lilly Laboratories Cell Porcine Kidney (LLC-PK1) 
cells. These models are stable cell lines and form tight epithelial monolayers, but 
their predictive value is low, mainly due to interspecies differences and the lack of 
functional differentiation[51]. Frequently used human-derived models include human 
embryonic kidney 293 (HEK293) and human kidney-2 (HK-2) cell lines. While HEK293 
cells are useful for overexpression of transport proteins, and are therefore suitable to 
study DDIs on the single transporter level and the contribution of a single transporter 
to drug-induced toxicity, this cell line expresses neuronal markers, rendering it 
irrelevant for studying integrated renal toxicity[51-53]. HK-2 cells on the other hand, 
demonstrate limited functional differentiation of PTEC, including gene expression 
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of efflux transporters Pgp and MRP4, but lack expression of influx transporters[53, 54]. 
These cells are therefore of limited value. Primary PTEC, which are freshly isolated 
from human tissue, resemble the physiological state of proximal tubule epithelial 
cells best. After 10 days in culture, they form tight junctions and demonstrate similar 
gene expression of OAT1, Pgp and BCRP compared to native human kidney cortex, 
while OAT3 and OCT2 are reduced[55]. Active transport of para-aminohippuric acid 
(PAH), triethalonamide (TEA) and verapamil, demonstrating functionality of OAT, OCT 
and Pgp transporters, respectively, was found in primary PTEC, but only at 5 days in 
culture after the cells were passed once[56]. Although this indicates that these models 
are valuable, they are dependent on supply of human renal cortex tissue, have limited 
proliferative capacity, suffer from dedifferentiation upon culturing and demonstrate 
high inter-donor variability[53]. For toxicity screening in pharmaceutical industry, models 
with a more reproducible phenotype and continuous supply of material are required. 
Stable cell lines, including conditionally immortalized proximal tubule epithelial cells 
(ciPTEC) and renal proximal tubule epithelial cells (RPTEC/TERT1), do not suffer from 
these issues. ciPTEC were immortalized by expression of human telomerase reverse 
transcriptase (hTERT), in combination with temperature-sensitive expression of the 
SV40 large T antigen[57]. These immortalized cells maintain endogenous expression 
and function of drug transporters, including OCT2, Pgp, MRP2/4, BCRP and receptor-
mediated endocytosis[57, 58]. In addition, matured monolayers of ciPTEC form tight 
junctions, as demonstrated by zonula occludens-1 (ZO-1) localization, they express 
primary cilia and demonstrate functional expression of phase-II enzymes UDP-
glucuronosyltransferases (UGTs), which mediate conjugation of glucuronic acid to 
xenobiotics to enhance their urinary excretion[59, 60]. Moreover, a hollow fiber-based 3D 
culture of ciPTEC demonstrated transepithelial transport of albumin-bound uremic 
toxins indoxyl sulphate and kynurenic acid, indicating that this in vitro proximal tubule 
model is an established and useful tool to study renal clearance and therefore drug-
induced toxicity[61]. Similar to ciPTEC, the RPTEC/TERT1 cell line was immortalized 
by expression of human telomerase reverse transcriptase (hTERT)[62]. This cell line 
demonstrates proximal tubule characteristics, including ZO-1, endogenous gene 
expression of drug transporters, including OCT2, OAT1, OAT3, MATE1 and MATE2-k, 
and maintain transport function of Pgp, OCT2 and receptor-mediated endocytosis[62, 63]. 
So far, functionality of OAT1 and OAT3 has not been demonstrated in RPTEC/TERT1. 
Finally, human embryonic stem cells (hESC) and induced pluripotent stem cells 
(iPSCs) are promising future opportunities to generate relevant in vitro models for 
drug-induced toxicity screening, as differentiation can be directed towards proximal 
tubule cells by exposure to medium supplemented with bone morphogenic protein 
2 and 7[64, 65]. Characterization of hESC-derived PTEC revealed gene expression of 
relevant drug transporters, although only Pgp expression was increased compared to 
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undifferentiated hESC cells[65]. Proximal tubule cells derived from iPSCs demonstrated 
increased expression of hallmark genes aquaporin 1 (AQP1), γ-glutamyltransferase 1 
(GGT1), and drug transporters OAT1/3 and OCT2, compared to undifferentiated iPSC. 
However, a high cisplatin concentration was needed to evaluate its toxic effect[64]. 
Therefore, the differentiation status of these human-derived cells needs to be 
investigated and tailored further towards the proximal tubule epithelial phenotype, 
before they provide a suitable model for studying drug-induced toxicity. 
In vitro drug-induced toxicity screening using monolayer cultures has the advantage 
of being simple and low in cost, is compatible with high-throughput systems, and 
has generated much of our current mechanistic understanding of nephrotoxicity. 
A representative example of drug screening includes the evaluation of a panel 
of 14 different well-known nephrotoxicants on the biochemical markers lactate 
production, ATP production, glutathione levels and cell viability, using regular in 
vitro cultures of the human-derived proximal tubule cell line RPTEC/TERT1. The same 
model was also applied for mechanistic investigation of cisplatin-induced toxicity 
at pharmacologically relevant concentrations[66, 67]. To increase the physiological 
relevance and sensitivity of renal drug-induced toxicity testing, 3D culture models 
have gained increasing interest. Distinct approaches to develop 3D culture models 
have been published, including organoid cultures, in vitro bioengineered kidneys 
and microfluidic kidney-on-a-chip devices, each displaying unique advantages and 
disadvantages[68, 69]. Supportive evidence for the hypothesis that 3D renal culture 
models improve sensitivity of drug-induced toxicity testing was generated using 
3D organoid cultures of hTERT-immortalized human renal cortical epithelial (NKI-2) 
cells, embedded in extracellular matrix of matrigel and collagen I[70]. Using lactate 
dehydrogenase (LDH) leakage and kidney injury molecule 1 (KIM-1) expression 
as markers for toxicity induced by cisplatin, an increased sensitivity was found 
in 3D cultures, compared to monolayers of the same cells[70]. Advanced 3D models 
that resemble the morphology of the nephron best, are the rudiments of in vitro 
bioengineered kidney. Single cell suspensions of isolated epithelial ureteric bud cells, 
representing renal progenitor cells, develop autonomously into rudimentary kidneys 
organized around a single collecting duct that demonstrate morphologically distinct 
structures, such as loops of Henle. Activity of OAT, OCT and MRP drug transporters 
was demonstrated using fluorescent model substrates and inhibitors, indicating the 
potential of this 3D renal model to study transport and mechanistic evaluation of 
drug-induced toxicity[71]. Kidney organoids derived from iPSCs are of special interest 
in this regard, as these can be acquired from human skin and adipose tissue while 
reducing the need for animal-derived material at the same time. Using induction 
of canonical Wnt signaling in iPSC aggregates, self-organizing nephrons developed 
16
in vitro, surrounded by renal interstitium and endothelial cells. Nephron segments 
including proximal tubules were shown, which are sensitive to cisplatin-induced 
toxicity[72]. Using similar techniques, human iPSCs-derived proximal tubule cells 
were shown to grow into 2D and 3D nephron-like structures, mimicking the in vivo 
developmental nephrogenesis process in a culture dish. In response to cisplatin and 
gentamicin, these organoids increased the expression of KIM-1[73]. 
An important renal characteristic that is missing from the 3D models described 
so far is fluid flow. As the kidneys filter blood, glomerular filtrate enters the tubule 
lumen exposing proximal tubule cells to an estimated pulsatile fluid shear stress of 
1 dyne•cm-2[74]. Each proximal tubule cell presents a single sensory organelle protruding 
from the apical membrane, the primary cilium, which transduces fluid shear stress 
into intracellular signaling and contributes to the differentiation of tubule epithelial 
tissue[75]. Supportive evidence that fluid shear stress improves drug-induced responses 
of PTEC, was generated using MDCK cells cultured on a fibronectin-coated chip 
surface[76]. Compared to MDCK cells cultured statically, fluid shear stress increased 
gene expression of MRP4 (ABCC4) and -5 (ABCC5) and, moreover, reduced integrin- 
related gene expression in response to treatment with the antineoplastic drug 
ifosfamide[76, 77]. In addition, receptor-mediated endocytosis of albumin was increased 
when opossum kidney (OK) cells and LLC-PK1 cells were exposed to a fluid shear 
stress of 0.1 dyne•cm-2[78]. Despite the limited relevance of animal-derived cell lines 
for drug-induced toxicity screening, these models successfully demonstrated the 
influence of flow-mediated signal transduction on renal tubule transport function. 
The most promising approach for 3D renal culture models in drug development that 
enables exposure to fluid shear stress, is the kidney-on-a-chip. These microfluidic-
based devices allow for 3D cultures of PTEC in a perfused microchannel, with the aim 
to recapitulate the microphysiological niche of the kidney tubule and to achieve more 
in vivo-like cellular responses compared to regular 2D tissue culture[69, 79]. Important 
characteristics include a tubule architecture, incorporation of extracellular matrix, 
multiple compartments to facilitate evaluation of renal clearance, and exposure to 
fluid shear stress[69, 80]. Jang and colleagues recapitulated the renal tubule by culturing 
human primary tubule cells on a collagen-type IV-coated porous membrane in a 
polydimethylsiloxane (PDMS)-based microfluidic device, that allows for exposure to a 
physiological fluid shear stress of 0.2 dyne•cm-2[81]. Confluent monolayers demonstrated 
expression of tight junction protein ZO-1 and expression of Na,K-ATPase, which was 
restricted to the basolateral membrane, indicating maintained polarization of PTEC. 
Moreover, exposing cells to fluid shear stress increased ZO-1 expression, cell height, 
receptor-mediated endocytosis of albumin and activity of the Pgp efflux transporter. 
17
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Finally, PTEC exposed to fluid shear stress showed reduced leakage of LDH, which 
indicates that cells are more viable at baseline[81]. A similar model based on primary 
renal cortex cells could be developed into a tubule-shaped architecture, further 
increasing physiological resemblance. Directed transport of PAH across the epithelial 
cell layer was observed, underlining that functional differentiation of proximal 
tubule cells is maintained in this model[82]. As this kidney-on-a-chip model allowed for 
preservation of human PTEC characteristics, it demonstrates the value of increased 
physiological relevance of 3D culture systems. Its implementation potential for drug-
induced toxicity screening in industry is, however, limited as these novel models 
usually lack high-throughput capacity.
Outline of the thesis
As current preclinical drug-induced nephrotoxicity studies lack predictive value, 
human-derived cell culture-based proximal tubule models with increased 
physiological relevance are required to provide a better platform for evaluating DDIs 
and drug-induced toxicity screening. Safety-related drug attrition in clinical phases 
of drug development can be reduced as a result, as well as the associated costs and 
use of animal models in preclinical studies. The aim of this thesis was to gain further 
insight into the role of drug transporters and endocytic receptors in drug-induced 
proximal tubule cytotoxicity, and to use this knowledge to develop advanced in vitro 
high-throughput renal toxicity screening models.
After this introduction, the development of such an advanced in vitro cell model is 
described in Chapter 2. Conditionally immortalized proximal tubule epithelial cell 
lines (ciPTEC) constitutively expressing OAT1 (ciPTEC-OAT1) or OAT3 (ciPTEC-OAT3) 
were generated. To determine their additional value, the contribution of OATs to DDIs 
and cytotoxicity induced by antiviral agents was tested. Building on these proximal 
tubule models that overexpress OAT1 or 3, the differential sensitivity to cisplatin, a 
chemotherapeutic drug that is typically handled by organic cation transporters, is 
studied in detail in Chapter 3. Using gene expression and an ASP+-based fluorescent 
transport assay, the mechanisms responsible for this observation are partly 
elucidated. Continuing on renal mechanisms of drug handling, the role of receptor 
mediated endocytosis in proximal tubule uptake and accumulation of antisense 
oligonucleotides (AONs) is unraveled in Chapter 4. To this end, low-molecular weight 
proteinuria was mimicked in vitro and trafficking of tagged AONs was evaluated by 
fluorescence microscopy. Chapter 5 reviews the application of kidney-on-a-chip 
technology that potentially increases the physiological relevance and predictive 
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capacity of proximal tubule epithelial cells in vitro. An extensive overview of 
recent developments in kidney-on-a-chip platforms is provided, focusing on drug 
transporter function, receptor-mediated endocytosis and relevance for drug-induced 
nephrotoxicity screening. All knowledge gained in the preceding chapters of this 
thesis is united in Chapter 6 that describes the development of such a kidney-on-
a-chip device. Together, the 3D microfluidic system OrganoPlate® and the proximal 
tubule model ciPTEC-OAT1, represent a novel high-throughput in vitro screening 
platform for drug-drug interactions, as demonstrated by efflux transporters Pgp 
and MRP2/4 using fluorescence-based assays. A general discussion of the findings 
described in this thesis is presented in Chapter 7, describing the future and potential 
use of in vitro drug-induced DDI and toxicity screening models from both an academic 
and industrial perspective, followed by a summary of this thesis in Chapter 8.
19
1
References
1. Hoenig MP, Zeidel ML. Homeostasis, the milieu interieur, and the wisdom of the nephron. Clin J 
Am Soc Nephrol. 9, 1272-1281 (2014).
2. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V. Handling of Drugs, Metabolites, 
and Uremic Toxins by Kidney Proximal Tubule Drug Transporters. Clin J Am Soc Nephrol. 10, 
2039-2049 (2015).
3. Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute 
renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol. 1, 43-51 (2006).
4. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, et al. Acute renal 
failure in critically ill patients: a multinational, multicenter study. Jama. 294, 813-818 (2005).
5. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, et al. Incidence and 
mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 17, 
1135-1142 (2006).
6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury 
Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 11, R31 (2007).
7. Bellomo R. Acute renal failure. Semin Respir Crit Care Med. 32, 639-650 (2011).
8. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 4, 1275-1283 (2009).
9. Hall AM, Unwin RJ. The not so ‘mighty chondrion’: emergence of renal diseases due to 
mitochondrial dysfunction. Nephron Physiol. 105, p1-10 (2007).
10. George B, You D, Joy MS, Aleksunes LM. Xenobiotic transporters and kidney injury. Adv Drug 
Deliv Rev. 116, 73-91 (2017).
11. Budiman T, Bamberg E, Koepsell H, Nagel G. Mechanism of electrogenic cation transport by the 
cloned organic cation transporter 2 from rat. J Biol Chem. 275, 29413-29420 (2000).
12. Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K. Oppositely directed H+ gradient functions 
as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol. 292, 
F593-598 (2007).
13. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin 
and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug 
and toxin extrusion family). J Pharmacol Exp Ther. 319, 879-886 (2006).
14. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug 
and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction 
with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 298, 
F997-f1005 (2010).
15. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and 
MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem 
Pharmacol. 74, 359-371 (2007).
16. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, Sugiyama Y. A species difference 
in the transport activities of H2 receptor antagonists by rat and human renal organic anion and 
cation transporters. J Pharmacol Exp Ther. 315, 337-345 (2005).
17. Kaufhold M, Schulz K, Breljak D, Gupta S, Henjakovic M, Krick W, Hagos Y, et al. Differential 
interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic 
anion transporters 1 and 3. Am J Physiol Renal Physiol. 301, F1026-1034 (2011).
18. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, et al. 
Characterization of methotrexate transport and its drug interactions with human organic anion 
transporters. J Pharmacol Exp Ther. 302, 666-671 (2002).
19. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-
inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-
mediated methotrexate transport. J Pharmacol Exp Ther. 320, 229-235 (2007).
20
20. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is 
induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 11, 
383-393 (2000).
21. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, et al. Tenofovir renal 
proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 91, 852-858 
(2011).
22. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of 
pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 57, 1305-1311 (2005).
23. Windass AS, Lowes S, Wang Y, Brown CD. The contribution of organic anion transporters OAT1 
and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 322, 1221-1227 (2007).
24. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP 
(ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 68, 800-807 (2005).
25. Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, et al. Effect of silymarin supplement 
on the pharmacokinetics of rosuvastatin. Pharm Res. 25, 1807-1814 (2008).
26. Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona 
RG, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna 
and dimesna. J Clin Pharmacol. 52, 530-542 (2012).
27. Masereeuw R, Russel FG. Regulatory pathways for ATP-binding cassette transport proteins in 
kidney proximal tubules. Aaps j. 14, 883-894 (2012).
28. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. Transcriptional 
regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to 
mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther. 335, 2-12 (2010).
29. Atilano-Roque A, Aleksunes LM, Joy MS. Bardoxolone methyl modulates efflux transporter and 
detoxifying enzyme expression in cisplatin-induced kidney cell injury. Toxicol Lett. 259, 52-59 
(2016).
30. Huang D, Wang C, Duan Y, Meng Q, Liu Z, Huo X, Sun H, et al. Targeting Oct2 and P53: Formononetin 
prevents cisplatin-induced acute kidney injury. Toxicol Appl Pharmacol. 326, 15-24 (2017).
31. Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D, Ruijtenbeek 
R, et al. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal 
Growth Factor Dependent Regulation of Renal Drug Transporters. Mol Pharm. 14, 2147-2157 
(2017).
32. Fukuda Y, Kaishima M, Ohnishi T, Tohyama K, Chisaki I, Nakayama Y, Ogasawara-Shimizu M, et al. 
Fluid shear stress stimulates MATE2-K expression via Nrf2 pathway activation. Biochem Biophys 
Res Commun. 484, 358-364 (2017).
33. Zhai XY, Nielsen R, Birn H, Drumm K, Mildenberger S, Freudinger R, Moestrup SK, et al. Cubilin- 
and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. 
Kidney Int. 58, 1523-1533 (2000).
34. Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: 
from experimental models to human disease. Kidney Int. 89, 58-67 (2016).
35. Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in man. 
Clin Pharmacol Ther. 9, 345-349 (1968).
36. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, et al. Clinical 
pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob 
Agents Chemother. 39, 1247-1252 (1995).
37. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion 
by cimetidine in man. Br J Clin Pharmacol. 23, 545-551 (1987).
38. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin 
extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 80, 1762-
1767 (2010).
39. Guideline on the investigation of drug interactions. EMA. London (2012)
21
1
40. In Vitro Metabolism- and Transporter- Mediated Drug-Drug Interaction Studies, Guidance for 
Industry. FDA. Rockville, MD (2017).
41. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally 
developed, targeted anticancer drug. Nat Rev Drug Discov. 1, 493-502 (2002).
42. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates 
of R&D costs. J Health Econ. 47, 20-33 (2016).
43. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug 
development costs. J Health Econ. 22, 151-185 (2003).
44. Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to 
Market and Revenues After Approval. JAMA Intern Med. 177, 1569-1575 (2017).
45. Mullard A. 2016 FDA drug approvals. Nat Rev Drug Discov. 16, 73-76 (2017).
46. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 3, 
711-715 (2004).
47. Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. 
Drug Metab Pharmacokinet. 26, 3-14 (2011).
48. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. Lessons 
learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev 
Drug Discov. 13, 419-431 (2014).
49. Redfern WS, Ewart L, Hammond TG, Bialecki R, Kinter L, Lindgren S, Pollard CE, et al. Impact and 
frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist. 114, 
1 (2010).
50. Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D. Drug-induced nephrotoxicity: clinical impact 
and preclinical in vitro models. Mol Pharm. 11, 1933-1948 (2014).
51. Astashkina AI, Mann BK, Prestwich GD, Grainger DW. Comparing predictive drug nephrotoxicity 
biomarkers in kidney 3-D primary organoid culture and immortalized cell lines. Biomaterials. 33, 
4712-4721 (2012).
52. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by 
human adenoviruses and the origin of HEK 293 cells. Faseb j. 16, 869-871 (2002).
53. Van der Hauwaert C, Savary G, Buob D, Leroy X, Aubert S, Flamand V, Hennino MF, et al. 
Expression profiles of genes involved in xenobiotic metabolism and disposition in human renal 
tissues and renal cell models. Toxicol Appl Pharmacol. 279, 409-418 (2014).
54. Jenkinson SE, Chung GW, van Loon E, Bakar NS, Dalzell AM, Brown CD. The limitations of renal 
epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal 
tubule. Pflugers Arch. 464, 601-611 (2012).
55. Brown CD, Sayer R, Windass AS, Haslam IS, De Broe ME, D’Haese PC, Verhulst A. Characterisation 
of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol 
Appl Pharmacol. 233, 428-438 (2008).
56. Lash LH, Putt DA, Cai H. Membrane transport function in primary cultures of human proximal 
tubular cells. Toxicology. 228, 200-218 (2006).
57. Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, Mathieson PW, et al. 
Novel conditionally immortalized human proximal tubule cell line expressing functional influx 
and efflux transporters. Cell Tissue Res. 339, 449-457 (2010).
58. Caetano-Pinto P, Janssen MJ, Gijzen L, Verscheijden L, Wilmer MJ, Masereeuw R. Fluorescence-
Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line. Mol Pharm. 13, 
933-944 (2016).
59. Jansen J, Schophuizen CM, Wilmer MJ, Lahham SH, Mutsaers HA, Wetzels JF, Bank RA, et al. A 
morphological and functional comparison of proximal tubule cell lines established from human 
urine and kidney tissue. Exp Cell Res. 323, 87-99 (2014).
22
60. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, Schepers E, et al. 
Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and 
mitochondrial respiration. Biochim Biophys Acta. 1832, 142-150 (2013).
61. Jansen J, Fedecostante M, Wilmer MJ, Peters JG, Kreuser UM, van den Broek PH, Mensink RA, et 
al. Bioengineered kidney tubules efficiently excrete uremic toxins. Sci Rep. 6, 26715 (2016).
62. Wieser M, Stadler G, Jennings P, Streubel B, Pfaller W, Ambros P, Riedl C, et al. hTERT alone 
immortalizes epithelial cells of renal proximal tubules without changing their functional 
characteristics. Am J Physiol Renal Physiol. 295, F1365-1375 (2008).
63. Aschauer L, Carta G, Vogelsang N, Schlatter E, Jennings P. Expression of xenobiotic transporters 
in the human renal proximal tubule cell line RPTEC/TERT1. Toxicol In Vitro. 30, 95-105 (2015).
64. Kandasamy K, Chuah JK, Su R, Huang P, Eng KG, Xiong S, Li Y, et al. Prediction of drug-induced 
nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells 
and machine learning methods. Sci Rep. 5, 12337 (2015).
65. Narayanan K, Schumacher KM, Tasnim F, Kandasamy K, Schumacher A, Ni M, Gao S, et al. Human 
embryonic stem cells differentiate into functional renal proximal tubular-like cells. Kidney Int. 
83, 593-603 (2013).
66. Crean D, Bellwon P, Aschauer L, Limonciel A, Moenks K, Hewitt P, Schmidt T, et al. Development 
of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. Toxicol In Vitro. 
30, 128-137 (2015).
67. Wilmes A, Bielow C, Ranninger C, Bellwon P, Aschauer L, Limonciel A, Chassaigne H, et al. 
Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, 
proteomics, metabolomics and biokinetics. Toxicol In Vitro. 30, 117-127 (2015).
68. Breslin S, O’Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug 
Discov Today. 18, 240-249 (2013).
69. Nieskens TT, Wilmer MJ. Kidney-on-a-chip technology for renal proximal tubule tissue 
reconstruction. Eur J Pharmacol. 790, 46-56 (2016).
70. DesRochers TM, Suter L, Roth A, Kaplan DL. Bioengineered 3D human kidney tissue, a platform 
for the determination of nephrotoxicity. PLoS One. 8, e59219 (2013).
71. Lawrence ML, Chang CH, Davies JA. Transport of organic anions and cations in murine embryonic 
kidney development and in serially-reaggregated engineered kidneys. Sci Rep. 5, 9092 (2015).
72. Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, et al. Kidney organoids 
from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 526, 
564-568 (2015).
73. Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. Nephron organoids derived 
from human pluripotent stem cells model kidney development and injury. Nat Biotechnol. 33, 
1193-1200 (2015).
74. Weinbaum S, Duan Y, Satlin LM, Wang T, Weinstein AM. Mechanotransduction in the renal 
tubule. Am J Physiol Renal Physiol. 299, F1220-1236 (2010).
75. Praetorius HA. The primary cilium as sensor of fluid flow: new building blocks to the model. 
A review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell 
Physiol. 308, C198-208 (2015).
76. Snouber LC, Letourneur F, Chafey P, Broussard C, Monge M, Legallais C, Leclerc E. Analysis of 
transcriptomic and proteomic profiles demonstrates improved Madin-Darby canine kidney cell 
function in a renal microfluidic biochip. Biotechnol Prog. 28, 474-484 (2012).
77. Choucha Snouber L, Jacques S, Monge M, Legallais C, Leclerc E. Transcriptomic analysis of the effect 
of ifosfamide on MDCK cells cultivated in microfluidic biochips. Genomics. 100, 27-34 (2012).
78. Raghavan V, Rbaibi Y, Pastor-Soler NM, Carattino MD, Weisz OA. Shear stress-dependent 
regulation of apical endocytosis in renal proximal tubule cells mediated by primary cilia. Proc 
Natl Acad Sci U S A. 111, 8506-8511 (2014).
23
1
79. Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R. Kidney-on-a-Chip Technology for 
Drug-Induced Nephrotoxicity Screening. Trends Biotechnol. 34, 156-170 (2016).
80. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 32, 760-772 (2014).
81. Jang KJ, Mehr AP, Hamilton GA, McPartlin LA, Chung S, Suh KY, Ingber DE. Human kidney 
proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol 
(Camb). 5, 1119-1129 (2013).
82. Weber EJ, Chapron A, Chapron BD, Voellinger JL, Lidberg KA, Yeung CK, Wang Z, et al. 
Development of a microphysiological model of human kidney proximal tubule function. Kidney 
Int. 90, 627-637 (2016).
83. Bear R, Rintoul D. Urinary System. Web Page. OpenStax (2013). http://cnx.org/contents/
SKih6aFN@5/Urinary-System.
24
I
25
Part I
2D Renal Proximal Tubule In Vitro 
Models to Evaluate Drug-Induced 
Kidney InjuryI
26
2
27
A Human Renal Proximal Tubule 
Cell Line with Stable Organic Anion 
Transporter 1 and 3 Expression 
Predictive for Antiviral Drug-Induced 
Toxicity
Tom TG Nieskens1, Janny GP Peters1, Marieke J Schreurs1, Niels Smits1, 
Rob Woestenenk2, Katja Jansen1, Thom K van der Made1, Melanie Röring1, 
Constanze Hilgendorf3, Martijn J Wilmer1* and Rosalinde Masereeuw1,4*
1  Department of Pharmacology and Toxicology, Radboud university medical center, Nijmegen, 
The Netherlands
2  Department of Laboratory Medicine - Laboratory of Hematology, Radboud university medical 
centre, Nijmegen, The Netherlands
3  AstraZeneca R&D, Innovative Medicines, Drug Safety and Metabolism, Sweden
4  Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, The 
Netherlands. 
 
*Authors contributed equally
American Association of Pharmaceutical Sciences Journal. 18. 465-75 (2016)
2
28
Abstract
Drug-induced nephrotoxicity still hampers drug development, because current 
translation from in vitro or animal studies to human lack high predictivity. Often, renal 
adverse effects are recognized only during clinical stages of drug development. The 
current study aimed to establish a robust and a more complete human cell model 
suitable for screening of drug related interactions and nephrotoxicity. In addition to 
endogenously expressed renal organic cation transporters and efflux transporters, 
conditionally immortalized proximal tubule epithelial cells (ciPTEC) were completed by 
transduction of cells with the organic anion transporter (OAT) 1 or OAT3. Fluorescence-
activated cell sorting upon exposure to the OAT substrate fluorescein successfully 
enriched transduced cells. A panel of organic anions was screened for drug-interactions 
in ciPTEC-OAT1 and ciPTEC-OAT3. The cytotoxic response to the drug-interactions with 
antivirals was further examined by cell viability assays. Upon subcloning, concentration-
dependent fluorescein uptake was found with a higher affinity for ciPTEC-OAT1 
(Km = 0.8±0.1 µM) than ciPTEC-OAT3 (Km = 3.7±0.5 µM). Co-exposure to known OAT1 and/
or OAT3 substrates (viz. para-aminohippurate, estrone sulfate, probenecid, furosemide, 
diclofenac and cimetidine) in cultures spanning 29 passage numbers revealed relevant 
inhibitory potencies, confirming the robustness of our model for drug-drug interactions 
studies. Functional OAT1 was directly responsible for cytotoxicity of adefovir, cidofovir 
and tenofovir, while a drug-interaction with zidovudine was not associated with 
decreased cell viability. Our data demonstrate that human-derived ciPTEC-OAT1 and 
ciPTEC-OAT3 are promising platforms for highly predictive drug screening during early 
phases of drug development.
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Introduction
The renal proximal tubules play a major role in eliminating waste products from the 
body, including drugs and their metabolites. Their active secretion and reabsorption 
mechanisms together with biotransformation capacity make proximal tubule cells 
especially sensitive to drug-induced toxicity and subsequent acute kidney injury 
(AKI)[1]. Not surprisingly, nephrotoxicity is a significant cause for drug attrition 
during pharmaceutical development, often recognized only during clinical stages 
of development as translation from in vitro and animal studies to human lack high 
predictivity[2, 3].
An in vitro model with high predictive value for drug-induced nephrotoxicity should 
closely reflect the in vivo processes involved in renal drug handling. More specific, a 
robust cell-based model should include a proximal tubule epithelium stably expressing 
a broad range of functional transporters and metabolic enzymes that act in concert in 
renal drug elimination[4]. This process may be affected in concomitant drug treatment, 
leading to clinically relevant drug-drug interactions (DDI). The renal elimination 
mechanism of xenobiotics can roughly be divided into two major pathways, viz. the 
organic anion and the organic cation system. As a first step in elimination of organic 
anions in humans, active tubular uptake is mediated by the organic anion transporter 
1 (OAT1; SLC22A6) and organic anion transporter 3 (OAT3; SLC22A8) present at the, 
blood-facing, basolateral side[5]. These transporters are characterized by their high 
affinity and capacity and, as a consequence, are major players in the development 
of drug-induced nephrotoxicity[6]. After uptake, secretion of anionic compounds into 
the tubular lumen is facilitated by apically expressed efflux transporters, such as 
the multidrug resistance proteins 2 and 4 (MRP2 and -4; ABCC2 and -4) and breast 
cancer resistance protein (BCRP; ABCG2)[7]. In parallel, renal elimination of organic 
cations in the human proximal tubular epithelium is facilitated by basolateral uptake, 
predominantly via the organic cation transporter 2 (OCT2; SLC22A2), and apical 
efflux via multidrug and toxin extrusion proteins 1 and 2-K (MATE1 and -2-K; SLC47A1 
and -2)[8] and P-glycoprotein (P-gp; ABCB1)[9].
Renal drug transporters demonstrate a large overlap in substrate specificity, 
introducing redundancy in uptake mechanisms of proximal tubule cells and 
contributing to the relative high sensitivity of the tissue[6, 10]. This especially counts 
for organic anions, as this class comprises the majority of drugs that are excreted by 
the kidneys. Drug-induced nephrotoxicity related to the proximal tubular epithelium 
by this class of compounds have been described broadly, including for the acyclic 
nucleotide phosphonates adefovir, cidofovir and tenofovir[11, 12]. These antiretroviral 
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compounds are used for treatment of HIV, hepatitis B and cytomegalovirus infections 
and function as nucleotide analog reverse transcriptase inhibitors (NtRTIs)[13]. 
The exact mechanism of antiviral-induced renal toxicity is still under debate[14], but 
the involvement of OATs in the uptake of many antivirals has been widely 
acknowledged[15-17]. To prevent NtRTIs-induced nephrotoxicity, their uptake can be 
inhibited by co-administration of an OAT1 inhibitor, such as probenecid[18]. As with many 
other diseases, current antiviral therapy in HIV infections is based on polypharmacy. 
Increased plasma concentrations and systemic toxicity have been observed with 
didanosine co-administration of tenofovir in anti-HIV triple therapy, possibly by 
DDI at the site of OAT1 that limited renal excretion[19]. Together, polypharmacy can 
optimize the life-span of infected patients, but this strategy simultaneously increases 
the risk for DDI and demands for personalized evaluation of the benefit/risk ratio for 
each drug[20]. 
The aim of this study was to establish a robust human cell model that allows 
prediction of drug-induced nephrotoxicity and DDI of organic anions, with a focus on 
antivirals. We evaluated conditionally immortalized proximal tubule epithelial cells 
(ciPTEC) as a preclinical in vitro prediction model[21]. This model already demonstrated 
to be highly predictive for studying DDI at the site of OCT2[22], and to endogenously 
exhibit metabolic enzymes[23] together with a panel of functional efflux transporters[21, 
24]. However, the expression of OAT1 and OAT3 was rapidly lost in culture. Here, 
these transporters were stably expressed in ciPTEC by transduction, followed by an 
elegant selection procedure using OAT transporter functionality, completing the 
relevant renal xenobiotic transporters in ciPTEC. The function of both transporters 
appeared to be stable upon prolonged culturing. These unique characteristics of the 
presented OAT containing human cell lines allowed screening for DDI using known 
pharmacological OAT1 and OAT3 substrates and/or inhibitors. Upon validation, we 
demonstrated that OAT mediated uptake in ciPTEC are key determinants in antiviral-
induced cytotoxicity. These findings underscore that ciPTEC-OAT1 and ciPTEC-OAT3 
are valuable tools for drug-induced toxicity screening. 
Materials and Methods 
Cell culture
Conditionally immortalized proximal tubule epithelial cells (ciPTEC) were developed 
as described by Wilmer et al. with informed consent of the donors in accordance with 
the approved guidelines of the Radboud Institutional Review Board[21]. Cells were 
seeded 7 days prior to the experiment at their corresponding density (55,000 cells/
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cm2 for ciPTEC parent cells, 63,000 cells/cm2 for ciPTEC-OAT1 and 82,000 cells/cm2 
for ciPTEC-OAT3) and grown for 1 day at 33°C and 5% v/v CO2 to allow proliferation, 
enabled by the temperature-sensitive mutant of SV large T antigen (SV40T). Next, 
cells were cultured for 6 days at 37°C and 5% v/v CO2 to stimulate differentiation and 
formation of an epithelial monolayer, described as ‘maturation’. Cells were cultured 
using Dulbecco’s modified eagle medium (DMEM HAM’s F12, Life Technologies, Paisly, 
UK), 5 µg/ml insulin, 5 µg/ml transferrin, 5 µg/ml selenium, 35 ng/ml hydrocortisone, 
10 ng/ml epidermal growth factor (EGF), 40 pg/ml tri-iodothyronine (Sigma, 
St. Louis, USA) and 10% fetal calf serum (FCS, Greiner Bio One, Kremsmuenster, 
Austria). Medium was refreshed every second day, supplemented with 1% penicillin/
streptomycin (pen/strep, Invitrogen, Carlsbad, USA) at 33°C and without pen/strep at 
the maturation temperature of 37°C. 3T3 mouse-fibroblast (3T3) cells were cultured 
at 37°C and used only as irradiated non-proliferating feeder cells for sub-cloning 
procedures upon transduction, as described[21].
Vector construction
Vector construction was performed using Gateway Cloning Technology (Invitrogen), 
according to the manufacturer’s instructions. Commercially obtained vectors 
containing OAT1 (pENTR201-hOAT1, Harvard Plasmids HsCD00044153) and OAT3 
(pENTR201-hOAT3, HsCD00044090) were transferred into a pLenti4/V5-DEST vector 
by LR recombinant reaction, resulting in expression vectors pLenti4/V5-EX-hOAT1 
and pLenti4/V5-EX-hOAT3. The inducible CMV-TetO2 promoter was replicated from 
pcDNA5-FRT-TO (Invitrogen) using primers that introduce ClaI (forward Cla1-CMV-
TetO2: GCCGCCATCGATGCCGCCGTTGACATTGATTATTGACT) and EcoRI restriction sites 
(reverse EcoRI-CMV-TetO2: GGCGGCGAATTCGGCGGCCGGAGGCTGGATCGGTCCCGG). 
The resulting PCR product (ClaI-CMV-TetO2-EcoRI) product was purified using the 
High Pure PCR Product Purification kit (Roche, Basel, Switzerland). Both PCR product 
and expression vectors were digested by ClaI and EcoRI (New England Biolabs, 
Ipswich, USA) for 1 hour at 37°C and, after purification, ligation was performed with 
a 1:3 (insert:vector) unit ratio using T4 ligase (Invitrogen) for 2 h at 37°C, resulting in 
the pLenti expression constructs (pLenti4/V5-EX-CMV-TetO2-hOAT1 and pLenti4/V5-
EX-CMV-TetO2-hOAT3).
OAT transduction in ciPTEC
To obtain lentiviral particles containing the OAT constructs, lentiviral stock was 
produced by transfecting the pLenti expression constructs with packaging plasmid 
mix into the HEK293FT cell line using ViraPower Lentiviral Gateway Expression Systems 
(Invitrogen), according to the manufacturer’s instructions. CiPTEC were cultured to 
50-70% confluency and exposed to lentiviral particles for 24 h. Both ciPTEC-OAT1 and 
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ciPTEC-OAT3 were selected and subcloned to obtain a homogeneous cell population. 
To this end, transduced ciPTEC-OAT3 cells were plated into 3 separate culture flasks 
(100, 300 and 900 cells) containing irradiated (30 Gy) non-proliferating 3T3-cells as 
described by Saleem et al[25]. After 2-3 weeks, single cell colonies of ciPTEC-OAT3 were 
picked and cultured. Transduction efficiency for ciPTEC-OAT1 was lower than for 
ciPTEC-OAT3, making immediate subcloning difficult. Therefore, the heterogeneous 
cell population of ciPTEC-OAT1 was enriched by positive selection of fluorescein 
transporting cells. Only successfully transduced ciPTEC express functional OAT; 
hence, positive selection could be performed upon exposure to the OAT substrate 
fluorescein using BD FACSAria SORP flow cytometer (BD biosciences, San Jose, USA). 
20 million ciPTEC-OAT1 cells were suspended in HBSS (Invitrogen) containing 1 µM 
fluorescein and incubated for 10 min at 37°C before fluorescence-activated cell 
sorting (FACS). Enriched ciPTEC-OAT1 cells were subcloned as described for ciPTEC-
OAT3. Both ciPTEC-OAT1 and ciPTEC-OAT3 were cultured for up to 30 passages after 
transduction to study stability of OAT1 and OAT3 expression.
OAT-mediated fluorescein uptake
To evaluate OAT transporter function and inhibition properties of several known 
OAT substrates, fluorescein uptake was measured by flow cytometry and multi-
plate reader. Mature monolayers of sub-cloned ciPTEC spanning 29 passages were 
co-incubated with fluorescein (1 µM, unless stated otherwise) and a test compound 
in HBSS for 10 min at 37°C. Compounds known for their inhibitory effect on OAT-
mediated transport, para-aminohippuric acid (PAH), estrone sulfate, probenecid, 
furosemide, cimetidine, diclofenac, adefovir, cidofovir, tenofovir and zidovudine, 
were tested. The organic cation metformin was included as a negative control. All 
chemicals were obtained from Sigma, unless stated otherwise. Uptake was stopped 
by washing 3 times with ice-cold HBSS (4°C). For flow cytometry, samples were 
harvested following fluorescein exposure using trypsin-EDTA, washed, fixed using 
0.5% paraformaldehyde and measured using FACS calibur (Becton Dickinson, Franklin 
Lakes, USA). For 96 well plate assay, cells were lyzed by 200 µl 0.1 M NaOH for 10 min 
at 37°C and fluorescence was measured (excitation 485 nm, emission 535 nm) using 
the multiplate reader Victor X3 (Perkin Elmer, Waltham, USA). 
Viability assays
To evaluate toxicity induced by antivirals, viability of ciPTEC was evaluated by an 
MTT assay[26]. Briefly, monolayers of ciPTEC (96-wells) were exposed to antivirals in 
serum-free medium (SFM) on day 6 of maturation. Cell toxicity was analyzed further 
in presence of MRP and BCRP efflux inhibitors MK571 (5 µM) and KO143 (10 µM). After 
incubation for 24, 48 and 72 h at 37°C, ciPTEC were washed and incubated with 0.5 
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mg/ml thiazolyl blue tetrazolium bromide (MTT, Sigma) for 3 h at 37°C in absence 
of antivirals. Formazan crystals formed in viable cells were dissolved in dimethyl 
sulfoxide (DMSO, Merck, Whitehouse Station, USA) and optical density was measured 
(560 nm, background at 670 nm was subtracted) using Benchmark Plus (Bio-Rad, 
Hercules, USA). 
Gene expressions in ciPTEC
Total RNA was isolated from matured ciPTEC (6-well plates) spanning 10 passages 
for ciPTEC-OAT1 and 11 passages for ciPTEC-OAT3 using TRIzol (Life Technologies 
Europe BV) and chloroform extraction. cDNA was synthesized using M-MLV Reverse 
Transcriptase (Promega, Madison, USA), according to the manufacturer’s instructions. 
The mRNA expression levels were evaluated using gene-specific primer-probe sets 
obtained from Life Technologies: OAT1 (SLC22A6, hs00537914), OAT3 (SLC22A8, 
hs00188599), GAPDH (hs99999905) and TaqMan Universal PCR Master Mix (Applied 
Biosystems). The quantitative PCR reactions were performed using CFX96-Touch Real 
Time PCR System (BioRad) and analyzed using BioRad CFX Manager (version 1.6). 
mRNA-levels for ciPTEC-OAT1 and ciPTEC-OAT3 were calculated using GAPDH as a 
reference gene and compared to gene expressions in human kidney homogenates 
in triplicate.
Data analysis
A Michaelis-Menten equation was combined with linear diffusion to fit fluorescein 
uptake data after background subtraction with GraphPad Prism (version 5.03). For 
calculation of IC50 values, log (concentration inhibitor) versus fluorescein uptake was 
plotted after background subtraction using GraphPad Prism. For MTT and fluorescein 
inhibition assays, data were normalized to the viability or activity of untreated 
control cells. Non-linear regression with variable slope constraining the top to 100% 
was used to fit the data after background subtraction with GraphPad Prism. Statistics 
was performed by two-way ANOVA (two-tailed, α=0.05) using GraphPad Prism as 
well. All data is presented as mean±SEM of at least three separate experiments (n=3) 
performed in triplicate, unless stated otherwise. 
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Results 
Functional OAT expression in ciPTEC
The absence of endogenous OAT1 and OAT3 expression in ciPTEC was demonstrated 
by exposure to fluorescein (1 µM) for 10 min, which did not increase the intracellular 
fluorescence intensity as measured by flow cytometry (Figure 2.1B, red line). 
Therefore, OAT transporters were introduced separately by lentiviral transduction. 
A schematic overview of the experimental approach is provided in Figure 2.1A. The 
transporter genes SLC22A6 and SLC22A8 were cloned under regulation of a CMV 
promoter and a TetO2 site to conditionally induce the expression. Remarkably, basal 
expression and function upon transduction of both OAT transporters was positive 
without tetracycline induction, and was not influenced by this inducer (data not 
shown). Fluorescein uptake capacity (without induction by tetracycline) was used 
to discriminate between successfully transduced cells and non-transduced cells, 
reflected by two sub-populations in the flow cytometer histogram (Figure 2.1C). 
When exposed to 1 µM fluorescein for 10 min, a small cell population accumulated 
the fluorescent substrate, which was immediately selected using FACS. The fraction 
of OAT1 positive cells selected (Figure 2.1D) accounted for only 8.3% of the total 
population. The enriched population accumulated fluorescein efficiently, and was 
sensitive to inhibition by para-aminohippuric acid, a known OAT1 substrates and/
or inhibitors (Figure 2.1E). The ciPTEC-OAT1 population enriched by FACS and the 
non-enriched ciPTEC-OAT3 population were subcloned to obtain homogeneous cell 
populations with high functional OAT transporter expression, demonstrated by qPCR. 
Expression levels of OAT1 and OAT3 in the respective cell lines were compared to 
gene expression levels in human kidney tissue homogenates, resulting in a ratio of 
0.7±0.2 and 0.14±0.02 for OAT1 and OAT3, respectively. Intact tubular phenotype 
was demonstrated by functionally active OCT2, for which a drug-interaction with 
cimetidine was shown to be similar to the parent cell line (Figure S2.1). 
Drug-interaction at the site of OAT1 and OAT3
Transport kinetics of OAT-mediated fluorescein transport was investigated further by 
studying the time and concentration dependent uptake of the substrate. Fluorescein 
uptake demonstrated partial saturation in OAT1 and OAT3 expressing cells (Figure 
2.2A, B and D) for which a Km and Vmax value was determined taking a passive diffusion 
component kd into account (Table 2.1). Fluorescein affinity was approximately 5-fold 
higher for OAT1 than for OAT3. Upon fluorescein exposure (10 min, 1 µM), confocal 
fluorescent imaging confirmed uptake in ciPTEC-OAT1 and ciPTEC-OAT3 (Figure 2.2C 
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Figure 2.1 Schematic overview of transduction procedure to obtain ciPTEC-OAT1 and ciPTEC-
OAT3. (A) CiPTEC parent was transduced with OAT1 or OAT3 lentiviral constructs and enriched by 
FACS using OATs’ capacity to transport fluorescein. Further subcloning using radiated 3T3 fibroblasts 
as feeder cells resulted in a homogeneous ciPTEC-OAT1 or ciPTEC-OAT3 cell line. Histogram obtained 
by flow cytometry of (B) ciPTEC parent, (C) ciPTEC-OAT1 and ciPTEC-OAT3 exposed to fluorescein 
(1 µM, 10 min, green line), fluorescein and para-aminohippuric acid (100 µM, red line), or untreated 
cells (black line). Parent cells exposed to fluorescein did not show increased fluorescence intensity, 
while ciPTEC-OAT1 and ciPTEC-OAT3 both showed a sub-population with increased fluorescence 
indicative for OAT functionality, which is sensitive to para-aminohippuric acid-induce inhibition. 
(D) Scattered plot showing forward scatter (y-axis) and fluorescein intensity (x-axis) of transduced 
ciPTEC-OAT1 exposed to 1 µM fluorescein for 10 min. The population with high fluorescence intensity 
indicated by gate P1 (8.3% of total population) was sorted to enrich successfully transduced ciPTEC-
OAT1. Transduction with OAT3 was more efficient than OAT1, represented by the larger positive 
subpopulation in Figure 2.1C, making the enrichment protocol redundant for ciPTEC-OAT3. (E) 
Histogram of enriched ciPTEC-OAT1 exposed to fluorescein (1 µM, 10 min) in presence (red line) 
or absence (green line) of competitor para-aminohippuric acid (100 µM) demonstrates increased 
fluorescence intensity compare to non-enriched ciPTEC, but a heterogeneous population sensitive 
to para-aminohippuric acid, pointing towards the requirement of subcloning of the enriched cells.
A B
C
D
E
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Figure 2.2 OAT-mediated fluorescein uptake in ciPTEC-OAT1 and ciPTEC-OAT3. (A) Concentration-
dependent OAT1 and OAT3 mediated uptake of fluorescein after 10 min incubation in ciPTEC-OAT1 
and ciPTEC-OAT3. The curve was fitted (n=4) according to a Michaelis-Menten model in combination 
with linear diffusion. (B, C) Fluorescein uptake (1 µM) by ciPTEC-OAT1 and (D, E) ciPTEC-OAT3 up to 60 
min in absence or presence of two concentrations of the typical inhibitors para-aminohippuric acid 
(PAH, for ciPTEC-OAT1) or estrone sulfate (ES, for ciPTEC-OAT3). (B, D) The curves were fitted (n=4) to 
a standard saturation model after background subtraction. Analysis using two-way ANOVA indicated 
significantly decreased uptake curves in both ciPTEC-OAT1 (10 µM and 100 µM PAH, p<0.001)) and 
ciPTEC-OAT3 (3 µM ES, p<0.01; 100 µM ES, ***p<0.001). (C, E) Representative images of fluorescein 
uptake (1 µM) by ciPTEC-OAT1 (C) and ciPTEC-OAT3 (E) after 10 min (magnification 20x). 
A
B C
ED
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and E). To demonstrate the uptake was transporter mediated, specific inhibition of 
fluorescein uptake in presence of two concentrations para-aminohippuric acid (10 
and 100 µM) and estrone sulfate (3 and 100 µM) in ciPTEC-OAT1 and ciPTEC-OAT3, 
was studied (Figure 2.2B and D). CiPTEC-OAT1 and ciPTEC-OAT3 were evaluated 
further by determination of IC50 values using concentration-dependent inhibition 
of fluorescein uptake in presence of para-aminohippuric acid, estrone sulfate, 
probenecid, furosemide, cimetidine and diclofenac (Figure 2.3, Table 2.2). Overall, 
IC50 values calculated in our models are in close agreement with previously reported 
values, although it should be noted that probe substrates may differ and influence IC50 
values (Table 2.2). Further confirmation of specificity was obtained using metformin, 
not affecting OAT mediated fluorescein uptake in both ciPTEC-OAT1 and ciPTEC-
OAT3, as metformin is an OCT substrate[27]. The experiments depicted in Figure 3 were 
performed in cells spanning 29 passages after transduction. The small variations in 
these data and maintained fluorescein uptake indicate stable transduction and high 
robustness of transporter function in ciPTEC-OAT1 and ciPTEC-OAT3.
Table 2.1 Michaelis-Menten parameters for OAT-mediated fluorescein uptake in ciPTEC-OAT1 
and ciPTEC-OAT3a.
ciPTEC-OAT1 ciPTEC-OAT3
Km (µM) 0.8±0.1 3.7±0.5
Vmax (RFU) 695±84 384±103
Kd (RFU*L/µmol) 2.4±1.2 4.3±0.9
a Data are expressed as mean±SEM, n=4.
OATs mediate antiviral-induced toxicity 
As toxicity of antivirals was reported to be associated with OAT1 and OAT3 mediated 
renal tubular uptake, we investigated their effects on OAT function and cell viability 
upon drug exposures. Concentration-dependent inhibition of fluorescein uptake 
via OAT1 was observed by adefovir, cidofovir, tenofovir and zidovudine, while OAT3 
was only associated with zidovudine-fluorescein interactions (Figure 2.4, Table 
2.3). Next, the DDI indices were determined. The United States Food and Drug 
Administration (FDA) draft a DDI guideline[28] recommending to perform clinical DDI 
studies when the ratio between unbound plasma concentration and IC50 (Cmax,u /IC50) 
is higher than 0.1. For adefovir, cidofovir and zidovudine the IC50 value was less than 
10 times the maximal free plasma concentration (Cmax,u/IC50>0.1), and, therefore, at 
clinically relevant plasma concentrations inhibition of OAT1 is likely and DDI with 
OAT1 transporter substrates were defined as clinically relevant in our study. Next, 
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Figure 2.3 Inhibition of OAT-mediated fluorescein uptake by a panel of OAT-perpetrators. 
Fluorescein uptake (1 µM) by ciPTEC-OAT1 and ciPTEC-OAT3 when co-incubated with para-
aminohippuric acid, estrone sulfate, probenecid, furosemide, cimetidine, diclofenac and metformin 
for 10 min in HBSS at 37°C, relative to uptake without inhibitor. The line represents the fit according 
to a one-site competition model with variable slope, except for metformin. Values are derived from 
experiments performed at passage x+8, x+11, x+14 and x+29 upon transduction (n=4).
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cytotoxicity caused by all four antivirals was evaluated after exposure of ciPTEC for 
24-72 h to the drugs. As a measure of cytotoxicity, cell viability was analyzed by 
cellular dehydrogenase capacity, metabolizing MTT into purple formazan. In the 
parent ciPTEC, viability was not affected by any of the antivirals (48 hr, 1 mM), while 
adefovir, cidofovir and tenofovir significantly affected cell viability in ciPTEC-OAT1 
and only tenofovir slightly decreased ciPTEC-OAT3 viability (Figure 2.5A). Antiviral-
induced toxicity was evaluated in more detail, demonstrating a concentration- 
and time-dependent decrease in viability by adefovir, cidofovir and tenofovir in 
ciPTEC-OAT1, while the effect was less pronounced in ciPTEC-OAT3 (Figure 2.5B and 
Table 2.4). These findings indicate the direct involvement of the OAT transporters in 
antiviral-mediated nephrotoxicity, although IC50 values found in the current study 
are higher compared to those obtained in previous studies (Table 2.4). The cytotoxic 
effect of the antivirals correlated nicely with the inhibitory effect on fluorescein 
uptake, except for zidovudine. Despite a clear inhibition of fluorescein uptake by 
zidovudine, suggesting OAT-mediated uptake, this compound did not affect cell 
Table 2.2 Inhibitory potencies of substrates and/or inhibitors of fluorescein uptake in ciPTEC-
OAT1 and ciPTEC-OAT3 and a selection of reference valuesa
Current study Literature
Cell line IC50
(µM)
IC50
(µM)
Ki 
(µM)
Substrate Cell line ref
para-aminohippuric acid ciPTEC-OAT1 18±4 8.8 6.02 6-carboxyfluorescein
ochratoxin A
CHO-OAT1
S2-OAT1
[29]
[49]
ciPTEC-OAT3 152±3 19.6
100
ochratoxin A
benzylpenicillin
S2-OAT3
HEK293-hOAT1
[49]
[50]
estrone sulfate ciPTEC-OAT1 54±13 >100 PAH S2-OAT1 [51]
ciPTEC-OAT3 2.1±0.3 3.0 estrone sulfate Xenopus-OAT3 [52]
probenecid ciPTEC-OAT1 12.7±0.5
6.3
4.29
12.1
ochratoxin A
6-carboxyfluorescein
PAH
S2-OAT1
CHO-OAT1
S2-OAT1
[49]
[29]
[16]
ciPTEC-OAT3 1.9±0.6 3.1
4.41
cimetidine
ochratoxin A
CHO-OAT3
S2-OAT3
[53]
[49]
furosemide ciPTEC-OAT1 25±4 18 PAH S2-OAT1 [54]
ciPTEC-OAT3 2.3±0.4 7.31
1.7
estrone sulfate
sitagliptin
S2-OAT3
CHO-OAT3
[54]
[53]
cimetidineb ciPTEC-OAT1 654±291 492 PAH S2-OAT1 [35]
ciPTEC-OAT3 215±162 79
53
sitagliptin
estrone sulfate
CHO-OAT3
Xenopus-OAT3
[53]
[55]
diclofenac ciPTEC-OAT1 5±1 4.46
4
PAH
adefovir
S2-OAT1
CHO-OAT1
[56]
[57]
ciPTEC-OAT3 3±1 7.78 estrone sulfate S2-OAT3 [56]
a Data are expressed as mean±SEM, n=4. bApparent IC50 value due to partial inhibition.
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Figure 2.4 Inhibition of OAT-mediated fluorescein uptake by adefovir, cidofovir, tenofovir and 
zidovudine. Fluorescein uptake (1 µM) by ciPTEC-OAT1 and ciPTEC-OAT3 when co-incubated with 
the antivirals for 10 min in HBSS at 37°C, relative to uptake without inhibitor. The line represents the 
fit according to a one-site competition model with variable slope (n=4).
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Figure 2.5 Antiviral-induced toxicity in ciPTEC-OAT1 and ciPTEC-OAT3. (A) Viability of ciPTEC parent, 
ciPTEC-OAT1 and ciPTEC-OAT3 after exposure to antiviral agent (1 mM) for 48 h in serum free medium 
relative to cell viability as measured with the MTT assay without exposure (n=3). **p<0.01, ***p<0.001. 
(B) Viability of ciPTEC-OAT1 and ciPTEC-OAT3 upon tenofovir, adefovir, cidofovir or zidovudine exposure 
for 24, 48 and 72 h in serum free medium, relative to cell viability without exposure. The line represents 
the fit according to a one-site competition model with variable slope (n≥3).
A
B
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viability as determined by the MTT assay. To investigate a potential protective effect 
via intact efflux transporters in ciPTEC, cells were exposed to zidovudine at 10x Cmax 
(50 µM) in presence of MRP4 and BCRP inhibitors MK571 and KO143, respectively. 
This did not affect cell viability in ciPTEC, ciPTEC-OAT1 nor ciPTEC-OAT3, indicating 
that efflux transporters did not counteract intracellular exposure of zidovudine and 
thereby reduce the cytotoxic potential of zidovudine.
Table 2.3 Inhibitory potencies of antivirals on fluorescein uptake using ciPTEC-OAT1 and 
ciPTEC-OAT3 compared with a selection of reference values. In the current study, fluorescein 
inhibition by the model compounds was measured. For references, the competitive substrate is 
provided.
Current study Literature DDI index 
Cell line IC50
(µM)
IC50
(µM)
Km
(µM)
Substrate Cell line Ref. Cmax 
(µM)
Cmax/
IC50
Ref.
adefovir ciPTEC-OAT1 23±4 8.1
28
23.8
PAH
6-carboxyfluorescein
-
HeLa-OAT1
CHO-OAT1
CHO-OAT1
[30]
[29]
[29]
1.6 
38.8 
0.18
4.2
[58]
[59]
ciPTEC-OAT3 N.A.
cidofovir ciPTEC-OAT1 71±34 60
58
6-carboxyfluorescein
-
CHO-OAT1
CHO-OAT1
[29]
[29]
15.8 
26.3 
0.53
0.88
[60]
[61]
ciPTEC-OAT3 N.A.
tenofovir ciPTEC-OAT1 42±8 29.3
33.8
PAH
-
HeLa-OAT1 [30]
[36]
0.52 
0.72 
0.014
0.019
[62]
[63]
ciPTEC-OAT3 N.A.
zidovudine ciPTEC-OAT1 14±7 45.9 - S2-OAT1 [16] 5.5 0.55
0.66
[64]
ciPTEC-OAT3 21 ±4 145 - S2-OAT1 [16] 6.6 0.69
0.83
[64]
a Data are expressed as mean±SEM, n=3. N.A., not applicable; PAH, para-aminohippurate; HeLa, human epitheloid cervix carcinoma cell; 
CHO, Chinese hamster ovary cell line; S2, SV40T immortalized mouse renal cell line.
Table 2.4 Inhibitory potencies of antivirals on cell viability as measured by MTT assay using 
ciPTEC-OAT1 and a selection of values as found in literaturea.
ciPTEC-OAT1
Current study Literature
24 h 48 h 72 h 48 h 120 h Ref.
adefovir 462±52 303±38 230±37 0.22±0.08 1.4±0.7 [36, 38]
cidofovirb 613±384 130±58 69±2 0.5±0.2 3±1 [36, 38]
tenofovir 114±25 189±48 223±67 10±2 21±7 [36, 38]
aData are expressed as µM (mean±SEM), n≥3. bApparent IC50 value due to partial inhibition.
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Discussion
To improve prediction of the nephrotoxic potential of novel chemical entities and 
to mechanistically understand the pathways associated with drug-induced toxicity, 
highly predictive and validated translational models are required. In the present 
report, we describe such a robust human-based cell model with intact proximal 
tubular characteristics. Stable OAT1 and OAT3 expression in the human renal cell 
line ciPTEC allowed studying reproducible DDI for a panel of model substrates and 
antiviral compounds. Functional OAT1 and OAT3 transport activity was demonstrated 
to be associated with drug-induced toxicity of the antivirals adefovir, cidofovir 
and tenofovir. These findings indicate that our model predicts drug-induced 
nephrotoxicity, and underscore that functional expression of influx transporters is 
pivotal in prediction of drug-induced renal toxicity.
Many reports related to studying drug-OAT interactions describe the use of non-
polarized overexpression systems, such as Chinese hamster ovary (CHO) cells, the 
human cervical epitheloid carcinoma cell line HeLa, or human epithelial kidney (HEK) 
293 cells, which are highly relevant for studying interactions at the single transporter 
level but might have a poor overall predictivity due to their simplicity[29, 30]. Since 
proximal tubule cells are the main site of adverse drug effects in the kidney, this 
cell type is preferred for in vitro assays investigating drug-induced nephrotoxicity[1]. 
Human primary proximal tubule cells reflect in vivo toxicological responses best, 
but lack reproducibility and robustness due to high donor-to-donor variability and 
limited availability. Moreover, primary cells lose their proximal tubular phenotype 
upon culturing, and OAT1-4, P-glycoprotein and MRP expressions were found to be 
rapidly decreased[31, 32]. To extend the life span of human proximal tubular cells and to 
provide a robust model for drug screening, we and others have immortalized primary 
kidney cells, yet without demonstrating functional OATs[21, 33], despite retained gene 
expressions[34]. 
The current study demonstrates the first human model with stable expression of 
OAT1 and OAT3 for up to 10 and 11 passages, respectively, as analyzed by qPCR and 
functionality of OAT1 and OAT3 for up to 29 passages as analyzed by fluorescein 
uptake. Experimental values obtained for DDI of model compounds correlated 
well with published data, confirming PAH has a higher inhibitory potency for OAT1 
compared to OAT3, whereas the inhibitory potencies of estrone sulfate, probenecid 
and furosemide were clearly higher for OAT3. The IC50 value of cimetidine in ciPTEC-
OAT1 is, however, more than 5-fold higher as described earlier, whereas ciPTEC-
OAT3 inhibition by cimetidine was found well within predetermined ranges[35]. This 
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discrepancy may be explained by different substrates used in the studies, where the 
OAT1-substrate PAH used in earlier studies, has a lower affinity for OAT1 as compared 
to fluorescein used in the current study. Since tetracyclin-inducible expression of 
OAT1 and OAT3 in ciPTEC was not achieved, we hypothesize that random integration 
of the vector could have caused silencing of this particular promoter element. The 
effects of prototypic inhibitor compounds on drug transport are promising with 
respect to the application of ciPTEC as a tool to study drug-induced nephrotoxicity 
and the proof-of-concept was evaluated further with a selected a panel of clinically 
relevant antivirals with various pharmacokinetic parameters.
DDIs are a major concern in anti-HIV therapy that includes co-administration of 
multiple antivirals. We evaluated adefovir, cidofovir, tenofovir and zidovudine DDI 
at the site of OAT1 and OAT3. The affinities of adefovir, cidofovir and tenofovir were 
higher for OAT1 than for OAT3, in agreement with previous studies in CHO cells 
overexpressing hOAT1 and hOAT3[36]. The DDI index has been used to determine the 
potential of clinical DDI and drug-induced toxicities[28, 37], and allows extrapolating in 
vitro observations to the clinical setting[28, 37]. In our study, IC50 values of less than 10 
times the maximal free plasma concentration (Cmax,u/IC50>0.1), were found for adefovir, 
cidofovir and zidovudine, indicating these antivirals are likely to inhibit OAT1 and 
OAT3 at clinically relevant concentrations.
Antiviral-induced nephrotoxicity was shown to be associated with OAT-mediated 
uptake and further evaluated in the current study[11, 15, 36, 38]. We demonstrated that OAT1 or 
OAT3 expression is required for induction of toxicity by adefovir, cidofovir and tenofovir 
in ciPTEC. The relation between OAT1 transporter affinity and toxicity was described 
earlier using HeLa cells, transiently expressing hOAT1, in which cidofovir showed a 
higher affinity as well as a higher toxicity compared to tenofovir[30]. In agreement, when 
the cytotoxic potential of NtRTIs in ciPTEC-OAT1 at 72 h of exposure was ranked, we 
found that cidofovir has the highest potency over tenofovir and adefovir[36, 38]. On the 
other hand, the low potency of adefovir in our study contrasts to the cytotoxicity 
reported for other cell models[35, 37]. In general, the toxic potency of the antivirals in 
ciPTEC is lower as compared to hOAT1-CHO and HEK-OAT1, which may be due to 
the presence of functional metabolic enzymes and an intact efflux machinery in 
ciPTEC[36, 38, 39]. RNA expression of phase I enzymes CYP3A4, CYP4A11 and several UDP-
glucuronosyltransferases (UGTs) in ciPTEC were found to be comparable to their 
expression levels in primary PTEC[23, 32]. Protein expression of the efflux transporters 
Pgp and MRP4 was demonstrated, as well as functional efflux transport activity of 
Pgp, MRP4 and BCRP[21, 24]. From these findings, we conclude that ciPTEC closely reflects 
the physiological situation, suggesting that our model is of higher predictive value 
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than single overexpression systems. Since MPR4 mediates the efflux of tenofovir, its 
functional presence in ciPTEC might explain the reduced cytotoxicity in our model 
as compared to overexpression systems lacking this transporter[15, 39]. Future research 
should clarify this.
Activity of phase I and phase II metabolizing enzymes was demonstrated in ciPTEC 
of which the UGT2B7 subfamily might have been the cause of the tolerance for 
zidovudine observed in the present study[23]. While adefovir, cidofovir and tenofovir 
are largely excreted unchanged by the kidneys, only 23% of zidovudine is eliminated 
via the urine without metabolic alterations[40]. Zidovudine undergoes either phase 
II metabolism into the non-toxic 5’-zidovudine-O-glucuronide or the antiviral is 
phosphorylated resulting in mitochondrial toxicity[12, 41]. As both glucuronidation and 
phosphorylation take place at the same functional group of zidovudine (5’-OH), the 
low toxicity of zidovudine suggests a favor for glucuronidation in ciPTEC. Although 
glucuronidation predominantly takes place in the liver, UGT2B7 expression in ciPTEC 
might contribute to zidovudine detoxification. Moreover, the toxic side effects of 
nucleoside analogues have been correlated with the kinetics of incorporation by the 
mitochondrial DNA polymerase, ranking zidovudine less toxic than tenofovir[42]. As 
efflux inhibition of MRP4 and BCRP did not further reduce viability of ciPTEC upon 
exposure with zidovudine, the toxicity of this compound is likely not influenced 
by these efflux transporters. Differences in expression of metabolic enzymes and 
transporter activities between various cell lines used for toxicity studies should 
be taken into account when comparing functional readout parameters. Moreover, 
the broad presence of metabolic enzymes and transporters in our model as well 
as in freshly isolated PTECs increases their predictive potential, but complicates 
comparison with more simple models. Taken together, the combined expression of 
efflux transporters (MRP4, BCRP, MATE2-K and Pgp) with influx transporters (OAT1/3, 
OCT2 and SLCO4C1) and metabolic enzymes make ciPTEC suitable to study multiple 
steps involved in renal elimination and drug-induced nephrotoxicity.
The clinical relevance and impact on drug safety of OAT transporters are well 
acknowledged by regulatory authorities and the pharmaceutical industry[43]. Both the 
FDA and the European Medicines Agency (EMA) have issued guidance documents, 
outlining that OAT interactions should be studied for new compounds[28, 44]. 
Furthermore, the International Transporter Consortium (ITC) provided decision trees 
to determine whether a drug candidate may be a substrate (victim) or an inhibitor 
(perpetrator) of transporters involved in clinically relevant DDI[45]. Consequently, 
pharmaceutical industry started a quest for reliable and high-throughput in vitro 
models that mimic the human kidney with improved prediction of drug-induced 
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nephrotoxicity and a decrease in use of animals in research[46]. Current preclinical 
tests for prediction of nephrotoxicity are mainly based on animal (rodent) models. 
These models provide information about systemic toxicity in living organisms, but 
they bear high costs, are time intensive and remain an ethical issue. Their clinical 
predictive value is limited due to inherent interspecies differences in drug disposition 
and emphasizes the urgent need for human based models that closely resemble the 
human kidney physiology[6, 47]. Current innovations in in vitro models allowing cells 
to grow in polarized structures under flow conditions, in combination with high-
throughput automated systems for toxicity read-outs, will become major steps 
forward in drug safety screening, for which the ciPTEC model may provide a suitable 
cellular basis[48]. In general, application of ciPTEC as a predictive tool for drug-induced 
toxicity requires comparison with freshly isolated PTECs and further validation by 
extrapolation of in vitro data to clinical outcomes.
Conclusion
We present the first human PTEC model with stable expression and functionality of 
OAT1 and OAT3, allowing screening for drug-induced nephrotoxicity and DDI. The 
NtRTI drugs tenofovir, adefovir and cidofovir-induced nephrotoxicity and exhibited 
DDI indices at clinically relevant concentrations. These findings underscore that 
ciPTEC-OAT1 and ciPTEC-OAT3 are valuable tools for drug-induced toxicity screening 
that, upon systematic validation, could improve translation of in vitro findings to 
clinical research and might decrease the use of animal studies in the preclinical 
stages of drug development.
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Supplemental data
Supplemental Figure S2.1 Intact OCT2 transport after transduction procedures. ASP+ uptake 
(1 μM) by ciPTEC parent, ciPTEC-OAT1 and ciPTEC-OAT3 when co-incubated with OCT2-substrate 
cimetidine for 60 min in HBSS at 37°C, relative to uptake without inhibitor. The lines represent the fit 
according to a one-site competition model. Values are expressed as mean±SEM, (ciPTEC, n=3; ciPTEC-
OAT1, n=4; ciPTEC-OAT3, n=2. Analysis using Two-way ANOVA indicated significant inhibition of ASP+ 
uptake at OCT2 with cimetidine, resulted in similar IC50 (p>0.05).
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Abstract
Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main 
adverse effect is organic cation transporter 2 (OCT2)-mediated nephrotoxicity, 
observed in 30% of patients. The contribution of other renal drug transporters 
is elusive. Here, cisplatin-induced toxicity was evaluated in human-derived 
conditionally immortalized proximal tubule epithelial cells (ciPTEC) expressing 
renal drug transporters, including OCT2 and organic anion transporter 1 (OAT1) or 
3 (OAT3). Parent ciPTEC demonstrated OCT2-dependent cisplatin toxicity (TC50 34±1 
µM after 24 h exposure), as determined by cell viability. Over-expression of OAT1 and 
OAT3 resulted in reduced sensitivity to cisplatin (TC50 45±6 µM and 64±11 µM after 
24 h exposure, respectively). This effect was independent of OAT-mediated transport, 
as the OAT-substrates probenecid and diclofenac did not influence cytotoxicity. 
Decreased cisplatin sensitivity in OAT-expressing cells associated directly with a 
trend towards reduced intracellular cisplatin accumulation, explained by reduced 
OCT2 gene expression and activity. This was evaluated by Vmax of the OCT2-model 
substrate ASP+ (23.5±0.1 min-1, 13.1±0.3 min-1 and 21.6±0.6 min-1 in ciPTEC-parent, 
ciPTEC-OAT1 and ciPTEC-OAT3, respectively). While gene expression of cisplatin efflux 
transporter multidrug and toxin extrusion 1 (MATE1) was 16.2±0.3 fold upregulated 
in ciPTEC-OAT1 and 6.1±0.7 fold in ciPTEC-OAT3, toxicity was unaffected by the MATE 
substrate pyrimethamine, suggesting that MATE1 does not play a role in the current 
experimental set-up. In conclusion, OAT expression results in reduced cisplatin 
sensitivity in renal proximal tubule cells, explained by reduced OCT2-mediated 
uptake capacity. In vitro drug-induced toxicity studies should consider models that 
express both OCT and OAT drug transporters.
55
3
Introduction
The chemotherapeutic drug cisplatin is commonly used to treat solid organ tumours 
located in various tissues, including the head, neck, lung, testis, ovary and bladder. 
Nephrotoxicity is the main adverse effect of cisplatin, causing acute kidney injury 
(AKI) in 30% of patients[1]. AKI is currently the dose-limiting factor in treatment 
with cisplatin and is characterized by dysfunction of the proximal tubule. Cisplatin 
continues to be prescribed, as less toxic alternatives including oxaliplatin, are 
suggested to have reduced anticancer potential[2, 3].
Proximal tubule epithelial cells mediate active excretion of xenobiotics and metabolites, 
and reabsorb low molecular weight proteins, such as β2-microglubulin, and glucose 
and amino acids filtered by the glomerulus. To this end, proximal tubule cells express 
dedicated membrane spanning proteins[4]. Influx of cisplatin in proximal tubule cells is 
critically mediated by organic cation transporter 2 (OCT2, SLC22A2)[5-7] and ubiquitously 
expressed copper transporter 1 (CTR1, SLC31A1)[8], both located in the proximal tubule 
epithelium at the basolateral membrane. Cisplatin is a substrate for efflux transporters 
multidrug and toxin extrusion 1 (MATE1, SLC47A1), and to a lesser extent MATE2-k 
(SLC47A2), both located at the apical membrane[9, 10]. The combined activity of influx and 
efflux transporters determines the amount of cisplatin accumulation, hence correlates 
to the drug’s nephrotoxicity[11]. Recent studies indicate that drug-drug interactions 
and interindividual genetic differences regarding OCT2 and MATE transporters may 
contribute to the nephrotoxic potential of cisplatin, underlining their concerted action 
is essential to maintain active clearance and avoid proximal tubule accumulation[12, 13].
Organic anion transporter 1 (OAT1, SLC22A6) and 3 (OAT3, SLC22A8) in proximal 
tubule cells play a main role in clearance of organic anions, including endogenous 
uremic toxins and a wide range of drugs[4]. Recently, renal adverse effects of 
cisplatin were demonstrated to be reduced in an Oat1 knockout mouse model, 
while disposition of this drug is strongly associated with cation transporters[14]. The 
mechanism is suggested to involve extra renal metabolism, yielding glutathione and 
cysteine conjugates that act as substrates for OAT transporters. Moreover, clinical 
studies demonstrated that cisplatin clearance was reduced upon co-treatment with 
OAT-inhibitor probenecid, consistent with a complete absence of renal adverse 
effects[15, 16]. As cisplatin transport is neither mediated by OAT1 nor OAT3, their role in 
cisplatin-induced nephrotoxicity remains to be elucidated.
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The present study was designed to investigate the role of OATs in cisplatin-induced 
toxicity in conditionally immortalized proximal tubule cells (ciPTEC), a human-derived 
cell line manifesting proximal tubule characteristics (ciPTEC)[17, 18]. In this cell line, we 
previously demonstrated functional apical absorption of albumin and phosphate, 
expression of OCT2, P-glycoprotein (Pgp, ABCB1), multidrug resistance-associated 
protein 4 (MRP4, ABCC4), breast cancer resistance protein (BCRP, ABCG2), and after 
stable transductions either OAT1 or OAT3 were reintroduced[17-20]. In addition, ciPTEC 
express several UDP-glucuronosyltransferases and consume oxygen, suggesting 
intact mitochondrial energy production[21, 22]. Therefore, ciPTEC is a relevant proximal 
tubule cell model with concerted action of different transport mechanisms, suitable 
for in vitro evaluation of drug-induced toxicity. The results of the present study show 
CTR1- and OCT2-dependent cisplatin-mediated toxicity in ciPTEC, which is alleviated 
in presence of active OAT1 or OAT3. Reduced sensitivity in OAT1- or OAT3-expressing 
cells was associated with a trend towards reduced cisplatin accumulation due to lower 
OCT2 uptake capacity. Since expression of OATs affects toxicity induced by drugs that 
are typically imported by OCTs, simultaneous expression of basolateral solute carrier 
transport proteins is important for in vitro drug-induced toxicity evaluation.
Methods and materials
Cell culture
Conditionally immortalized proximal tubule epithelial cells (ciPTEC-parent) were 
developed as described by Wilmer et al. with informed consent of the donors in 
accordance with the approved guidelines of the Radboud Institutional Review 
Board[18]. ciPTEC-OAT1 and ciPTEC-OAT3 were derived from ciPTEC-parent cells and 
demonstrate constitutive expression of organic anion transporter 1 (OAT1) or 3 
(OAT3), respectively, as described by Nieskens et al.[17]. ciPTEC constitutively expressing 
eYFP (ciPTEC-eYFP) were developed by transduction of eYFP from the COX8-eYFP 
vector[23] into the same pLenti4/V5-DEST vector as used for the OAT constructs, by 
LR recombinant reaction using Gateway Cloning Technology (Invitrogen, Carlsbad, 
USA) and resulting in expression vector pLenti4/V5-EX-CMV-TetO2-eYFP. Upon 
transduction as described for ciPTEC-OAT1 and -OAT3, ciPTEC-eYFP cells were selected 
for YFP fluorescence using BD FACSAria SORP flow cytometer (BD biosciences, San 
Jose, USA). Proliferating cell culture was maintained up to 90% confluency using T75 
culture flasks (Greiner Bio-One, Kremsmünster, Germany) at 33°C and 5% v/v CO2. 
Cells were seeded 7 or 8 days prior to the experiment in either T75 culture flasks 
(Greiner Bio-One), 12-well plates (Greiner Bio-One) or 96-well plates (Corning Life 
Sciences, New York, USA) with a seeding density of 55,000 cells/cm2 for ciPTEC-parent, 
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63,000 cells/cm2 for ciPTEC-OAT1 and 82,000 cells/cm2 for ciPTEC-OAT3. Cells were 
subsequently incubated for 24 h at 33°C and 5% v/v CO2 to stimulate proliferation, 
followed by 6 or 7 days at 37°C and 5% v/v CO2 to allow differentiation and monolayer 
formation, referred to as maturation. Cells were cultured using Dulbecco’s modified 
eagle medium (DMEM HAM’s F12, Life Technologies, Paisly, UK), supplemented with 
5 μg/ml insulin, 5 μg/ml transferrin, 5 μg/ml selenium, 35 ng/ml hydrocortisone, 10 
ng/ml epidermal growth factor (EGF), 40 pg/ml tri-iodothyronine (Sigma, St. Louis, 
USA), and 10% fetal calf serum (FCS, Greiner Bio-One), and is referred to as complete 
medium (CM). Medium in which FCS was omitted, is referred to as serum free medium 
(SFM). The medium was refreshed every 2 to 3 days, supplemented with 1% penicillin/
streptomycin (Invitrogen) only at 33°C.
Viability assay
To evaluate cisplatin-induced toxicity, viability of ciPTEC-parent, ciPTEC-OAT1 and 
ciPTEC-OAT3 was evaluated by an MTT assay[24]. Briefly, ciPTEC were matured in 96-
well plates, washed 3 times with SFM, and subsequently exposed to cisplatin (8.7-222 
µM, Sigma) in SFM for 24 h. To evaluate the effect of competitive transport inhibitors 
on cisplatin-induced toxicity, cisplatin was co-exposed with probenecid (100 µM, 
Sigma), diclofenac (50 µM, Sigma), cimetidine (1.25 mM, Sigma) or pyrimethamine 
(10 and 100 nM, Sigma). For probenecid, a pre-exposure during ciPTEC maturation 
was additionally performed for 6 days in CM. Following cisplatin exposure, cells were 
washed 3 times with SFM and incubated with 0.5 mg/ml MTT (Sigma) in SFM for 3 h 
at 37°C. Formazan crystals formed in viable cells were dissolved in dimethyl sulfoxide 
(DMSO, Merck, New Jersey, USA) on a microplate shaker (VWR, Radnor, USA) for 1 h. 
Absorption was measured at 560 nm, subtracting the background at 670 nm, using 
the BioRad Benchmark Plus (BioRad, Hercules, USA). All values were normalized to 
unexposed control. Results were plotted with GraphPad Prism (version 5.03, GraphPad 
Software, San Diego, USA) using non-linear regression with four parameters (variable 
slope) on log-transformed x-values.
Cisplatin accumulation
To evaluate the effect of OCT2- and MATE-mediated transport on intracellular 
cisplatin accumulation, ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 were matured 
in T75 culture flasks, washed once in CM and exposed to cisplatin (250 µM, Sigma), 
with and without OCT2 and MATE substrates cimetidine (1.25 mM, Sigma) or 
pyrimethamine (100 nM, Sigma) in CM for 90 min. Cells were washed 3 times in HBSS 
(37°C), harvested using accutase (Invitrogen) and placed on ice. Cell suspensions 
were centrifuged at 1,500 rcf for 5 min (4°C) and cell pellets were resuspended in 
200 µl nitric acid (100 mM, Merck). Lysates were obtained by applying 3 freeze-thaw 
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cycles of liquid nitrogen and a 37°C waterbath, followed by centrifugation at 10,000 
rcf for 10 min (4°C). Cisplatin content of cell samples was evaluated using an atomic 
absorption spectrophotometer AAnalyst800 (Perkin Elmer, Waltham, USA) equipped 
with a transversally heated graphite tube atomizer and a platinum hollow cathode 
lamp (Photron, Melbourne, Australia), loaded with 20 µl of each sample, as described 
in detail before[25, 26]. All values were corrected for blank (unexposed), normalized to 
ciPTEC-parent (for uninhibited control) or uninhibited control of each respective 
cell line (for competitive inhibitors) and results were plotted with GraphPad Prism 
(version 5.03, GraphPad Software).
Gene expression
To evaluate expression of drug transporter genes involved in cisplatin influx and efflux, 
ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 were matured in 12-well plates, washed 
3 times and exposed to SFM for 24 h, before total RNA was isolated using the RNeasy 
Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturer´s instructions. 
When evaluating Nrf2 pathway induction, SFM was supplemented with 50 nM 
bardoxolone methyl (CDDO-Me, Sigma), cDNA was synthesized using M-MLV Reverse 
Transcriptase (Promega, Madison, USA), according to the manufacturer’s instructions. 
mRNA expression levels of transporters were determined using gene-specific primer 
probe sets obtained from Life Technologies: OCT2 (SLC22A2, hs01010723_m1), 
MATE1 (SLC47A1, hs00217320_m1), MATE2-K (SLC47A2, hs00945650_m1), MRP2 
(ABCC2, hs00166123_m1), NQO1 (hs01045993_g1), GCLC (hs00155249_m1), GAPDH 
(hs99999905_m1) and TaqMan Universal PCR Master Mix (Applied Biosystems, Foster 
City, USA). Real-time qPCR reactions were performed using CFX96 Touch Real-Time 
PCR system (BioRad) according to the manufacturer’s instructions, and analysed 
by CFX Manager software (version 1.6, BioRad). mRNA levels were calculated using 
GAPDH as reference gene and expressed as either -ΔΔCt or fold change (2
-ΔΔCt) 
compared to ciPTEC-parent. Results were plotted with GraphPad Prism (version 5.03, 
GraphPad Software).
ASP accumulation
To evaluate the accumulation of hOCT2 model substrate ASP+[27, 28]; ciPTEC-parent, 
ciPTEC-OAT1 and ciPTEC-OAT3 were matured in 96-well plates[19]. Prior to the 
experiment, cells were washed 3 times in HEPES-Tris buffer, consisting of 132 mM 
NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM glucose, 10 mM Hepes, buffered 
to pH=7.4 using Tris pH=8.8. Next, cells were exposed to ASP+ (4-di-1-ASP+, 0.8-50 
µM, Thermo Scientific, Waltham, USA) with and without cimetidine (1.25 mM, Sigma), 
pyrimethamine (10 and 100 nM, Sigma) or probenecid (100 µM, Sigma) for 1 h at 
37°C. For probenecid, a pre-exposure during ciPTEC maturation was additionally 
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performed for 6 days in CM to study the effect of long-term OAT activity inhibition 
on ASP+ transporting proteins. After accumulation for 1 h, the fluorescent signal 
was measured (excitation 485 nm; emission 590 nm) using a Victor X3 plate reader 
(Perkin Elmer, Waltham, USA). Values were corrected for extracellular signal (empty 
wells with corresponding ASP+ concentration) and either presented as arbitrary units 
(for kinetic curves) or normalized to control (for competitive inhibitors). Results were 
plotted with GraphPad Prism (version 5.03, GraphPad Software) using Michaelis-
Menten regression analysis for concentration-dependent transport rate curves.
Glutathione level
To evaluate total cellular glutathione level, ciPTEC were matured in 6-well plates and 
glutathione level was evaluated using the Glutathione Assay Kit (Sigma), according 
to the manufacturer’s instructions. Briefly, cells were harvested using accutase 
(Invitrogen), washed with HBSS and deproteinized with 5% sulfosalicylic acid (Sigma). 
Lysates were obtained by applying 2 freeze-thaw cycles of liquid nitrogen and a 37°C 
water bath, followed by 5 min incubation on ice and centrifugation at 10,000 rcf for 
10 min (4°C). Samples were measured undiluted and absorption was evaluated at 412 
nm every min for 5 min, using the Benchmark Plus (BioRad). All values were corrected 
for blank, normalized to ciPTEC-parent and results were plotted with GraphPad Prism 
(version 5.03, GraphPad Software).
Data analysis and statistic
All data analysis and statistics were performed using GraphPad Prism (version 
5.03, GraphPad Software) and presented as mean±S.E.M. of three independent 
experiments (n=3) performed in experimental triplicate, unless stated otherwise. 
For calculation of EC50 values, log cisplatin concentration versus viability was plotted 
after background subtraction. Statistics were performed by Student’s t-test (two-
tailed, α=0.05) or by two-way ANOVA (two-tailed, α=0.05) using the Bonferroni post 
test (p<0.05), as indicated in the figures. 
Results
The toxic potential of cisplatin was evaluated in parent ciPTEC by exposure for up to 
72 h, which resulted in a concentration- and time-dependent loss in cell viability as 
measured via the MTT assay, presented in Figure 3.1A. To elucidate the role of influx 
transporter activity on cisplatin-induced toxicity, ciPTEC-parent was co-exposed to 
cisplatin in presence of the OCT2 substrate cimetidine or CTR1 substrate CuSO4 for 24 
h. Both substrates significantly attenuated toxicity of cisplatin, demonstrating their 
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involvement in uptake and related toxicity of the drug (Figure 3.1B). Next, cisplatin 
exposure to ciPTEC either expressing OAT1 or OAT3 demonstrated reduced sensitivity 
compared to ciPTEC-parent, reflected by increased TC50 values, for which the largest 
shift was observed for ciPTEC-OAT3 (Figure 3.1C, Table 3.1). The involvement of OAT-
mediated transport in cisplatin-induced toxicity was investigated further by cisplatin 
exposure in the presence of OAT substrates probenecid and diclofenac. These did not 
affect the cytotoxicity after 24 h nor after 7 days of pre-exposure, suggesting that 
OAT-mediated influx is not directly involved in reducing cisplatin sensitivity, nor that 
OAT transport results in the induction of protective cellular changes on a long term 
(Table 3.1). It should be noted that 7-day exposure to competitive inhibitor solvent 
(DMSO, 0.1% v/v) slightly reduced cisplatin-induced toxicity, which may be explained 
by inactivation of the drug by prolonged exposure to DMSO (Table 3.1)[29]. In order 
to avoid possible adaptive responses that may affect drug sensitivity, cisplatin 
preconditioning at shorter incubation times was not performed. Moreover, longer 
term exposures usually take place in vivo when patients are treated with cisplatin, 
making 24 or 48 h exposures clinically more relevant. To investigate the intracellular 
capacity to handle oxidative stress induced by cisplatin, total glutathione content was 
analysed in the three cell lines. No significant changes were observed in glutathione 
content between ciPTEC-parent, ciPTEC-OAT1 (p=0.44) and ciPTEC-OAT3 (p=0.56) 
(Supplemental Figure S3.1). As decreased sensitivity to cisplatin might be due to 
the transduction process used to over-express OAT1 or OAT3, we evaluated cisplatin 
sensitivity in ciPTEC expressing enhanced yellow fluorescent protein (ciPTEC-eYFP) 
generated by the same transduction methodology. No difference in toxicity (p=0.53) 
was observed between ciPTEC-eYFP (TC50 39±7 µM) and ciPTEC-parent (TC50 34±1 
µM, Table 3.1), supporting our hypothesis that OAT protein expression is responsible 
for diminished cisplatin-sensitivity in OAT1 or OAT3 expressing cells and excluding 
nonspecific aberrations induced by the transduction methods. 
The next step was to determine cisplatin accumulation in the three cell lines, which 
showed a reduced trend in ciPTEC-OAT1 (p=0.29) and ciPTEC-OAT3 (p=0.12) as 
compared to ciPTEC-parent after exposure to excess cisplatin concentrations for 
90 min (Figure 3.2A). Hence, cisplatin accumulation in the cell lines was directly 
associated with their sensitivity to cisplatin as assessed by cell viability. This could 
be the result of decreased OCT2 expression levels or increased MATE1 and MATE2-k 
expression, which facilitate cisplatin influx and efflux, respectively. ciPTEC expressing 
OAT3 showed slightly but significantly decreased OCT2 (SLC22A2) gene expression 
of 0.4±0.1 fold, while the 0.5±0.1 fold reduction in ciPTEC-OAT1was not significant. 
On the other hand, MATE1 (SCL47A1) was 16.2±0.3 fold increased in ciPTEC-OAT1 
and 6.1±0.7 fold in ciPTEC-OAT3 (Figure 3.2B, Ct values are shown in Supplemental 
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Figure 3.1 Cisplatin sensitivity in ciPTEC is reduced by OAT1 and OAT3 expression, and is 
dependent on OCT2- and CTR1-mediated transport. (A) Time and dose- dependent decrease in 
viability of ciPTEC-parent following exposure to cisplatin (8.7-222 µM) for 24, 48 or 72 h as determined 
by MTT assay (mean±S.E.M., n=3). (B) Decreased viability of ciPTEC-parent upon cisplatin exposure 
could be partially restored by competitive inhibition of OCT2 (cimetidine;1.25 mM) or CTR1 (CuSO4; 
1.25 mM) for 24 h, determined by MTT assay (mean±S.E.M., n=3, *p<0.05, **p<0.01; compared to 
control by Student’s t-test). (C) Reduced sensitivity of ciPTEC-OAT1 and ciPTEC-OAT3 following 
exposure to cisplatin (8.7-222 µM) for 24 h compared to ciPTEC-parent, as determined by MTT assay 
(mean±S.E.M., n=3). Results are normalized to unexposed ciPTEC. 
Table 3.1 Cisplatin-induced toxicity is independent of OAT-mediated transport in ciPTEC-OAT1 
and ciPTEC-OAT3. TC50 values (represented in µM) calculated from MTT viability assays following 
cisplatin (8.7-222 µM) exposure for 24 h are not affected by 24 h (n=3) and 7 day (n=6) competitive 
inhibition of OAT (probenecid, 100 µM; diclofenac, 50 µM) in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-
OAT3 (mean TC50±S.E.M., *p<0.05, ***p<0.001; compared to ciPTEC-parent, no significant differences 
were found for treatments by two-way ANOVA, N.D. is not determined).
co-exposure (24 h) co- and pre-exposure (7 days)
- + - +
ciPTEC-parent
probenecid
diclofenac
33 ± 3
34 ± 1
29 ± 4
34 ± 1
47 ± 4
N.D.
45 ± 3
N.D.
ciPTEC-OAT1
probenecid
diclofenac
53 ± 2*
45 ± 6
49 ± 3
45 ± 4
45 ± 6
N.D.
45 ± 6
N.D.
ciPTEC-OAT3
probenecid
diclofenac
92 ± 8***
64 ± 11*
93 ± 7***
62 ± 13*
80 ± 2***
N.D.
76 ± 6***
N.D.
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Table S3.1). In addition, MATE2-k gene expression was increased in ciPTEC-OAT1, 
but decreased in ciPTEC-OAT3. Although MRP2 (ABCC2) expression has also been 
associated with reduced cisplatin sensitivity[30], we did not find differential regulation 
of this drug transporter between the three cell lines studied (Supplemental Table 
S3.2). To evaluate the functional contribution of influx and efflux transporters further, 
cisplatin accumulation was analyzed in the presence of the competitive OCT2 
inhibitor cimetidine and resulted in a reduction of intracellular cisplatin levels, that 
was significant for ciPTEC-OAT1, but not for ciPTEC-parent (p=0.32) or -OAT3 (p=0.33). 
Pyrimethamine did not affect cisplatin accumulation at concentrations for which it is 
a selective MATE1 substrate[31], suggesting a limited role of MATE-mediated efflux in 
the current experimental conditions (Figure 3.2C). Competitive MATE inhibition by 
pyrimethamine did not affect cisplatin-induced toxicity following co-exposure for 24 
h, again supporting the limited role of MATE in the current conditions (Table 3.2).
To study the influence of OAT expression on OCT2 protein activity in more detail, we 
investigated uptake of ASP+ as specific substrate for the transporter in all ciPTEC cell 
lines in presence and absence of OCT2, MATE and OAT substrates. Vmax of ASP
+ uptake 
was significantly reduced in ciPTEC-OAT1 (13.1±0.3 min-1) and ciPTEC-OAT3 (21.6±0.6 
min-1) compared to ciPTEC-parent (23.5±0.1 min-1), suggesting that OCT2-mediated 
uptake capacity of ASP+ is reduced in ciPTEC expressing OAT1 or OAT3 (Figure 3.3A, 
Table 3.3). As expected, competitive inhibition of OCT2 by cimetidine reduced ASP+ 
accumulation (Figure 3.3B), while the competitive MATE inhibitor pyrimethamine did 
not affect ASP+ accumulation, suggesting that ASP+ is transported by OCT2 and not 
by MATE, which is in line with cisplatin accumulation assays (Figure 3.3C). Competitive 
OAT inhibition by probenecid did not affect ASP+ accumulation after 24 h (Figure 
3.3D), neither after 7 days (Figure 3.3E) of treatment, suggesting that OAT-mediated 
uptake did not regulate OCT2 transport capacity.
The Nrf2 pathway is known to attenuate cisplatin-mediated toxicity by regulation of 
cisplatin transporters[32]. Therefore, the involvement of this pathway in the regulation 
of OCT2 and MATE transporters was evaluated in ciPTEC. Bardoxolone stimulated 
the  Nrf2 pathway in ciPTEC parent, as assessed by increasing expression of both 
target genes NQO1 and GCLC upon 24 h exposure by a factor of 6.1±0.1 and 4.1±0.2, 
respectively (Figure 3.4A). This was accompanied by a 1.7±0.2 fold increased MATE1, 
a 8.5±0.6 fold increased MATE2-k and a 0.3±0.1 fold decreased OCT2 expression, 
supporting the nephroprotective effect of Nrf2. A similar decrease in OCT2 
expression was observed for ciPTEC-OAT1 and ciPTEC-OAT3, as described above. The 
involvement of Nrf2 in differential regulation of cisplatin transporters in ciPTEC-OAT1 
and ciPTEC-OAT3 compared to ciPTEC-parent could however not be confirmed, as 
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Table 3.2 Cisplatin-induced toxicity is independent of MATE-mediated transport in ciPTEC-
parent, ciPTEC-OAT1 and ciPTEC-OAT3. TC50 values (represented in µM) calculated from MTT 
viability assays following cisplatin (8.7-222 µM) exposure for 24 h are not affected by competitive 
MATE inhibition (pyrimethamine, 10 and 100 nM) in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 
(mean TC50, n=2).
control pyrimethamine
10 nM 100 nM
ciPTEC-parent 41 45 46
ciPTEC-OAT1 59 57 57
ciPTEC-OAT3 103 111 136
Figure 3.2 Decreased intracellular cisplatin accumulation and OCT2 gene expression in ciPTEC-
OAT1 and ciPTEC-OAT3. (A) Whole-cell cisplatin content is decreased in ciPTEC-OAT1 and ciPTEC-
OAT3 compared to ciPTEC-parent, following exposure to cisplatin (250 µM) for 90 min. Results are 
normalized to ciPTEC-parent (mean±S.E.M., n=3, performed with 2 experimental replicates, no significant 
differences were found by one-way ANOVA). (B) Gene expression of OCT2 (SLC22A2) is decreased, while 
gene expression of MATE1 (SLC47A1) and MATE2-k (SLC47A2) is increased in ciPTEC-OAT1 and ciPTEC-
OAT3 compared to ciPTEC-parent, using GAPDH as reference gene (mean±S.E.M., n=3, performed with 1 
experimental replicate, *p<0.05, ***p<0.001; compared to ciPTEC-parent by one-way ANOVA). (C) Whole-
cell cisplatin content is decreased by co-exposure to OCT2-substrate cimetidine (1.25 mM), but is not 
affected by co-exposure to MATE-substrate pyrimethamine (100 nM) during exposure to cisplatin for 90 
min in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Results are normalized to control without substrate 
(mean±S.E.M., n=3, performed with 2 experimental replicates, **p<0.01; compared to control by Student’s 
t-test).
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only the Nrf2 target NQO1 was increased 2.7±0.2 fold in ciPTEC-OAT1, while GCLC was 
neither upregulated in ciPTEC-OAT1 nor ciPTEC-OAT3 (Figure 3.4B). This illustrates 
that stimulation of Nrf2 via bardoxolone is distinct from the gene expression pattern 
observed in ciPTEC-OAT1 and ciPTEC-OAT3, indicating that the differences in OCT2 
and MATE expression observed are not solely caused by Nrf2 pathway induction.
Figure 3.3 Reduced ASP+ accumulation reflects attenuated OCT2 transport capacity in ciPTEC-
OAT1 and ciPTEC-OAT3. (A) ASP+ (0.8-50 µM) accumulation for 60 min is decreased in ciPTEC-OAT1 
and ciPTEC-OAT3 compared to ciPTEC-parent, evaluated by intracellular fluorescence intensity 
after 60 min (mean±S.E.M., n=3). (B, C, D) ASP+ (3.1 µM) accumulation for 60 min in ciPTEC-parent, 
ciPTEC-OAT1 and ciPTEC-OAT3 is reduced by (B) competitive inhibition of OCT (cimetidine,1.25 mM), 
but not affected by competitive inhibition of (C) MATE (pyrimethamine,10 and 100 nM) or (D) OAT 
(probenecid, 100 µM), evaluated by intracellular fluorescence intensity. Results are normalized to 
unexposed ciPTEC-parent (mean±S.E.M., n=3, *p<0.05, **p<0.01, ***p<0.001; compared to control 
by Student’s t-test). (E) ASP+ (3.1 µM) accumulation in for 60 min in ciPTEC-parent, ciPTEC-OAT1 and 
ciPTEC-OAT3 is not affected by 7-day competitive OAT inhibition (probenecid,100 µM), evaluated by 
intracellular fluorescence intensity. Results are normalized to unexposed ciPTEC-parent (mean±S.E.M., 
n=2, no significant differences were found for treatment by Student’s t-test).
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Table 3.3 ASP+ accumulation is decreased in ciPTEC-OAT1 and ciPTEC-OAT3. Km (represented in 
µM) and Vmax values (represented in min
-1) calculated from Michaelis-Menten fitted ASP+ accumulation 
assays in ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 (mean±S.E.M., n=3, *p<0.05, **p<0.01, 
***p<0.001; compared to ciPTEC-parent by one-way ANOVA).
Km Vmax
ciPTEC-parent 2.3 ± 0.3 23.5 ± 0.1
ciPTEC-OAT1 4.7 ± 0.4* 13.1 ± 0.3***
ciPTEC-OAT3 6.2 ± 0.3*** 21.6 ± 0.6**
Figure 3.4 Nrf2 pathway activation by bardoxolone in ciPTEC-parent is associated with cisplatin 
transporter regulation, but is not increased in ciPTEC-OAT1 and -OAT3, compared to parent 
ciPTEC. (A) Gene expression of Nrf2 target genes NQO1 and GCLC is increased after 24 h pre-exposure 
to bardoxolone (50 nM), which is associated with decreased OCT2 (SLC22A2) gene expression, while 
gene expression of MATE1 (SLC47A1) and MATE2-k (SLC47A2) is increased in parent ciPTEC, using 
GAPDH as reference gene (mean±S.E.M., n=3, performed with 1 experimental replicate, *p<0.05, 
**p<0.01, ***p<0.001; compared to control by Student’s t-test). (B) Gene expression of Nrf2 target 
genes NQO1 and GCLC is not consistently increased in ciPTEC-OAT1 and ciPTEC-OAT3, compared to 
ciPTEC-parent, using GAPDH as reference gene (mean±S.E.M., n=3, performed with 1 experimental 
replicate, ***p<0.001; compared to ciPTEC-parent by one-way ANOVA).
Discussion
Cisplatin is a well-described nephrotoxicant, affecting the proximal tubule in 
particular. Here, we demonstrate that the human-derived proximal tubule epithelial 
cell model, ciPTEC, is sensitive to OCT2- and CTR1-mediated cisplatin-induced 
toxicity. Expression of OAT1 and OAT3 reduced ciPTEC sensitivity to cisplatin, which 
is independent of OAT transport activity, and is associated with a trend towards 
reduced intracellular cisplatin accumulation, explained by reduced OCT2-mediated 
uptake capacity.
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The mechanism responsible for reduced cisplatin sensitivity in ciPTEC-OAT1 and 
ciPTEC-OAT3 involves reduced OCT2-dependent influx of the drug. ASP+ is a model 
substrate for OCT2 and was used to evaluate OCT2 transport capacity, which was 
decreased in ciPTEC expressing OAT. We can only speculate on how this is regulated, 
but this could involve the Nrf2 pathway, as Nrf2-null mice developed more extensive 
nephrotoxicity after cisplatin treatment compared to wild types[33]. Nrf2-mediated 
signalling reduces expression of OCT2 in rat cortical tissue and MDCK cells, and 
increases expression of MATE1 in primary human proximal tubule cells, reducing 
renal cisplatin accumulation and toxicity[32, 34, 35]. In ciPTEC-parent, the involvement of 
Nrf2 in down-regulation of OCT2 and upregulation of MATE1 could be confirmed 
supporting previous in vivo and in vitro studies[32, 33]. Remarkably, we found a profound 
increase of MATE2-k gene expression, while the effect for MATE1 was less pronounced. 
Regulation of MATE2-k via Nrf2 was recently published when proximal tubule cells 
were exposed to flow[36]. With respect to cisplatin-induced toxicity, OAT expression 
affected OCT2 and MATE1/2-k, for which the direct involvement of Nrf2 remains 
elusive as established target genes of this pathway were not consistently regulated. 
Therefore, the protective effect on cisplatin toxicity via bardoxolone-mediated Nrf-
2 stimulation was not tested in the current study focusing on the differential effect 
of OAT expression. Alternatively, tyrosine kinase inhibitors reduced OCT2 activity 
and oxaliplatin-induced acute neuropathy in vivo, suggesting a role for tyrosine 
phosphorylation in regulation of OCT2[37]. It is important to note that cisplatin 
sensitivity and accumulation were reduced most pronounced for ciPTEC-OAT3, while 
ASP+ accumulation was reduced mostly in ciPTEC-OAT1. This suggests that additional, 
non-elucidated cell protecting mechanisms in parallel of the Nrf2 pathway or tyrosine 
kinase activity might play a role in the protection against cisplatin toxicity. 
In addition to drug transport function, OAT1 and OAT3 are associated with several 
metabolite pathways, including fatty acid, amino acid, nucleic acid, glucose, pyruvate 
and glutathione metabolism[38, 39]. As a result, a hypothesis was postulated on the role 
of drug transporters in detecting and maintaining levels of endogenous metabolites, 
antioxidants, signalling molecules, hormones and nutrients[40, 41]. OAT-mediated 
transport is bidirectional and therefore its activity influences the intracellular 
concentration of counter-transported compounds, including metabolites of the 
citric acid cycle, predominantly alpha-ketoglutarate[42-44]. Reduced or competitively 
inhibited OAT function might therefore reduce energy metabolism, illustrated by 
reduced active transport of para-aminohippuric acid upon inhibition of mitochondrial 
ATP production[45]. This, in turn, may affect drug-induced toxicity response in proximal 
tubules by pre-disposing redox state and supplementing or depleting the energy 
pool. Since reactive oxygen species (ROS) are key players in cisplatin-induced 
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nephrotoxicity, the proximal tubule redox state and cellular content of the ROS 
scavenger glutathione are highly important for sensitivity to drug-induced toxicity[2, 
3]. No significant differences in total glutathione content were observed among the 
ciPTEC cell lines, suggesting that redox metabolism is not directly affected by (lack of ) 
OAT function in ciPTEC. The expression of OAT could have influenced the intracellular 
proton gradient thereby decreasing the membrane potential which drives transport 
by OCTs[46, 47]. This might explain the increased Km values for ASP
+ accumulation in 
ciPTEC-OAT1 and ciPTEC-OAT3 as observed in the present study. Metabolomic 
analysis of compounds involved in energy production, especially of the citric acid 
cycle, may generate a more profound understanding of the role of OAT transporters 
in cellular homeostasis and drug sensitivity.
The present findings contradict previously reported publications, involving 
in vivo studies. Jacobs et al. suggested that cisplatin co-treatment with 
probenecid competitively inhibited OAT-mediated transport, thereby reducing 
the renal clearance of cisplatin and protecting patients from nephrotoxicity, even 
at dose-escalation[15, 16]. In line with this, reduced cisplatin excretion and attenuated 
nephrotoxicity were observed in cisplatin-treated Oat1 knockout mice, and probenecid 
co-treated wild-type mice[14]. The authors of the latter study suggested that cisplatin 
is converted into a highly reactive mercapturic acid metabolite, which is a substrate 
for OAT1 and OAT3, similar as described for cadmium and mercury[48-50]. However, the 
first conversion step involves extra-renal conjugation of cisplatin to glutathione, 
generating a water soluble metabolite filtered by the glomerulus. Proximal tubule 
cells are therefore mainly apically exposed to the conjugated metabolite, suggesting 
limited involvement of basolaterally located OAT1 and OAT3. This indicates that 
current in vitro models underestimate the complexity of drug-induced renal injury. 
To account for the contribution of metabolism, our in vitro model could be extended 
to include pre-exposure of cisplatin to cultured hepatocytes or precision-cut liver 
slices[51]. In contrast to studies in which OAT function contributes to nephrotoxicity, 
the beneficial effects of OAT-mediated transport on renal function have also been 
described. Ischemia reperfusion resulted in severe kidney injury in rats, which was 
accompanied by reduced expression of Oat1 and Oat3. Indomethacin prevented 
ischemia-induced downregulation of Oat1 and Oat3, while probenecid abolished 
indomethacin-mediated attenuation[52]. As cisplatin-induced proximal tubule 
toxicity can induce a similar decrease of Oat1 and Oat3 expression[53], investigating 
indomethacin-mediated regulation of OAT1 and OAT3, might provide an interesting 
mechanism that can explain reduced renal adverse effects.
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Most in vitro models applied in drug-induced toxicity prediction lack human- and 
tissue-relevant expression of transporters and metabolizing enzymes[54-57]. The proximal 
tubule model used here circumvents these issues as it demonstrates a tissue-specific 
expression profile in a human-derived stable cell line. To enable drug-induced toxicity 
evaluation of compounds that require influx by OAT transporters, OAT1 or OAT3 
were re-introduced by lentiviral transfection of parent ciPTEC, generating ciPTEC-
OAT1 and ciPTEC-OAT3[17]. As this method may have induced genetic aberrations, a 
similar transduction process was performed with eYFP, to show that the transfection 
procedure did not significantly affect cisplatin sensitivity.
Functional MATE-mediated transport was lacking in our experimental conditions, 
illustrated by the inability of pyrimethamine to modulate ASP+ and cisplatin 
accumulation, and subsequent cisplatin-induced toxicity. This may be the result of 
limited polarization of ciPTEC under the current culture conditions, although activity 
of OCT2, OAT1 and OAT3 which are exclusively expressed at the basolateral membrane 
in vivo, was demonstrated. Although pyrimethamine is offered extracellularly, which 
may compromise inhibition of MATE-mediated cisplatin extrusion, MATE protein 
levels were below the limit of detection with Western blotting in ciPTEC (data not 
shown). Therefore, MATE transport function was not studied further in ciPTEC. 
Additional experiments using a polarized culture system could be used to enhance 
the expression levels and possibly transport activity of MATE1 and MATE2-k.
ASP+ and cisplatin have been described as MATE1-substrates in vitro and MATE1 
has been shown to mediate efflux of cisplatin in rodents in vivo[9, 10, 31, 58]. The driving 
force for MATE-mediated transport is a counter-directed gradient of H+[59]. Transport 
of cisplatin was demonstrated upon intracellular acidification, resulting in a non-
physiological outward-directed proton gradient and MATE-mediated influx[9]. All 
experiments in ciPTEC were performed at a buffered pH of 7.4, thus lacking driving 
force for MATE. Important to consider is the limited cationic charge of cisplatin in 
buffers that contain a physiological chloride concentration, reflecting blood plasma, 
while it is twofold positively charged when exposed to low chloride, reflecting the 
cytoplasm[60, 61]. Apparent transport affinities might be different for the neutral or 
charged form, possibly affecting accumulation of the drug and further increasing the 
mechanistic complexity of cisplatin-induced toxicity. In short, the in vivo contribution 
of MATE-mediated efflux to cisplatin-induced nephrotoxicity in humans remains to 
be elucidated. Evaluating cisplatin-induced toxicity in bi-compartmental Transwell® 
or 3D culture models that allow for mimicking of the pH gradient as experienced in 
the physiological proximal tubule, may help to elucidate the involvement of MATE in 
this process.
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In conclusion, we demonstrated that expression of OAT1 or OAT3 in a human-derived 
proximal tubule epithelial cell model resulted in reduced sensitivity to cisplatin. This 
was independent of OAT transport function and most likely explained by a reduced 
OCT2-mediated influx capacity. As organic anion transporters influence sensitivity to 
drugs that are typically handled by organic cation transporters, reliable in vitro drug-
induced nephrotoxicity evaluation requires simultaneous expression of basolateral 
solute carrier transport proteins. 
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Supplemental data
Supplemental Figure S3.1 Glutathione content is similar in ciPTEC-parent, ciPTEC-OAT1 and 
ciPTEC-OAT3. Evaluation of whole-cell total glutathione content in ciPTEC-parent, ciPTEC-OAT1 and 
ciPTEC-OAT3. Results are normalized to ciPTEC-parent (mean±S.E.M., n=3; no significant differences 
were found by one-way ANOVA).
Supplemental Table S3.1 Gene expression of OCT2 and MATE1/2-k is differentially regulated 
between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Ct values (A.U.) of OCT2, MATE1 and 
MATE2-k derived from RT-qPCR assays following SFM exposure for 24 h are within the quantifiable 
range and are differentially regulated between ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3 (mean 
Ct±S.E.M., n=3).
ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3
GAPDH 17.7 ± 0.1 17.9 ± 0.1 17.3 ± 0.1
OCT2 (SLC22A2) 33.6 ± 0.2 35.0 ± 0.4 34.8 ± 0.2
MATE1 (SLC47A1) 28.4 ± 0.3 24.6 ± 0.1 25.5 ± 0.1
MATE2-k (SLC47A2) 31.9 ± 0.3 30.1 ± 0.3 32.5 ± 0.3
Supplemental Table S3.2 Gene expression of MRP2 is not differentially regulated between 
ciPTEC-parent, ciPTEC-OAT1 and ciPTEC-OAT3. Ct values (A.U.) of MRP2 derived from RT-qPCR 
assays following SFM exposure for 24 h are not differentially regulated between ciPTEC-parent, 
ciPTEC-OAT1 and ciPTEC-OAT3 (mean Ct±S.E.M., n=3).
ciPTEC-parent ciPTEC-OAT1 ciPTEC-OAT3
GAPDH 18.0 ± 0.2 18.2 ± 0.5 16.8 ± 0.4
MRP2 (ABCC2) 33.1 ± 0.6 33.2 ± 0.6 31.6 ± 0.3
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Abstract
Despite their promising potential as therapeutic molecules, reports of mild urinary 
low molecular weight proteinuria during antisense oligonucleotide therapy 
warrant mechanistic safety assessment studies focusing on the kidney. Treatment 
of Duchenne Muscular Dystrophy patients with drisapersen, a modified 2’O 
methylribose phosphorothioate antisense oligonucleotide, was associated with a 
reversible increase in urinary alpha-1-microglobulin without further kidney injury 
in a clinical study. Here, we used human kidney cells to demonstrate that the 
observed low molecular weight proteinuria reflects a transient disturbance rather 
than a direct, nephrotoxic effect. Oligonucleotides were rapidly taken up in human-
derived conditionally immortalized proximal tubule epithelial cells (ciPTEC) and 
accumulated intracellularly in a dose-dependent manner, without affecting cell 
viability when incubated for up to 7 days. The presence of oligonucleotides affected 
the absorption of alpha-1-microglobulin, albumin and receptor associated protein, 
most likely through competitive inhibition of receptor-mediated endocytosis. In 
addition, confocal microscopy showed accumulation of oligonucleotides stably 
captured in the lysosomes of proximal tubule cells. Therefore, we conclude that these 
phosphorothioate oligonucleotides compete with receptor-mediated endocytosis 
of low molecular weight proteins from the glomerular filtrate without inducing 
irreversible tubular cytotoxic effects.
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Introduction
Single stranded antisense oligonucleotides are a promising therapeutic platform 
to treat a variety of genetic diseases, cancer and viral infections. To improve the 
drug-like properties of these molecules, the backbone structures of antisense 
oligonucleotides have been chemically modified. When the non-bridging oxygen 
atom in the phosphodiester is replaced by sulfur, the resulting phosphorothioate 
(PS) oligonucleotides demonstrate increased protein binding and resistance to 
endogenous nuclease breakdown[1]. Addition of a methyl group to the 2’ hydroxyl 
of the ribose moiety (2ʹ-O-methyl; further referred to as 2’O Me) further improved 
nuclease resistance and target engagement[1, 2]. Antisense oligonucleotides are large, 
water soluble poly-anions and are cleared from the circulation by the kidney, with the 
unbound oligonucleotide being filtered by the glomerulus, followed by reabsorption 
into the proximal tubule epithelium. Due to the high nuclease resistance of synthetic 
antisense oligonucleotides, this results in accumulation of these compounds in the 
kidney, and when exceeding critical threshold levels, may become associated with 
tubule dysfunction in animals and in man[3, 4].
Preferential accumulation of antisense oligonucleotides in the kidney has been 
demonstrated in animal studies, and visualized microscopically by the presence of 
basophilic granules in the cytoplasm of proximal tubule epithelial cells (PTEC)[5-7]. These 
basophilic granules are considered to reflect the physiological clearance mechanism 
of antisense oligonucleotides, and in the absence of associated degenerative 
changes, are not considered of toxicological importance. Dose and concentration 
dependent effects on renal PTEC have been well characterized and described for the 
class of PS 2′-O-methoxyethylribose (MOE) gapmer oligonucleotides, and in view of 
the similarities in physicochemical properties, these principles likely apply to related 
platform of 2’O Me-modified PS antisense oligonucleotides.
It has been hypothesized that antisense oligonucleotides are actively reabsorbed 
from the ultrafiltrate by receptor-mediated endocytosis in PTEC. This is supported 
by the observation of reversible low molecular weight proteinuria of alpha-
1-microglobulin in a clinical trial of the 2’O Me-PS antisense oligonucleotide 
drisapersen treating Duchenne Muscular Dystrophy patients[8]. In addition, uptake of 
antisense oligonucleotides was demonstrated to be saturable, which suggests that 
antisense oligonucleotides in the ultrafiltrate specifically bind to a receptor at the 
apical membrane[9, 10]. However, supporting evidence from mechanistic studies related 
to these in vivo findings is still lacking.
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This study aims to unravel the mechanism of antisense oligonucleotide uptake 
by PTEC and their effect on kidney function, which is an important step in safety 
assessment. Here, cultures of human-derived conditionally immortalized proximal 
tubule cells (ciPTEC) demonstrated uptake of oligonucleotides and accumulation 
in the lysosomal compartment, without affecting cell viability when incubated for 
up to 7 days. Oligonucleotides did reduce the uptake of alpha-1-microglobulin, 
albumin and receptor associated protein, most likely through competitive inhibition 
of receptor-mediated endocytosis. Therefore, our data provide a molecular model for 
antisense oligonucleotide competitively inhibiting receptor-mediated endocytosis in 
PTEC without cytotoxic effects or irreversible tubule dysfunction. 
Materials and Methods
Compounds
The oligonucleotides used in this study have a fully modified 2’O Me ribose PS 
backbone and were synthesized at BioMarin Nederland B.V. (Leiden, The Netherlands). 
Drisapersen (also known as PRO051) is a 20-mer with the sequence 5’- UCA AGG 
AAG AUG GCA UUU CU and targets dystrophin exon 51. AON1 is a 25-mer with the 
sequence 5’- UAU GAG UUU CUU CCA AAG CAG CCU C with 5’-methylated Cs. AON2 
is a 24-mer with the sequence 5’- GAG UUU CUU CCA AAG CAG CCU CUC. The latter 
two AONs target dystrophin exon 55. The fluorophore-conjugated AONs, AON1-Texas 
red and drisapersen-Cy3, were synthesized by Biospring (Frankfurt, Germany) and 
BioMarin Nederland respectively. 
Cell culture
CiPTEC were developed as previously described[11]. In this model, cell proliferation 
is controlled by the expression of a temperature-sensitive mutant of SV large 
T antigen (SV40T), allowing cell expansion at 33°C and differentiation and formation 
of an epithelial monolayer at 37°C. Cells were seeded 7 days before the experiment 
at 55,000 cells/cm2 and grown for 1 day at 33°C and 5 %v/v CO2, followed by 6 days at 
37°C and 5 % v/v CO2 (cell maturation). Cells were cultured using Dulbecco’s modified 
eagle medium (DMEM HAM’s F12, Life Technologies, Paisly, UK), supplemented with 
5 μg/ml insulin, 5 μg/ml transferrin, 5 μg/ml selenium, 35 ng/ml hydrocortisone, 10 
ng/ml epidermal growth factor (EGF), 40 pg/ml tri- iodothyronine (Sigma, St. Louis, 
USA) and 10% fetal calf serum (FCS, Greiner Bio One, Kremsmuenster, Austria). To 
increase sensitivity of cubilin/megalin-mediated uptake, ciPTEC were incubated in 
culture medium without FCS, referred to as ‘serum free medium’ (SFM). Medium was 
refreshed every 2 to 3 days, supplemented with 1% penicillin/streptomycin (pen/
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strep, Invitrogen, Carlsbad, USA) at 33°C and without pen/strep at the maturation 
temperature (37°C). 
Antisense oligonucleotide uptake and determination of 
concentration by hybridization-ligation
To evaluate uptake of antisense oligonucleotides, monolayers of ciPTEC matured in 6-well 
plates for 7 days were washed with 1 ml HBSS (Invitrogen, Carlsbad, USA) and exposed 
to 0.35-11.5 µM AON1 or AON2 for 4 h or 24 h at 37°C. Samples were either harvested 
immediately, or subsequently incubated in SFM as recovery phase for 20 h (4 h exposure) 
or 48 h (24 h exposure) before harvesting. For harvesting, cells were washed 2 times 
with 2 ml HBSS at room temperature, and washed with 1 ml heparin (20 U/ml, Sigma, 
St. Louis, USA) at room temperature by shaking the plates gently, and washed with 2 ml 
HBSS at room temperature again. After complete aspiration of the supernatant, cells were 
lysed in 500 μl RLT buffer (Qiagen, Hilden, Germany) and incubated for 1 min at room 
temperature. Lysates were homogenized by pipetting up and down 3 times and antisense 
oligonucleotide content of 400 μl lysate was evaluated by the hybridization-ligation 
assay as described previously[12]. In brief, after lysis using RTL buffer, ciPTEC incubated 
with AON1 or AON2 were stored at -80°C until analysis. ciPTEC lysates were diluted up to 
1,000X in diluted control ciPTEC lysate (1% in PBS). A signal probe (containing the peptide 
for antibody recognition) and a template (complementary to antisense oligonucleotide 
and the probe) were sequentially added to cell lysates. A ligation step will take place 
only when both oligonucleotide and probe are bound to the template. After this step 
and washing away of the unbound signal probe, enzyme-linked antibodies were used to 
detect the amount of probe– antisense oligonucleotide. 
Antisense oligonucleotide fluorescent imaging 
To visualize the subcellular localization of antisense oligonucleotides in ciPTEC, cells 
were incubated for 4 and 24 h with fluorescently labeled oligonucleotides (AON1-
Texas red or drisapersen-Cy3) in normal culture medium, in absence or presence 
of BSA-Alexa-Fluor®647 (ThermoFisher Scientific A34785, 5 μg/ml) or RAP-GST 
(recombinant protein produced in house, 2.5 μg/ml). After incubation cells were 
washed and incubated with Hoechst to stain the nucleus. Cells incubated with 
drisapersen-Cy3 and BSA-Alexa-Fluor®647 were imaged directly (live cells) whereas 
the cells incubated with AON1-Texas red and RAP-GST were first fixed (4% PFA for 
15 min at RT) and permeabilised (0.1% Triton-X-100, 15 min at RT) before overnight 
incubation with anti-GST-ab (GE Healthcare 27457701, Goat polyclonal, 1:1600 in 1% 
BSA/PBS) and staining with a fluorescently labeled secondary ab (Alexa Fluor 488, 
Donkey anti goat, 1:500 in 1% BSA/PBS). Images were taken with a Yokogawa CV7000 
confocal imager and analyzed using ImageJ. 
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A1M-FITC and BSA-FITC uptake determination by flow cytometry
To evaluate interaction at the megalin/cubilin receptor(s), monolayers of ciPTEC 
were grown in complete medium and matured for 6 days. All A1M-FITC and BSA-
FITC experiments were performed in SFM to improve ligand uptake by the cells. Cells 
were washed and pre-incubated with SFM for 24 h at 37°C 5 %v/v CO2. On day 8 
after seeding, cells were washed with SFM and co-incubated in SFM with AON1 or 
AON2 (0.12, 1.15, 11.5 or 115 µM) or drisapersen (0.14, 1.35 or 13.5 µM), and BSA-
FITC (0.73 µM) or A1M-FITC (3.85 µM; α1-microglobulin from antibodies-online.com, 
conjugated to FITC from Life Technologies) for 30 min, 2 h or 4 h at 37°C. A control 
set using BSA-FITC or A1M-FITC only was additionally incubated at 4°C. After co-
incubation at 37°C, cells were washed 2 times with 500 µl HBSS and harvested using 
trypsin-EDTA (Invitrogen, Carlsbad, USA). The cell suspension was next washed using 
HBSS, fixed using 0.5% paraformaldehyde and analyzed on a FACS Calibur (Becton 
Dickinson, Franklin Lakes, USA).
RAP-GST binding and uptake
Protein cell surface binding and protein uptake was evaluated using the uptake of 
receptor associated protein (RAP) containing a glutathione S-transferase (GST) tag 
(RAP-GST). Cells were incubated with medium containing 0.38 µM RAP-GST at 4°C for 
cell surface binding or at 37°C for active protein uptake. After incubation cells were 
washed two times with medium, fixed in 4% PFA for 10 min, washed with PBS and 
permeabilized for 5 min using 0.1% Triton-X-100 in PBS. Next, cells were washed with 
PBS and incubated overnight with primary anti-GST antibody in 1% BSA/PBS (1:1600, 
GE Healthcare, 27457701). Uptake was visualized by 2 h incubation with fluorescently 
labeled secondary ab (1:500, Alexa Fluor 488) after which cells were washed with 
PBS and fluorescence (excitation 485 nm, emission 535 nm) was quantified using 
multiplate reader Victor X3 (Perkin Elmer, Waltham, USA) or using fluorescent 
microscopy. 
Functional uptake assay upon long-term pre-incubation
To evaluate long-term antisense oligonucleotide induced effects on megalin/cubilin-
mediated uptake capacity, BSA-FITC uptake capacity of ciPTEC was evaluated after 
extended pre-incubation. Briefly, monolayers of ciPTEC matured in 96-well plates for 
7 days were exposed to 1.15 µM AON1 in complete culture medium for 7 days at 37°C 
5 %v/v CO2. Exposure medium was refreshed every day. After incubation for 7 days 
at 37°C, cells were washed 2 times with 100 µl SFM and incubated in SFM in absence 
of antisense oligonucleotides for 24 h at 37°C 5 %v/v CO2. BSA-FITC uptake capacity 
was evaluated by washing cells with SFM and incubation with 0.15-7.3 µM BSA-FITC 
in SFM for 4 h at 37°C. Incubation was stopped by washing 3 times with ice-cold 
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(4°C) HBSS (Invitrogen, Carlsbad, USA) and fluorescence was immediately measured 
(excitation 485 nm, emission 535 nm) using the multiplate reader Victor X3 (Perkin 
Elmer, Waltham, USA). 
Viability assay upon long-term pre-incubation
To evaluate toxicity induced by antisense oligonucleotides, viability of 
ciPTEC was evaluated by was determined by a standard spectrophotometric 
3-(4,5-dimethylthiazole-2-yl)-2,5 diphenyltetrazolium bromide (MTT; Sigma) assay 
after extended pre-incubation with AON. Briefly, monolayers of ciPTEC matured 
in 96-well plates for 7 days were exposed to 1.15 µM AON1 (in complete culture 
medium for 7 days at 37°C 5 %v/v CO2. Exposure medium was refreshed every day. 
After incubation for 7 days at 37°C, cells were washed 2 times with 100 µl SFM and 
subsequently MTT assay was performed immediately or cells were first incubated in 
SFM in absence of antisense oligonucleotides for 24 h at 37°C 5 %v/v CO2, before 
MTT was performed. For MTT assay, cells were incubated with 0.5 mg/ml thiazolyl 
blue tetrazolium bromide (MTT, Sigma, St. Louis, USA) for 3 h at 37°C in absence of 
antisense oligonucleotides. Formazan crystals formed in viable cells were dissolved 
in dimethyl sulfoxide (DMSO, Merck, Whitehouse Station, USA) and optical density 
was measured (560 nm, background at 670 nm was subtracted) using Benchmark 
Plus (Bio-Rad, Hercules, USA).
Data analysis and statistics
For antisense oligonucleotide uptake assays, data are presented as lysate 
concentration and plotted with GraphPad Prism (version 6.07). Calibration curves of 
the analyzed antisense oligonucleotide were prepared by spiking a known amount 
of antisense oligonucleotide to diluted control cell lysate (1%) and used to quantify 
antisense oligonucleotide levels. All analyses were performed in duplicate. For A1M-
FITC, BSA-FITC and RAP-GST uptake and inhibition assays, data are either presented 
as absolute fluorescence values or normalized to the activity of samples without 
antisense oligonucleotide and plotted after background subtraction with GraphPad 
Prism (version 6.07). For MTT viability assay, data were normalized to the viability 
of control cells and plotted with GraphPad Prism. Statistics was performed by one 
or two-way ANOVA (two-tailed, α=0.05) using GraphPad Prism as well. All data are 
presented as mean ± SD of at least two separate experiments (n=2) performed in 
triplicate, unless stated otherwise.
84
Results
To evaluate uptake and internalization of antisense oligonucleotides, ciPTEC 
were maturated for 7 days and incubated with drisapersen or oligonucleotides with 
similar 2’O Me-PS chemistry but different nucleotide sequences, AON1 and AON2 
(Figure 4.1A). Incubations for 4 h or 24 h at 37°C using concentrations ranging from 
0.1x to 10x Cmax of drisapersen in patient clinical trials
[8] showed that AON content 
in ciPTEC increased with longer exposure time and higher concentrations (Figure 
4.1B,C). The recovery period of 20 h or 48 h following AON incubation did not reduce 
AON levels in the cell, indicating that the antisense oligonucleotides are stable inside 
the cells and are not degraded within this time period. Intracellular distribution was 
visualized with confocal microscopy using fluorescently labeled AONs (Figure 4.1D,E), 
which demonstrated that the AONs accumulate within the cell in a vesicular pattern, 
despite the presence of non-specific staining, suggesting uptake by endocytosis. 
In view of the reversible nature of the low molecular weight proteinuria observed 
in patients treated with drisapersen[8], this adverse effect may be the result of 
competition for receptor-mediated endocytosis rather than a consequence of direct 
tubule toxicity. The membrane proteins megalin and cubilin at the apical side of the 
proximal tubule are responsible for this process by binding and uptake of alpha-1-
microglobulin[13, 14], RAP and albumin. RAP is a 39kDa chaperone protein that binds 
megalin with high affinity[15, 16], while albumin is a large plasma protein ~68kD that 
in small amounts can pass the glomerular filter to be efficiently reabsorbed by 
the proximal tubule[17, 18]. Co-localization of the antisense oligonucleotides with 
fluorescently labeled bovine serum albumin (BSA-Alexa-657) (Figure 4.1D) or RAP-
GST (Figure 4.1E), confirmed that the uptake of antisense oligonucleotides in tubule 
cells occurs via the same endocytosis pathway. 
To determine how antisense oligonucleotides affect receptor mediated endocytosis 
in proximal tubule cells, we examined the uptake of fluorescently labeled alpha-
1-microglobulin (A1M-FITC) (Figure 4.2A-D), fluorescently labeled BSA (BSA-FITC) 
(Figure 4.2E-G), and RAP-GST (Figure 4.2H-L) in ciPTEC in the absence or presence of 
antisense oligonucleotides. At 37°C, A1M-FITC was actively taken up by ciPTEC over 
time (Figure 4.2A) and could be specifically inhibited by competition with excess 
unlabeled alpha-1-microglobulin (Figure 4.2B). When increasing concentrations of 
antisense oligonucleotides (AON1 or drisapersen) were added, A1M-FITC uptake was 
reduced in ciPTEC in a time- and concentration-dependent manner (Figure 4.2C-D), 
suggesting competitive interaction with the same receptor. Co-incubation with AON1 
or AON2 also significantly inhibited BSA-FITC uptake (up to 50%) in ciPTEC at both 30 
min and 4 h in a concentration-dependent manner (Figure 4.2E-G). The presence of 
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Figure 4.1 Endocytic uptake and limited degradation of antisense oligonucleotides in ciPTEC. 
(A) Schematic overview of the different AON incubation and recovery times in ciPTEC. Accumulation 
of AON1 (0.35-11.5 µM) (B) or AON2 (0.35-11.5 µM) (C) in ciPTEC when incubated for 4 h and 24 h at 
37°C and harvested immediately, or when followed by a recovery period of 20 h and 48 h respectively 
(n=1). Uptake after 24 h of fluorescently labeled Driaspersen (in red) with BSA (green) (D), or 
fluorescently labeled AON1 (red) with RAP-GST (green) (E), nuclei are stained blue (Hoechst). 
A
B C
ED
86
A B
C
E F G
D
H
K L
I J
87
4
< Figure 4.2 Antisense oligonucleotides compete with protein reabsorption in proximal tubular 
cells in vitro. (A) A1M-FITC uptake by ciPTEC, for 2 h at 4°C, and for 2 h and 4 h at 37°C (n=2). (B) A1M-
FITC uptake by ciPTEC incubated for 2 h at 37°C in the presence or absence of an equal concentration 
of unlabeled A1M (3.85 µM) (n=2). (C-D) A1M-FITC (3.85 µM) uptake by ciPTEC when co-incubated 
with different concentrations of (C) AON1 (0.12, 1.15, 11.5 and 115 µM) or (D) drisapersen (0.14, 
1.35 and 13.5 µM) for 2 h and 4 h at 37°C, relative to uptake without antisense oligonucleotide, as 
evaluated by flow cytometry (n=2). (E) Fluorescent intensity after BSA-FITC uptake by ciPTEC when 
incubated at 4°C or 37°C for either 30 min or 4 h (n=2). (F,G) BSA-FITC uptake by ciPTEC when co-
incubated with AON1 or AON2 for 30 min or 4 h at 37°C, as evaluated by flow cytometry (n=2). (H) 
RAP-GST cell surface binding (4°C for 30 min) and active uptake in proximal tubular cells (37°C at 1 
and 4 h) in absence of antisense oligonucleotide. Co-incubation with either AON1 or drisapersen 
inhibited the cell surface binding of RAP-GST (30 min at 4°C) (I) and the active uptake of RAP-GST (4 
h at 37°C) (J) in a concentration-dependent manner. Cells were pre-incubated with AON1 for 24 h (K) 
and 48 h (L) prior to analyzing RAP-GST endocytic capacity in absence of AON1. ND is not determined. 
**p<0.01, ***p<0.001. A.U.= arbitrary units
Figure 4.3 Long-term exposure to antisense oligonucleotides does not affect ciPTEC 
endocytosis capacity or result in cytotoxicity. (A) Schematic overview of ciPTEC pre-incubation 
with AON1, recovery and evaluation of BSA-FITC uptake capacity and MTT viability assay. (B) BSA-FITC 
(0.15-7.3 µM) uptake by ciPTEC for 4 h at 37°C when pre-incubated with AON1 (1.15 µM) for 7 days 
and subsequently recovered for 24 h, as evaluated by multiwell platereader (n=2). (C) Viability of 
ciPTEC after exposure to AON1 (1.15 µM) for 7 days, with and without recovery, relative to cell viability 
without exposure (n=2). 
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antisense oligonucleotides also interfered with RAP-GST cell surface binding at 4°C 
(up to 70% reduction in binding) and inhibited active uptake of RAP-GST at 37°C (up 
to 25% reduction) (Figure 4.2H-J). To determine whether decreased RAP-GST uptake 
at 37°C was due to a non-specific cytotoxic response through AON accumulation, 
ciPTEC were pre-incubated only with AONs for 24 h or 48 h prior to incubation with 
the labelled substrate. This pre-incubation did not significantly inhibit the uptake of 
RAP-GST at 37 °C (Figure 4.2H,I), indicating that AON incubation directly competes 
with receptor binding capacity and has no cytotoxic effect that affects megalin/
cubilin mediated endocytosis rate. Some residual inhibition was seen at 4°C after pre-
incubation, which is likely due to occupation of ligand binding sites at the cell surface, 
which were not washed away at 4°C. Together these data indicate that antisense 
oligonucleotides directly compete with receptor-mediated protein reabsorption in 
ciPTEC, without adversely affecting the reabsorption capacity of the cells.
To evaluate long-term effects of renal proximal tubule exposure to antisense 
oligonucleotides, ciPTEC were pre-incubated with AON1 for 7 days, followed by 24 h 
recovery before BSA-FITC uptake capacity and cell viability were determined (Figure 
4.3A). In the absence of AON1, BSA-FITC was internalized via endocytosis by ciPTEC 
in a concentration-dependent manner, reaching partial saturation at the highest 
concentrations. The 7-day pre-incubation with AON1 did not affect BSA uptake by 
ciPTEC (Figure 4.3B). In addition, cell viability was not significantly changed following 
7-day exposure to AON1, both with and without 24 h recovery (Figure 4.3C). These 
results argue for intact endocytosis function in ciPTEC upon long-term exposure to 
antisense oligonucleotides, without causing irreversible cytotoxicity.
Discussion
Antisense oligonucleotide accumulation in renal proximal tubules has been 
observed widely, however, little is known about the cellular mechanism and 
potentially hazardous consequences. In this study, we investigated the effects of 
2’O Me-PS oligonucleotides on epithelial reabsorption and cytotoxicity in vitro. 
Our data demonstrate that antisense oligonucleotides compete for receptor-
mediated endocytosis with endogenous proteins and accumulate in the lysosomal 
compartment of the proximal tubule model ciPTEC. This did not affect endocytosis 
capacity or viability of PTEC after exposure for up to 7 days. 
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A clinical study in which patients with Duchenne muscular dystrophy were treated with 
the antisense oligonucleotide drisapersen that changes the splicing of the dystrophin 
gene (DMD) to correct its function, showed increased urinary  alpha-1-microglobulin 
levels[8]. But no signs of proximal tubule dysfunction (renal Fanconi’s syndrome) were 
found and, moreover, urinary elevation of alpha-1-microglobulin was not progressive, 
as values moved towards normal after treatment. This transient proteinuria suggests 
a reversible interference with protein reabsorption in the proximal tubule[8]. Although 
there are no indications that oligonucleotide treatment affected kidney function in 
patients with Duchenne muscular dystrophy[19], rare cases of tubule nephrotoxicity have 
been reported[3, 20]. In both cases, (sub)chronic treatment with antisense oligonucleotides 
that demonstrate high renal clearance induced acute tubule necrosis which was 
reversible after drug discontinuation[3, 20]. Pro-inflammatory immune responses, such 
as complement- and TLR-receptor activation have been observed more commonly in 
monkeys[6, 21] and rodents[22-24], respectively, causing glomerulonephritis and vasculitis. 
In addition to base pair sequence and base modifications, backbone chemistry is the 
major contributor to pro-inflammatory effects[23, 25, 26]. Since immune-mediated adverse 
effects present significant problems for clinical use if found, future studies should 
evaluate the immunomodulatory potential of the antisense oligonucleotides used 
in this study.
To understand the cellular mechanism and demonstrate a link between oligonucleotide 
treatment and proteinuria, we evaluated in vitro protein reabsorption by receptor-
mediated endocytosis in human proximal tubule cells in the presence and absence of 
oligonucleotides. The ciPTEC model is human-derived and has functional basolateral and 
apical drug transporters, including OCT2, Pgp and MRPs, and intact receptor-mediated 
endocytosis, including expression of megalin and cubilin[11, 27, 28]. These receptors play 
a pivotal role in reabsorption of low molecular weight protein in PTEC and mutations 
in these genes have been directly linked to proteinuria in both animal models and 
human disease[29]. In line with this, saturation of the receptors can lead to competitive 
inhibition causing low molecular weight proteinuria, which was hypothesized here to 
be causative for the observed proteinuria upon oligonucleotide treatments. Alpha-1-
microglobulin and, to a lower extend, albumin are both present in the glomerular filtrate 
and are fully reabsorbed by receptor-mediated endocytosis in PTEC. Incubation with 
antisense oligonucleotides indeed reduced the binding and uptake of megalin ligands 
alpha-1-microglobulin, albumin and the megalin-chaperone protein RAP. In contrast 
to co-incubation studies, pre-incubation with antisense oligonucleotide for 24 h and 
up to 7 days did not diminish protein reabsorption. This suggests a direct competition 
on the receptor level, rather than a reduction in proximal tubule reabsorption capacity 
due to intracellular oligonucleotide accumulation. The comparable effects of three 
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different 2’O-Me PS antisense oligonucleotide indicate a common mechanism of 2’O-
Me PS antisense oligonucleotide-mediated interference with protein reabsorption. 
This finding is in line with literature that describes receptor-mediated endocytosis as 
high-capacity, but low-specificity uptake mechanism[30]. The co-localization studies with 
albumin in endocytic vesicles further supported our hypothesis of receptor mediated 
uptake of oligonucleotides in proximal tubules, as reported in literature[31].
The degradation of oligonucleotides in PTEC follows a first order kinetics and allows 
accumulation until a steady state is reached[25]. Due to the modifications in the backbone 
of drisapersen, its degradation is strongly reduced, with a half-life of up to 2 weeks[25]. 
Human PTEC also efficiently accumulated the oligonucleotides in the current study in 
a time and concentration dependent manner, but no cytotoxic effects were detected 
after 7 days exposure to antisense oligonucleotide at concentrations equivalent to 
peak plasma levels. Consistent with the long half-life of the oligonucleotides used, no 
significant degradation was seen at 20 h or 48 h exposure. Future studies should evaluate 
the long-term degradation of oligonucleotides in PTEC in relation to renal function.
In conclusion, our data indicate that 2’O Me-PS antisense oligonucleotides, including 
drisapersen, directly compete with receptor-mediated endocytosis in PTEC and reduce 
the uptake of endogenous cubilin/megalin ligands such as alpha-1-microglobulin, 
explaining reversible low molecular weight proteinuria observed in treated patients.
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Abstract
The renal proximal tubule epithelium is responsible for active secretion of endogenous 
and exogenous waste products from the body and simultaneous reabsorption of vital 
compounds from the glomerular filtrate. The complexity of this transport machinery 
makes investigation of processes such as tubular drug secretion a continuous 
challenge for researchers. Currently available renal cell culture models often lack 
sufficient physiological relevance and reliability. Introducing complex biological 
culture systems in a 3D microfluidic design improves the physiological relevance 
of in vitro renal proximal tubule epithelium models. Organ-on-a-chip technology 
provides a promising alternative, as it allows the reconstruction of a renal tubule 
structure. These microfluidic systems mimic the in vivo microenvironment including 
multi-compartmentalization and exposure to fluid shear stress. Increasing data 
supports that fluid shear stress impacts the phenotype and functionality of proximal 
tubule cultures, for which we provide an extensive background. In this review, we 
discuss recent developments of kidney-on-a-chip platforms with current and future 
applications. The improved proximal tubule functionality using 3D microfluidic 
systems is placed in perspective of investigating cellular signalling that can elucidate 
mechanistic aberrations involved in drug-induced kidney toxicity.
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Introduction
The main physiological role of the kidneys is to clear endogenous waste products 
from the body. Exogenous drugs and toxins are often cleared via the same elimination 
route, making the kidney susceptible to drug-induced aberrations. Active cellular 
uptake of xenobiotics and metabolites by basolateral transport proteins contribute 
to the nephrotoxic potential of drugs[1]. Renal sensitivity to drug-induced toxicity is 
further stimulated by the high fraction of cardiac output directed to the kidneys. This 
fraction is the driving force for renal filtration and tubular flow, resulting in high renal 
exposure to potential toxins[1, 2].
Early detection of adverse renal effects caused by lead compounds during drug 
development is seriously hampered by low predictive value of classical 2D cell culture 
models: compound attrition due to nephrotoxicity is only 2% in preclinical studies and 
rises to 9% in expensive clinical trials[3]. Recent studies support that reconstruction of 
the physiological microenvironment increases the clinical relevance of renal in vitro 
models and can lead to enhanced in vitro predictivity of drug-induced renal adverse 
effects. 
A kidney-on-a-chip is a microfluidic device that allows culturing of living renal cells 
in 3D channels. Microfluidic technology is able to mimic a complicated 3D kidney 
structure allowing tubule growth, enable compartmentalization, offer constant 
flow resulting in fluid shear stress, and can include many different cell types[4]. By 
recreating the renal tubule microenvironment, in vitro cellular responses are likely to 
approach the in vivo situation better compared to 2D systems. This would improve 
drug-induced toxicity screening and provide a promising tool to study 3D kidney 
regeneration. 
This review will focus on current developments and future perspectives of proximal 
tubule kidney-on-a-chip techniques, with an emphasis on pharmacological 
interactions, drug-induced nephrotoxicity and tubular regeneration. To this end, the 
function of proximal tubule cells and its relation to fluidic shear stress is discussed. 
Finally, the development of multi-organ-chips and possible applications for 
regenerative medicine will be highlighted. 
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Functionality of the proximal tubule epithelium
Reconstruction of a proximal tubule in a physiological relevant environment will 
substantially contribute to our understanding of renal physiology and pharmacology. 
To evaluate the quality of a cultured system in terms of functional characteristics, a 
clear understanding of the relevant transport mechanisms in the proximal tubular 
epithelium is required (Figure 5.1). 
Receptor mediated endocytosis
Connected to Bowman’s capsule, the proximal tubular lumen is exposed to the 
glomerular filtrate. The apical membrane of the proximal tubule forms a brush border 
and is extremely effective in the reabsorption of vital compounds that are freely 
filtered over the glomerular basement membrane. Low molecular weight proteins are 
largely reabsorbed from the glomerular filtrate via receptor mediated endocytosis. 
At the apical membrane, multi-ligand receptors megalin and cubilin bind low-
molecular weight proteins in the glomerular filtrate with high capacity, which is 
followed by reabsorption via endocytosis[5]. Low molecular weight proteinuria can 
consequently result from defects in this endocytic recycling machinery, for example 
caused by mutations in genes encoding transport proteins that are expressed at the 
lysosomal membranes. In the lysosomes, acidification results in dissociation of the 
receptor-ligand complex. Defects in receptor mediated endocytosis were reported 
for lysosomal transporter proteins chloride channel (CLC)-5 and cystinosin, which are 
associated with Dent’s disease and nephropathic cystinosis, respectively[6, 7]. A kidney-
on-a-chip platform with an apical fluid flow and intact endocytic machinery will be 
valuable in future research of such pathological conditions, moreover as endocytosis 
under flow conditions was demonstrated to be increased[8-10]. 
Researchers often employed Opossum Kidney (OK) or Brown Norway rat yolk sac 
(BN-16) epithelial cells to study receptor mediated endocytosis, as these are known 
for their active megalin mediated endocytic machinery[8, 11, 12]. Although expression 
of megalin and the endocytic capacity is relatively high in these animal derived 
cells, the use of a human renal epithelial cell line will be the preferred model for 
pathological and pharmacological studies. For example, the human kidney cell line 
(HKC)-8 cell line was used to demonstrate that albumin-induced apoptosis targets 
the mitochondria[13] and endocytosis of albumin in HKC-8 could be stimulated by 
phosphorylation of endocytic adaptor disabled-2 (Dab2) via protein kinase B (Akt)
[14]. Albumin reabsorption was also increased in primary human kidney proximal 
tubule epithelial cells exposed to laminar apical flow in a microfluidic device, 
pointing towards the influence of a physiological environment on proximal tubular 
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function[9]. A drawback of primary cells is the limited availability and batch-to-
batch variations. The use of urine-derived proximal tubule epithelial cells allowed 
studying albumin uptake in cells isolated from patients with Dent’s disease or 
nephropathic cystinosis that manifest with albuminuria. To obtain sufficient material, 
urine derived cells from healthy subjects and patients with mutations in the CTNS 
or CLC5 genes were conditionally immortalized using SV40 temperature sensitive 
large T antigen (SV40T) and human telomerase reverse transcriptase (hTERT)[6, 15, 16]. 
These conditionally immortalized proximal tubule epithelial cells (ciPTEC) were used 
to demonstrate intact megalin dependent albumin and RAP reabsorption[16, 17], while 
defects in albumin reabsorption via megalin and cubilin mediated endocytosis were 
demonstrated in ciPTEC derived from patients with Dent’s disease and nephropathic 
cystinosis[6, 18]. Together, studies using HKC-8 or ciPTEC can elucidate albumin handling 
in renal disease states such as acquired or inherited proteinuria. In respect of this 
review, the demonstration of fluidic shear stress affecting apical albumin handling 
in the proximal tubule epithelium supports that microfluidic devices should be used 
for future research focusing on receptor mediated endocytosis. Apical exposure 
to high levels of albumin under flow conditions can mimic albuminuria and 
microfluidic devices allow detailed (metabolic) analysis of the perfusion medium. In 
addition, urine-derived ciPTEC isolated from genetically well-characterized patients 
manifesting inherited low molecular weight proteinuria can be cultured in a kidney-
on-a-chip to mimic these pathological conditions. 
Transporter-mediated reabsorption
Next to receptor mediated endocytosis, apical membrane transporters of the solute 
carrier family (SLC) are responsible for the reabsorption of vital solutes from the 
glomerular filtrate, like phosphate (NaPi-IIa, SLC34A1, NaPi-IIc, SLC34A3), amino acids 
(members of the SLC1, SLC7, SLC36, SLC38 and SLC43), and glucose (GLUT2, SLC2A2; 
SGLT1, SLC5A1; SGLT2, SLC5A2). Similar to increased albumin uptake under flow 
conditions, Jang and colleagues demonstrated that laminar flow in a microfluidic 
device increased the expression of SGLT2, resulting in improved reabsorption of 
glucose[9], again supporting the role of fluidic shear stress on apical transport function.
Transporter-mediated secretion: drug transporters
The proximal tubule epithelium facilitates renal secretion of waste compounds and 
xenobiotics that are not freely filtered by the glomerulus due to their charge, size 
or because they are protein-bound. This transcellular transport from blood into the 
urine depends on drug transporters acting in concert at the basolateral and apical 
membrane[19]. These polyspecific membrane transporters enable efficient clearance of 
different classes of compounds, viz. organic cations and organic anions. Generally, drug 
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transporters are categorized depending on their driving force: membrane transporters 
using the electrochemical gradient belong to the SLC family, while transporters 
coupled to ATP hydrolysis belong to the ATP binding cassette transporters (ABC). At 
the renal proximal tubule basolateral membrane, organic cation transporter 2 (OCT2; 
SCL22A2) and organic anion transporters 1 (OAT1; SLC22A6) and 3 (OAT3; SLC22A8) 
mediate elimination of waste compounds and xenobiotics from the circulatory system 
into the proximal tubule epithelium[20]. It should be noted that these metabolic waste 
products, often called uremic toxins (e.g. indoxyl sulfate or kynurenic acid) accumulate 
in chronic kidney disease[21]. Next to metabolic waste products, renal elimination of 
many pharmaceutical compounds is very efficient and compete for the same excretion 
pathways[22]. This complicates the use of pharmaceutics in chronic kidney disease 
as drugs potentially compete with accumulating uremic toxins at the site of drug 
transporters, hence, drug serum levels can be elevated. 
Removal of drugs and waste compounds from the circulatory system make the 
proximal tubular epithelium an important target for drug-induced kidney toxicity. 
For example, the dosing of the anti-neoplastic agent cisplatin, often used as a first 
treatment option against solid tumors, is limited due to the risk of nephrotoxicity 
associated with OCT2 transport activity[23]. The group of Ciarimboli used HEK293 cells 
over-expressing human OCT2 to demonstrate the specific involvement of OCT2 in 
drug-drug-interactions of cisplatin with cimetidine. Other studies employed isolated 
human proximal tubules from kidney tissue in which OCT2 transport function was 
demonstrated by analyzing internalization of fluorescent probe 4-(4-dimethylamino)
styryl-N-methylpyridinium (ASP+) over the basolateral membrane[24]. As these studies 
are technically challenging and inter-experimental variations are relatively high, 
human ciPTEC stably expressing functional OCT2 might be more suitable for high-
throughput drug screening[25]. Further improvements could be achieved when such 
stable cell lines are cultured under flow conditions in a 3D tubule structure with an 
apical and basal compartment in order to approach the in vivo situation. 
Intracellular accumulation of substrates internalized via basolateral transport, 
is prevented at physiological conditions by efficient efflux into the proximal 
tubule lumen via ABC and SLC transporters present on the apical membrane or 
via intracellular metabolism. The most widely studied ABC transporter is probably 
p-glycoprotein (Pgp or MDR1; ABCB1), which gene expression was up regulated in 
multidrug-resistant clones of human leukemia and ovarian carcinoma cells[26]. Later 
studies demonstrated the broad expression of this drug transporter on epithelia of 
many tissues such as blood-brain barrier, the kidney, intestine, testis and placenta, 
underscoring their protective role against toxins[27]. More recently, cell-based 
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assays investigating the concerted action of basolaterally expressed OCT2 with 
apically expressed multidrug and toxin extrusion transporters 1 (MATE1; SLC47A1) 
and MATE2-K (SLC47A2) in Madin Darby Canine Kidney cells (MDCK) opened new 
avenues, including predictive renal clearance studies in pre-clinical stages of drug 
development[28, 29]. The advantage of using such double-transfected MDCK cells is the 
formation of a tight epithelial monolayer with a high transepithelial electrochemical 
resistance (TEER). Consequently, active trans-epithelial transport is relatively easily 
exceeding the passive diffusion component. Strikingly, MDCK cells have commonly 
a TEER of >300 Ohm cm-1 while primary proximal tubule cells present a TEER of 
approximately 75 Ohm cm-1 when grown on semi-permeable filter supports[30]. Future 
studies in microfluidic platforms seeded with human proximal tubule cells should 
take these differences in TEER values into account as this challenges trans-epithelial 
transport assays using physiologic models.
Next to organic cation secretion, the renal epithelium efficiently eliminates organic 
anions from the circulatory system. Similar to the adverse effects observed with 
organic cation drug-interactions, co-administration of organic anions can also result 
Figure 5.1 Reabsorption and secretion by renal proximal tubule epithelial cells. Megalin and 
cubilin mediate endocytosis of low molecular weight proteins from the luminal side of the tubule. 
Apical transport proteins (SGLT, GLUT, NaPi, and SLC) mediate reabsorption of essential serum 
components, such as glucose, inorganic phosphate (Pi) and amino acids (aa) from the glomerular 
filtrate. Transcellular transport of organic anions (oa) and organic cations (oc) requires transporter 
mediated influx at the basolateral membrane and transporter mediated efflux at the apical membrane, 
acting in concert to facilitate selective renal elimination of waste compounds or drugs.
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in drug-induced nephrotoxicity. For example, nucleotide analog reverse transcriptase 
inhibitors (NtRTIs) such as adefovir, cidofovir and tenofovir are related to drug-induced 
nephrotoxicity associated with OAT activity[31, 32]. Many researchers have used Chinese 
Hamster Ovary (CHO) cells as a model to over-express OAT1 or OAT3 and demonstrate 
cytotoxicity of organic anions[33-35]. Although CHO-OAT1 has proven to be relevant for 
studying drug interactions at the site of OAT for over a decade, the deficiency of 
the cooperating apical efflux transporters multidrug resistance-associated proteins 
2 (MRP2; ABCC2), and 4 (MRP4; ABCC4) and breast cancer resistance protein (BCRP; 
ABCG2) make incorporation in a kidney-on-a-chip not useful. The use of primary 
proximal tubules cultured directly on semi-permeable inserts with intact organic 
anion influx and efflux transporters allowed to study transepithelial transport of 
p-amino hippurate, however, OAT expression was rapidly decreased[30]. Recently, our 
group demonstrated stable expression of OAT1 and OAT3 in transfected ciPTEC that 
endogenously expressed functional MRP and BCRP transport as well[17, 32]. 
Fluid shear stress induces intracellular signalling in 
the proximal tubule epithelium
The kidneys play a major role in the excretion of waste products, for which 25% 
of cardiac output is directed to the kidneys resulting in approximately 180 L of 
glomerular filtrate entering the renal tubule lumen daily[2]. Consequently, epithelial 
cells lining the renal tubule are exposed to an apical fluid shear stress calculated to 
be approximately 1 dyne•cm-2[10]. Renal tubule cells ‘sense’ apical fluid shear stress by 
a single sensory organelle known as the primary cilium[36]. Cilium-mediated signal 
transduction contributes to differentiation of the renal tubule epithelial tissue.
The renal non-motile primary cilium is a thin organelle (with a diameter of 0.25 µm) 
typically protruding 2 to 3 µm from the apical membrane into the tubule lumen[37]. 
It is present as a single structure on almost all renal cells, except for the intercalated 
cells of the collecting duct[37]. In short, it consists out of 9 circumferentially arranged 
doublet tubulin-based microtubules enclosed by an extension of the cell membrane. 
Cilia were demonstrated to gradually bend in response to fluid shear stress over the 
apical membrane or by direct modulation using a micropipette in cultured MDCK 
cells[38]. The intracellular Ca2+ concentration increased accordingly, requiring Ca2+ 
influx from the apical compartment (Figure 5.2). The response to fluid shear stress was 
completely abolished when the primary cilium was chemically removed by exposing 
MDCK cells to chloral hydrate for 68 hours[39]. However, completely removing the 
cilium via this method likely results in a-specific effects such as affected proliferation, 
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since the cilium is anchored to the cytoskeleton via the basal body, which acts as 
microtubule-organizing centre during mitosis[37]. Targeting structural cilium proteins 
or cilium-mediated signal transduction pathways provide a more specific approach 
to investigate cilium function. Essential for the structure and signal transduction of 
primary cilia are polycystic kidney disease 1 (PKD1) and -2 (PKD2) genes encoding 
the proteins polycystin 1 (PC1) and transient receptor potential channel 2 (TRPP2). 
Loss-of-function mutations in these genes were identified to cause autosomal 
dominant polycystic kidney disease (ADPKD)[40, 41]. Affecting 1 in 1000, ADPKD is the 
most common cause of inherited kidney disease in human adults[42]. It is clinically 
characterized by progressive formation of fluid-filled cysts in the kidney, pancreas 
and liver, together with cardiovascular symptoms[42]. 
PC1 and TRPP2 are transmembrane proteins that interact at the primary cilium to 
form a protein complex (Figure 5.2)[43]. In response to fluid shear stress, PC1 is activated 
resulting in the opening of the TRPP2 channel which allows a localized Ca2+ influx[44]. 
Figure 5.2 Cilium-mediated signal transduction in renal proximal tubule epithelial cells. (A) 
In absence of fluid shear stress, the Ca2+ channel of the PC1-TRPP2 protein complex is closed. The 
PC1 C-terminus undergoes proteolytic cleavage and translocates together with STAT6 to the nucleus 
to function as nuclear transcription factor. (B) In presence of fluid shear stress, the primary cilium 
bends causing the PC1-TRPP2 protein complex to act as channel for extracellular Ca2+. This causes 
a local rise in intracellular Ca2+ concentration, possibly further propagated by a Ca2+ release from 
the endoplasmic reticulum. Cilium-mediated signalling leads to increased cell volume, receptor-
mediated endocytosis, expression of tight-junction protein complexes at apical focal adhesion points 
and polarized expression of AQP1, OCT2 and Na,K-ATPase.
A B
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The signal is then further propagated by triggering release of intracellular Ca2+ from 
the ER, mediated by the ryanodine receptor. In addition to Ca2+ dependent signals, PC1 
was shown to regulate multiple pathways that could explain cyst formation observed 
in ADPKD. Expression of PC1 induces the JAK-STAT pathway, inducing cell-cycle arrest, 
which is absent when mutations prevent formation of the PC1-TRPP2 protein complex[45]. 
In addition, the C-terminal tail of PC1 was found to interact with nuclear transcription 
factor STAT6, which co-localizes with the primary cilium under fluidic conditions 
(Figure 5.2)[46]. When apical fluid shear stress is absent, the C-terminus of PC1 undergoes 
proteolytic cleavage and translocates together with STAT6 to the nucleus where it 
functions as transcription factor, possibly mediating signal transduction. PC1 also 
interacts with tuberin, which is a regulator of mTOR kinase activity[47]. In tubule epithelial 
cells isolated from cysts of ADPKD patients, the mTOR pathway was stimulated, providing 
a possible mechanism for increased cell growth observed in cyst formation[47, 48].
Evolution of renal culture systems towards 3D
2D cultures have been used to study renal physiology, pharmacology and pathology 
for over 50 years. Such 2D models have the advantage to be relatively simple and 
low in cost and form the basis of our current knowledge in cellular mechanisms 
(Figure 5.3). However, 2D cell cultures do not reproduce the in vivo microenvironment 
of the nephron, which likely contributes to the functionally differentiated state of cells. 
To this end, different approaches have been initiated to increase the physiological 
relevance of in vitro culture systems, including incorporation of extracellular matrix 
and application of fluid shear stress.
3D spheroids embedded in a matrix 
To better mimic the in vivo situation, 3D renal culture models were developed that 
incorporate extracellular matrix (ECM) (Figure 5.3). ECM in the kidney consists of 
various types of collagen, glycosaminoglycans, laminin and fibronectin that connect 
to integrin proteins located in the plasma membrane of cells. The basolateral side 
of renal tubule epithelial cells faces ECM mainly composed of collagen type IV 
which dictates the 3D structure of the renal tubule and allows for integrin-mediated 
signalling, regulating cell adhesion, differentiation and regeneration[49]. To mimic the 
basement membrane in vitro, commercially available Matrigel is commonly used. It is 
derived from Engelbreth-Holm-Swarm mouse tumour cells and consists of collagen 
IV, laminin, perlecan and growth factors, which are also found in the basement 
membrane[50]. When single MDCK cells are embedded within Matrigel, fluid-filled 
spheroids will develop by proliferation, polarization and subsequent lumen formation 
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in a step-by-step process[51]. Initially, membrane proteins are randomly distributed 
over the plasma membrane. ECM components, in particular laminin, provide a strong 
basolateral signal, resulting in translocation of apical membrane targeted proteins to 
the membrane opposite from the ECM and finally cause the formation of a polarized 
cell[52, 53]. Tight junction complexes consisting of claudin, occludin and zonula occludens 
1 (ZO-1) proteins are formed and physically separate the apical from the basolateral 
membrane[54]. The final step in lumen formation by MDCK cells in Matrigel involves 
the apical expression of podocalyxin. This glycosylated molecule carries a highly 
negative charge and results in dissociation of cell-cell interactions, except at tight 
junctions, allowing the formation of a fluid-filled lumen[55, 56]. Increased resistance to 
chemotherapeutic drugs was demonstrated in 3D spheroid models of breast cancer 
cell lines MEC (mammary epithelial cell) HMT3522 and MCF-7 (Michigan cancer 
foundation-7) breast cancer cells cultured in Matrigel when compared to standard 2D 
monolayer cultures. These findings point towards the effect of ECM and 3D structures 
on the pharmacological response[57, 58].
Micro-engineered 3D kidney rudiments
While MDCK cells form relatively simple spheroids when cultured in ECM, other cell 
types are able to form more advanced 3D tubule-like structures, demonstrating 
higher similarity to the in vivo kidney (Figure 5.3). DesRochers and colleagues have 
reported an in vitro system in which human telomerase reverse transcriptase (hTERT)-
immortalized human renal cortical (NKi-2) cells were cultured in a 1:1 mixture of Matrigel 
and rat tail collagen I[59]. A 3D interconnected tubular structure was formed within 2 
weeks and could be maintained for up to 8 weeks. These tissues expressed epithelial 
cell marker E-cadherin (CDH1) and proximal tubule cell marker γ-glutamyltransferase 
1 (GGT1, GGT1), demonstrated Na+-dependent glucose transport and stained positive 
for expression of transporters OAT1 and OAT4. NKi-2 cells expressed mRNA transcripts 
for MRP2, MRP4 and MRP5 and the endocytosis receptor megalin (LRP2), suggesting 
its potential application in drug interaction studies. The 3D tubule structures were 
exposed to well-known nephrotoxic drugs cisplatin, gentamicin and doxorubicin 
and viability was evaluated by leakage of cytoplasmic lactate dehydrogenase (LDH), 
reflecting membrane integrity. Cisplatin was found to demonstrate similar LD50 
values for both 2D and 3D cultures. For gentamicin and doxorubicin however, the 
3D tissue culture models were demonstrated to be significantly more sensitive[59]. 
An even more complex system with multiple cell types was reported by Lawrence 
and colleagues, who developed functional kidney rudiments in vitro from renal 
progenitor cells[60]. Single cell suspensions of isolated murine epithelial ureteric 
bud surrounded by condensed mesenchyme at embryonic day 11.5, are capable of 
producing rudimentary engineered kidneys[61]. The tubule structures are organized 
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around a single collecting duct that demonstrate cortical and medullary zones and 
form morphologically distinct structures, such as loops of Henle. Transport function 
was elegantly evaluated using fluorescent substrates. Uptake of the fluorescent anion 
6-carboxyfluorescein could be inhibited by OAT substrate probenecid, indicating 
OAT-specific transport. Efflux of 6-carboxyfluorescein, inhibited by MRP inhibitor 
MK571, indicated MRP-specific transport. Uptake of the fluorescent cation DAPI 
was inhibited by OCT substrates metformin and cimetidine, indicating OCT-specific 
transport[60]. While murine-derived kidney rudiments recapitulate the in vivo kidney 
in terms of 3D microenvironment and interactions between multiple cell types, 
their predictivity for human clinical drug toxicity and pharmacological interaction 
studies is relatively low[62]. Kidney rudiments derived from human pluripotent stem 
cells (hPSC) do not have this limitation. Freedman and colleagues demonstrated that 
undifferentiated hPSC first develop into spheroids when cultured between two layers 
of diluted Matrigel. Subsequent inhibition of glycogen syntheses kinase-3b (GSK3b) 
leads to development of convoluted, translucent tubular organoids[63]. Treatment 
with nephrotoxic drugs cisplatin and gentamicin induced expression of kidney injury 
molecule-1 (KIM-1) at the luminal surface of tubules, suggesting this culture system 
can be used to study clinically-relevant biomarkers. In addition, endocytosis activity 
was demonstrated using rhodamine-labelled dextran accumulation in tubular 
lumens, which was reduced in presence of endocytosis inhibitor latrunculin B.
A disadvantage of most spheroid and micro engineered cultures is that they rely on 
ECM, such as Matrigel, with varying composition of different batches (Figure 5.3). In 
addition, sizes and distribution through the gel are not uniform and the luminal fluid 
is not easily accessible for sampling or differential control of exposure conditions to 
apical and basolateral membranes[64]. Moreover, spheroid, organoid and engineered 
kidney cultures are not exposed to fluid shear stress, unlike the physiological renal 
lumen. These issues make spheroid and micro engineered cultures not suitable for 
high-throughput screening of drug-induced toxicity. Kidney-on-a-chip devices may 
reintroduce these physiologically important characteristics of renal tissue.
Reconstruction of the physiological 
microenvironment in a kidney-on-a-chip 
An organ-on-a-chip is a microfluidic device that allow 3D cultures of living cells in 
perfused channels on a micro scale. The aim is to recreate a physiologically relevant 
niche for a particular cell type or tissue to such an extent, that cellular responses are 
more in vivo-like compared to standard 2D tissue culture. Important features include 
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dimensional and structural architecture, fluid shear stress, mechanical forces and 
the ability to culture multiple cell types, preferably in multiple compartments[4]. In 
the simplest example a ‘chip’ consists of one single microfluidic channel lined with 
cells of one cell type, cultured immediately on the structural surface (Figure 5.3). 
Using perfusion by gravity or active pumping systems, cells can be exposed to 
a fluid shear stress similar to what is experienced in the physiological tissue. Due 
to the channel’s micrometer size, fluid flow in microfluidic systems is exclusively 
Figure 5.3 Evolution of 3D culture models. Overview of 2D and 3D tissue culture models, including 
advantages and disadvantages. ECM, extra cellular matrix; HTS, high throughput screening.
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laminar: turbulence is minimal or absent. In a more advanced system, two parallel 
channels can be separated by a porous membrane or by PhaseGuideTM technology 
to create membrane-free parallel channels, which allows compartmentalization for 
transcellular transport studies[9, 65]. When combined with different cell types, parallel 
channels allow for studying cell-cell interactions[66]. In addition, mechanical forces as 
experienced by cells located in the lung and gut for example, can be incorporated by 
culturing cells on an elastic surface[67, 68]. Eventually, serially linking of chambers that 
are lined with cells representing different organs may be used to mimic inter-organ 
interactions and advance towards a ‘human-on-a-chip’ model[69, 70]. 
Material and production process of organ-on-a-chip devices
Microfluidic devices are often produced of poly-dimethylsiloxane (PDMS) and the 
process requires molding and/or photolithographic etching techniques[71]. Briefly, 
the structural outline of the organ-on-a-chip system originates from a computer 
assisted photo mask, which is projected over a silicon base covered with a thin layer 
of photosensitive material. By applying ultraviolet light and dissolving the exposed 
material, the inverse pattern of the chip is fabricated. By subsequently pouring the 
liquid polymer PDMS on the etched surface, the layout of the chip is created[72]. 
Hollow channels result from fixing the PDMS to a flat surface, such as plastic or glass. 
The chip interior can be coated with cell type specific ECM prior to the addition of 
cells in suspension[73]. 
The advantages of using PDMS are its biocompatibility, its permeability to gas and its 
optical clarity, allowing evaluation of cellular responses by live imaging. Moreover, the 
design of PDMS-based microfluidic devices allows for a controlled fluid shear stress. 
On the contrary, PDMS absorbs small organic compounds such as drugs, which poses 
problems for toxicological and pharmacological studies as the final exposure to the 
cells is equivocal[74]. This drawback can be circumvented by inert plastic or glass[65, 75]. 
Fluid shear stress affects renal phenotype
Next to the design and fabrication, renal cell functionality determines the potential 
applications of a chip. Efficient excretion of metabolites and xenobiotics is dependent on 
cellular transport activity and renal metabolism. Commonly used renal cell models, such 
as OK cells, LLC-PK1, HK-2 and MDCK cells, lack functional differentiation that limits their 
application for drug-induced injury testing and drug interaction studies[76-78]. Remarkably, 
transcriptomic and proteomic analysis in MDCK cells cultured on a fibronectin-coated 
surface PDMS-based biochip exposed to fluid shear stress revealed increased expression 
of phase I enzymes (i.e. CYP1B1), phase II enzymes (i.e. GSTA3 and GSTT1), and ABC 
transporters (ABCC4 and ABCC5), as well as SLC transporters (SLC20A1, SLC37A2, SLC23A2 
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and SLC7A11)[79]. MDCK cells cultured in the kidney-on-a-chip demonstrated a reduction 
in inflammatory responses by modulating the nuclear factor (erythroid-derived 2)-
like 2 (Nrf-2), ataxia telangiectasia mutated (ATM), tumour protein p53 and nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways, and reduced 
integrin-related gene expression in response to treatment with the antineoplastic drug 
ifosfamide[80]. Despite the drawbacks in terms of pharmacological relevance, the MDCK 
cell line was successfully used to demonstrate the influence of fluid shear stress on 
cellular physiology[62]. 
Raghavan and colleagues have evaluated uptake of FITC-labelled albumin via 
receptor mediated endocytosis in OK cells, LLC-PK1 and MDCK cells, while applying a 
physiological fluid shear stress of 0.1 dyne•cm-2[10, 81]. Compared to static conditions, an 
increase of albumin uptake in OK and LLC-PK1 cells was observed with a concomitant 
increase in intracellular Ca2+ concentration (Figure 5.2)[10]. These findings are consistent 
with the current models of cilia-mediated signal transduction induced by fluid shear 
stress and underline the importance when evaluating renal tubule transport function.
Multi-compartmentalization combined with fluid shear stress
The current golden standard to study transepithelial transport of drugs and 
their metabolites via influx and efflux transporters is to culture epithelial cells on 
semi-permeable membrane supports. Exposure to fluid shear stress is in this 
setup difficult if not impossible to control. Jang and colleagues therefore applied 
PDMS-based microfluidic techniques in combination with a similar porous polyester 
membrane[82]. When primary rat inner medullary collecting duct (IMCD) cells were 
cultured on fibronectin-coated membranes and were exposed to fluid shear stress of 1 
dyne•cm-2, renal epithelial polarization was improved: cell height increased by 3-fold, 
expression of aquaporin 2 (AQP2) was restricted to the apical membrane and Na,K-
ATPase was restricted to the basolateral membrane. In addition, reorganization of the 
cytoskeleton was stimulated as long bundles and networks without a distinction of 
the cell periphery transformed into thick actin fibres at the cell periphery. Moreover, 
E-cadherin localization was restricted under fluid shear stress to narrow areas where 
cells interact, reflecting formation of tight junction protein complexes[82]. When 
primary human kidney proximal tubule cells were cultured on collagen IV-coated 
membranes in the same microfluidic device and fluid shear stress was adjusted to 0.2 
dyne•cm-2, renal epithelial characteristics were improved to a similar extend[9]. While 
tight junction protein ZO1 was expressed under both static and fluidic conditions, fluid 
shear stress increased cell height by 2-fold, expression of Na,K-ATPase was restricted 
to the basolateral membrane, expression of AQP1 was increased and a significant 
increase in the amount of ciliated cells was observed (Figure 5.2). To limit the effect of 
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semi-permeable membranes that create multiple culture compartments, membrane-
free microfluidic devices are developed that separate the ECM compartment from 
the medium perfusion compartment using the PhaseGuideTM technology[65, 75]. Fluid 
shear stress in the OrganoPlate® is achieved without pumps and associated tubing 
systems, allowing for increased throughput in a standard well plate format. These 
characteristics allow for high-throughput toxicity studies on kidney epithelial tubules 
with basal and apical compartments.
Next to obvious phenotypic alterations, multi-compartmentalized systems open the 
ability to study renal clearance in transepithelial transport assays and investigate the 
toxicological response upon basolateral or apical exposures under fluid shear stress. Pgp 
efflux activity was increased under fluidic conditions, indicating an improved protection 
against toxicants[9]. Further, the toxic response to basolaterally exposed cisplatin was 
partially ameliorated by fluid shear stress, as measured by lactate dehydrogenase 
(LDH) release. Under static conditions, the effect of the cisplatin-induced insult was 
still observed after a 4-day recovery period, while cells under fluidic conditions were 
completely recovered. These findings indicate that fluid shear stress may enhance the 
regenerative capacity of renal proximal tubule cells and underscores the importance of 
a dynamic culture system for regenerative medicine studies. 
Applications of kidney-on-a-chip: current and future 
developments
Recent advances in organ-on-a-chip technology open new applications. The ability for 
high throughput screening have gained attention at the pharmaceutical industry, while 
the improvements in the physiological environment are of interest for fundamental 
studies with clinical relevance or even clinical applications.
Kidney-on-a-chip in drug development
A current challenge in drug development is to bridge the gap between preclinical systems 
and the clinical situation. Kidney-on-a-chip devices improve the physiological relevance 
of culture conditions, allowing evaluation of disease processes that develop within 4 to 
6 weeks, the timeframe in which the recapitulated tissue remains viable[9]. The improved 
complexity of such culture devices could further improve prediction and reduce animal 
experiments upon careful validation in the future. Microfluidic devices are promising 
for studying drug-induced toxicity and drug interaction studies[9, 59, 60, 80]. In addition, 
microfluidic devices have the potential for high-throughput and multiplex biomarker 
screening, using live cell fluorescent imaging or analysis of the perfusion medium.
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However, using kidney-on-a-chip devices for high-throughput nephrotoxicity 
screening still faces important challenges[4]. First of all, the chip-system should be 
technically and biologically reproducible in order to be implemented in drug screening 
programs. Differentiation and formation of tight monolayers, ECM composition and 
fluid shear stress in each individual kidney-on-a-chip should be robust, demanding 
high quality of both the biological and non-biological materials. Next, microfluidic 
channels should be fabricated using a biocompatible, low-cost and preferably inert 
non-absorptive material with the ability of mass-production. Suitable materials 
may include poly (methyl methacrylate), polystyrene and polycarbonate[83]. Finally, 
kidney-on-a-chip models should be validated against established nephrotoxicity 
assays with approved read-outs. End-point measurements need to be translated to 
clinical observations, which requires in vitro to in vivo extrapolation (IVIVE). Validation 
requires compounds for which in vitro, animal and clinical data are available, and 
should demonstrate whether 3D renal models exceed sensitivity and specificity of 
existing 2D in vitro and animal models. Despite the remaining challenges, future drug 
development can benefit from kidney-on-a-chip technology by increased predictivity 
and reduced animal experiments, resulting in safer drugs entering clinical studies. 
Kidney-on-a-chip in kidney replacement therapy
While development of kidney-on-a-chip technology is currently driven towards 
toxicological and pharmacological studies, it may have potential as the functional 
unit in bioartificial kidneys. Renal replacement therapy using haemodialysis has been 
applied in the clinic for many years, drastically improving the prognosis of patients 
with acute and chronic kidney disease[84]. However, current dialysis only replaces 
glomerular filtration and compounds known as uremic toxins accumulate in patients 
suffering from chronic kidney disease[84]. Improvement of current dialysis treatment 
is therefore required for which the development of bioartificial kidney devices are 
explored[21, 85]. These include the incorporation of a ‘living membrane’ supporting 
the growth of renal tubule epithelial cells on a synthetic microfluidic scaffold[86, 87]. 
Current approaches rely on culturing renal tubule progenitor cells[88] or ciPTEC on 
semi-permeable hollow-fibre membranes coated with ECM proteins[87]. When ciPTEC 
were grown on collagen IV coated polyethersulfone hollow fibre membranes, OCT2 
transport function was demonstrated using live confocal microscopy by uptake of 
fluorescent substrate ASP+, and subsequent inhibition by cimetidine[89]. Such transport 
function in living cells cultured on hollow-fibres can contribute to selective excretion 
of waste products, such as uremic toxins, when incorporated in a bioartificial 
kidney[21]. An initial phase I/II clinical trial using bioartificial kidneys harbouring renal 
tubule cells supported that this approach can lead to an improvement of survival 
in patients suffering from AKI[90]. Shen and colleagues cultured HK-2 and MDCK cells 
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on polyethylene glycol (PEG)-based curved hollow fibres with inside diameters of 
1200, 800 and 400 µm[91]. Curvature was demonstrated to induce activity of metabolic 
enzymes GGT and alkaline phosphatase, promote transport of glucose and increase 
MRP2-mediated efflux of 5-carboxyfluorescein diacetate[91]. The next step in the 
development of the bioartificial kidney is to miniaturize it into a wearable device, for 
which microfluidic technology could open new opportunities[92]. A microfluidic-based 
bioartificial kidney in combination with a microfluidic haemofilter would allow active 
secretion of uremic solutes in addition to continuous clearance of small solutes. 
Microfluidic techniques approach the physiological environment with functional 
tubule epithelial cells, including compartmentalization required for excretion under 
complete control over fluidic parameters. The capacity of such an application requires 
efficient elimination of uremic toxins, such as indoxyl sulfate or kynurenic acid, in 
order to decrease elevated serum levels in patients with CKD towards physiologic 
levels. Experimentally determined clearance rates of a sub-set of uremic toxins using 
a microfluidic device can demonstrate the feasibility of such an application, taking 
into account that size, time and flow rate are limited. Therefore, kidney-on-a-chip 
technology could aid in the development of miniaturized bioartificial renal devices. 
Kidney-on-a-chip to investigate epithelial repair mechanisms
Rudiment kidney cultures demonstrate improved spatial heterogeneity compared 
to traditionally cell cultures, and are therefore ideal to study regenerative medicine 
that involves cells at different stages of differentiation. Kidney-on-a-chip technology 
encompassing tubule structures may be suitable to investigate self-organized 
epithelial repair mechanisms and in particular the role of fluid shear stress in this 
process, which can be controlled experimentally.
As the adult human kidney is unable to initiate de novo nephron formation, kidney 
repair after an ischemia-induced or drug-induced insult depends on repair of 
damaged nephrons by cellular regeneration. Surviving epithelial cells at or near the 
site of insult will replace the injured or lost neighbour tubule cells by dedifferentiation, 
proliferation, migration and redifferentiation[93-95]. Interestingly, the pathways involved 
in dedifferentiation and proliferation observed in epithelial repair are overlapping 
to some extent with those associated with the formation of cysts in PKD, such as 
mTOR, STAT6, canonical Wnt signalling and planar cell polarity pathways, suggesting 
the involvement of primary cilia and fluid shear stress in this process[46, 47, 96]. Cilium 
length is reported to increase from ~3 µm in a healthy renal tubule cell to more than 
10 µm in cells of injured nephrons, and tubule cells exposed to fluid shear stress 
reduces lengthening of the primary cilium[97, 98]. Since microfluidic devices allow for 
controlled exposure to laminar fluidic shear stress and can recapitulate other renal 
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niche characteristics, kidney-on-a-chip may be a helpful tool to investigate the role 
of cilia-mediated signalling in epithelial repair.
Multi-organ-on-a-chip models in drug development
Drug-metabolism in the liver can significantly influence renal adverse effects. Certain 
drugs, such as cyclosporine A and tetrafluoroethylene, are metabolised by the liver 
and this can either suppress or enhance nephrotoxicity[99, 100]. To study the effects of 
liver-mediated drug-metabolism on nephrotoxicity, a kidney-on-a-chip linked to a 
liver-on-a-chip may provide a suitable platform. 
A liver-on-a-chip device with high in vivo relevance was developed by Midwoud 
and colleagues[101]. Precision-cut liver slices were wedged between a polycarbonate 
and PDMS membrane, allowing distribution of both culture medium and oxygen, 
and placed into a microfluidic PDMS-based device. These precision-cut liver slices 
were remained functionally for at least 24 h, sufficient for active compound 
metabolism[101]. While liver tissue from rats was used for this study, human-derived 
tissue or human-derived hepatocyte cell lines would allow investigating human-
relevant drug metabolism, drug clearance, drug interactions and drug-induced liver 
toxicity[71]. By guiding the perfusate of such a liver-on-a-chip to a kidney-on-a-chip, 
the effect of liver metabolites on the kidney could be evaluated.
Multi-organ-chips are reported that support in vitro growth of tissue derived 
from four different organs with the aim to fully recapitulate human pharmaco- 
kinetics[69, 70]. A highly advanced model developed by Maschmeyer and colleagues 
incorporates human primary cells or human-derived cell lines representing the intestine 
epithelium, hepatocytes, isolated skin and renal proximal tubule cells[69]. The device was 
fabricated of PDMS and all tissues were maintained on a polyester membrane with 1 
µm pores, with fluid on both sides representing a blood circuit or excretion circuit in 
case of the kidney compartment. A physiological tissue-to-fluid ratio was obtained 
and fluid shear stress in both circuits was controlled by peristaltic pumps. Co-cultures 
were viable for up to 28 days, with a stable glucose balance. Glucose concentration 
was lowest in the excretory circuit of the kidney culture compartment, suggesting 
intact physiological glucose reabsorption in proximal tubule cells, further supported 
by active sodium-coupled glucose transporter SLC5A2 mRNA expression[69]. Another 
multi-compartmental 3D microfluidic system incorporated cells that resembled 
liver, lung, kidney and fat tissue[70]. Tissue culture compartments were separated from 
fluidic channels by small openings, called micropillars, and were linked in a closed 
loop, requiring the use of a common culture medium. Functionality of the different 
monolayer cultures was demonstrated by albumin secretion (liver), pentoxyresorufin 
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O-dealkylase activity (lung), γ-glutamyltransferase activity (kidney) and adiponection 
secretion (fat tissue)[70]. In conclusion, these advanced microfluidic devices are the 
next step towards ‘human-on-a-chip’ technology with high potential to investigate 
absorption, distribution, metabolism and excretion kinetics in vitro, enhancing the 
efficiency of drug development.
Conclusions
In conclusion, microfluidic technology supports long-term in vitro survival, 
differentiation and function of renal proximal tubule cells. A kidney-on-a-chip 
recreates the physiologically relevant renal microenvironment, including the 
3D structure, extracellular matrix and apical fluid shear stress. Organ-on-a-chip 
technology has the potential to culture multiple cell types for development 
towards a human-on-a-chip or advanced techniques such as renal replacement or 
studying renal repair mechanisms. Together, the 3D design and microenvironment 
of a microfluidic renal device provide researchers with a valuable tool in the fields of 
pharmacology, toxicology and physiology for which recent developments are just the 
start of a new era in cell culturing. 
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Abstract
Drug-transporter interactions could impact renal drug clearance and should ideally be 
detected in early stages of drug development to avoid toxicity-related withdrawals in 
later stages. This requires reliable and robust assays for which current high-throughput 
screenings have, however, poor predictability. Kidney-on-a-chip platforms have the 
potential to improve predictability, but often lack compatibility with high-content 
detection platforms. Here, we combined conditionally immortalized proximal tubule 
epithelial cells overexpressing organic anion transporter 1 (ciPTEC-OAT1) with the 
microfluidic titerplate OrganoPlate to develop a screenings assay for renal drug-
transporter interactions. In this platform, apical localization of F-actin and intracellular 
tight-junction protein zonula occludens-1 (ZO-1) indicated appropriate cell 
polarization. Gene expression levels of the drug transporters organic anion transporter 
1 (OAT1; SLC22A6), organic cation transporter 2 (OCT2; SLC22A2), P-glycoprotein (P-
gp; ABCB1) and multidrug resistance-associated protein 2 and 4 (MRP2/4; ABCC2/4) 
were similar levels to 2D static cultures. Functionality of the efflux transporters 
P-gp and MRP2/4 was studied as proof-of-concept for 3D assays using calcein-AM 
and 5-chloromethylfluorescein-diacetate (CMFDA), respectively. Confocal imaging 
demonstrated a 4.4 ± 0.2-fold increase in calcein accumulation upon P-gp inhibition 
using PSC833. For MRP2/4, a 3.0 ± 0.2-fold increased accumulation of glutathione-
methylfluorescein (GS-MF) was observed upon inhibition with a combination of 
PSC833, MK571 and KO143. Semi-quantitative image processing methods for P-gp 
and MRP2/4 was demonstrated with corresponding Z’-factors of 0.1 ± 0.3 and 0.4 ± 0.1, 
respectively. In conclusion, we demonstrate a 3D microfluidic PTEC model valuable 
for screening of drug-transporter interactions that further allows multiplexing of 
endpoint read-outs for drug-transporter interactions and toxicity.
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Introduction
Excretion of metabolic waste products and drugs from blood into the urine takes 
place in the kidney and is a result of glomerular filtration, active tubular secretion 
and reabsorption. It has been estimated that about one third of the commonly used 
drugs and compounds tested in clinical trials are being (partially) removed via the 
urine without further metabolism[1, 2]. Renal clearance thus is a pivotal parameter to 
take into account during drug disposition studies in drug development.
Active tubular secretion of drugs in the kidney takes place mainly by the proximal 
tubule epithelial cells (PTEC) of the nephron, and involves transporters[3]. Uptake 
from blood to PTEC is mediated by members of the solute carrier (SLC) transporter 
family, such as organic cation transporter 2 (OCT2/SLC22A2) and organic anion 
transporter 1 and 3 (OAT1/SLC22A6; OAT3/SLC22A8). To complete elimination via 
urine from compounds internalized via SLC-mediated transport over the basolateral 
membrane, a range of drug transporters is expressed at the apical membrane of 
PTEC. This energy demanding process is facilitated by transporters classified in the 
ATP-binding cassette (ABC)-transporter family, such as P-glycoprotein (P-gp/ABCB1), 
breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated 
proteins 2 and 4 (MRP2/ABCC2; MRP4/ABCC4). Other drug transporters present at the 
apical membrane are the multidrug and toxin extrusion proteins 1 and 2-k (MATE1/
SLC47A1; MATE2-k/SLC47A2). In drug development, investigating interactions with a 
sub-set of drug transporters is recommended by the regulatory agencies, such as 
the United States Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA)[4, 5]. Clinical studies have shown drug-transporter interactions with e.g. 
digoxin, ritonavir or valspodar (PSC833) and with tenofovir via P-gp and MRP2/4, 
respectively[6-8]. 
In the past decade, multiple renal immortalized cell lines have been established, 
allowing in vitro screening of nephrotoxicity and renal drug transporters. Conditionally 
immortalized proximal tubule epithelial cells (ciPTEC) are derived from a healthy 
volunteer and manifest a stable expression and functionality of OCT2, P-gp and 
MRP4[9]. Further transduction resulted in stable expression and functionality of OAT1 
or OAT3[10]. Multiple studies have shown the potential of ciPTEC for studying drug 
transport and drug-induced toxicity cultured under conventional static conditions, 
often referred to as two-dimensional (2D) cell culture[10-13]. In addition, transepithelial 
barrier function, polarization and transport of cations and anions have been 
demonstrated in ciPTEC cultured in a three-dimensional (3D) model using a tailor-
made hollow fiber membrane system exposed to flow[13, 14]. Benefits of 3D microfluidic 
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models incorporating fluid shear stress (FSS) and cell-extracellular matrix (ECM) 
interactions are often referred to as organ-on-a-chip or microphysiological systems. 
Using PTEC, kidney-on-a-chip platforms have been demonstrated to improve 
proximal tubule characteristics, such as increased expression of tight-junction protein 
zonula occludens-1 (ZO-1) and increased number of ciliated cells[15]. Kidney-on-a-chip 
platforms could therefore advance predictability of large in vitro screenings, also 
referred to as high-throughput screening (HTS), which are typically employed during 
early phases in drug development.
The current study focuses on implementing a kidney-on-a-chip platform for the 
determination of drug-transporter interactions during drug development. To this 
end, we culture human ciPTEC-OAT1 in a microfluidic titerplate, the OrganoPlate, 
that enables 3D culture under FSS. The OrganoPlate consists of 40 or 96 chips and 
is based upon a 384-well microtiter plate format[16, 17]. Flow is induced by passive 
leveling by gravity of medium in medium channel inlets and outlets of chips, creating 
a bi-directional flow. Using this platform, we assessed stability in drug transporter 
expression and functionality via fluorescence based 3D drug efflux assays to evaluate 
P-gp and MRP2/4 transporter activities. In addition, we set up a user-friendly data 
analysis method using open-source software compatible with HTS. This approach 
resulted in a 3D microfluidic PTEC model suitable for HTS of drug-transporter 
interactions.
Materials & Methods
Cell culture
CiPTEC-OAT1 were obtained as described previously[9, 10]. Briefly, cells were retrieved 
from urine from a healthy volunteer in compliance with the guidelines of the Radboud 
Institutional Review Board and conditionally immortalized via transduction with the 
temperature-sensitive mutant of SV large T antigen (SV40T) and human telomerase 
reverse transcriptase (hTERT)[9]. Transduction of OAT1 in ciPTEC was performed using 
lentiviral particles containing genes encoding for human OAT1[10].
Cells were sub-cultured at a dilution of 1:2 to 1:6 at 33°C and 5% (v/v) CO2 to allow 
proliferation and were used from passage number 48 to 60 for experiments. Cells 
were cultured in a 1:1 mixture of Dulbecco’s modified eagle medium (DMEM) and 
Ham’s F-12 Nutrient Mixture without phenol red (DMEM HAM’s F12, Life Technologies, 
Paisley, UK) and supplemented with insulin (5 μg/ml, Sigma-Aldrich, Zwijndrecht, 
The Netherlands), transferrin (5 μg/ml, Sigma-Aldrich), selenium (5 ng/ml, Sigma-
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Aldrich), hydrocortisone (36 ng/ml, Sigma-Aldrich), epidermal growth factor (10 ng/
ml, Sigma-Aldrich), tri-iodothyrine (40 pg/ml, Sigma-Aldrich), 1% (v/v) penicillin/
streptomycin (Life Technologies) and 10% (v/v) fetal calf serum (FCS, Greiner Bio One, 
Kremsmuenster, Austria), further referred to as PTEC complete medium. 
For 2D static cell culture, cells were seeded at 55,000 cells/cm2 in 6-well plates and 
cultured for one day at 33°C 5% (v/v) CO2 without penicillin/streptomycin to allow 
proliferation. Then, cells were cultured for seven days at 37°C 5% (v/v) CO2 to induce 
maturation into confluent cell mono layers. Cells were harvested on day eight after 
seeding.
For 3D FSS cell culture, a 400 µm two-lane OrganoPlate (Mimetas, Leiden, The 
Netherlands) was used for culturing ciPTEC-OAT1 in a microfluidic platform. Prior to 
seeding, 50 µl of Hank’s balanced salt solution (HBSS, Life Technologies) was added 
to the observation window (Figure 6.1A). An ECM mix containing collagen I (4 mg/
ml, AMSbio Cultrex 3D Collagen I Rat Tail), sodium bicarbonate (3.7 mg/ml, Sigma-
Aldrich) and HEPES (100 mM, Life Technologies) was prepared and 2 µl was added 
to the gel channel[17]. Then, the OrganoPlate was placed at 37°C 5% (v/v) CO2 for 30 
min to allow polymerization of the ECM. Proliferating cells were harvested from a 
culture flask using accutase (Sigma-Aldrich), centrifuged (300 x g, 5 min) and then 
resuspended in PTEC complete medium. Per chip, 40,000 cells in a suspension of 2 µl 
were seeded in the medium channel inlet (Figure 6.1A,B). In chips used for background 
correction of fluorescent signal, 2 µl of medium was used. The OrganoPlate was then 
placed vertically at 33°C 5% (v/v) CO2 for 30 min with the gel channel facing down to 
allow cells to attach to the ECM (Figure 6.1B). Next, 30 µl of PTEC complete medium 
was added to the medium channel inlet. The OrganoPlate was oriented horizontally 
again at 33°C 5% (v/v) CO2 for four to six hours. Upon addition of another 30 µl PTEC 
complete medium to the medium channel inlet, 60 µl PTEC complete medium was 
added to the medium channel outlet. CiPTEC-OAT1 in the OrganoPlate was cultured 
at 33°C 5% (v/v) CO2 to allow proliferation without any FSS for three days. Medium was 
supplemented with 1% (v/v) penicillin/streptomycin when culturing at 33°C. 
At day three after seeding, medium channels were refreshed with PTEC complete 
medium without penicillin/streptomycin and the OrganoPlate was placed on an 
interval rocker platform (angled at -7° or +7° from base, 8 min interval) at 37°C 5% 
(v/v) CO2 to allow the cells to maturate under FSS induced by a bi-directional flow 
(Figure 6.1B,C). Experiments in the OrganoPlate were performed on day eight after 
seeding, unless states otherwise. Medium was refreshed every two to three days. 
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For long-term cell culture of ciPTEC-OAT1 in the OrganoPlate, chips were pre-coated 
(30 min, 37°C) prior to seeding with L-3,4-dihydroxydiphenylalanine (L-DOPA, 2 mg/
ml in 10 mM Tris pH 8.5, Sigma-Aldrich) as earlier described[18]. Cells were then cultured 
at 33°C on an interval rocker, as above described, for 20 days.
Immunofluorescence staining of ciPTEC-OAT1 in the OrganoPlate
At day 8 and 20 after seeding, PTEC complete medium was aspirated from the medium 
channel and cells were fixated with 3.7% (w/v) formaldehyde (Sigma-Aldrich) in HBSS. 
The plate was incubated for 15 min at room temperature. For all described incubation 
and wash steps, 50 µl was added to the inlet and outlet of the medium channel, and plate 
was placed at angle to allow perfusion, unless stated otherwise. Fixative was aspirated 
and medium channels were washed twice with washing solution (4% (v/v) FCS in HBSS). 
Then, cells were permeabilized by adding 0.3% (v/v) Triton-X100 (Sigma-Aldrich) in HBSS 
and incubated for 10 min at room temperature. Cells were subsequently washed with 
washing solution and then incubated with blocking solution (2% (v/v) FCS, 2% (w/v) 
bovine serum albumin (BSA, Sigma-Aldrich), 0.1% (v/v) Tween-20 (Sigma-Aldrich) in 
HBSS) for 45 min at room temperature. Primary and secondary antibodies were diluted 
in blocking solution and perfusion during incubation was allowed by adding 30 µl to 
the medium channel inlet and 10 µl to the outlet. Primary antibodies against zonula 
occludens-1 (ZO-1, 1:125, rabbit, ThermoFisher), a tight-junction protein; acetylated-
tubulin (clone 6-11B-1, 1:1000, mouse, Sigma-Aldrich), a constituent of the primary 
cilium; and pericentrin (1:500, rabbit, Abcam), a centrosome marker, were used and 
incubated for 60 min at room temperature. Next, cells were washed three times with 
washing solution and then incubated with secondary antibodies Alexa Fluor® 488 goat 
anti-rabbit (1:250, Life Technologies or Abcam), Alexa Fluor® 488 goat anti-mouse (1:250, 
Life Technologies), and Alexa Fluor® 647 goat anti-rabbit (1:250, Life Technologies) for 
30 min at room temperature. Cells were then washed three times, followed by addition 
of probes in the last wash step to stain F-actin and nuclei with ActinRed 555 (2 drops/
ml in HBSS, Life Technologies) and DRAQ5 (1:1000 in HBSS, Abcam) or DAPI (300 nM in 
HBSS, Life Technologies), respectively. Fluorescent images of the ZO-1 staining were 
acquired with a Leica TCS SP5 laser point confocal microscope (Leica, Wetzlar, Germany) 
or a Zeiss LSM880 confocal scanning microscope (Carl Zeiss, Jena, Germany) using a 
20X objective. Z-stacks were acquired using a 2 µm interval over a 200-220 µm range. 
To investigate polarization of the PTEC monolayer of ciPTEC-OAT1 in the OrganoPlate, 
fluorescent images were acquired of acetylated-tubulin and pericentrin staining with 
a Zeiss LSM880 confocal scanning microscope using a 40X water immersion objective. 
A range of 45 µm was imaged using a 0.88 µm interval between Z-stacks. Images 
were adjusted for windows and level, and then 3D images were reconstructed in Fiji 
(version 1.51n)[19]. 
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Gene expression of ciPTEC-OAT1 
Cells were harvested from 6-well plates using accutase, and then RNA was extracted 
using the RNeasy Mini kit (Qiagen, Venlo, the Netherlands). RLT lysis buffer was added 
to the cell pellet and RNA was then extracted according to the protocol provided by 
the manufacturer.
RNA from cells in the OrganoPlate was isolated using the RNeasy Micro kit (Qiagen). 
From each chip, RNA was isolated by adding 50 µl and 25 µl RLT lysis buffer to the 
medium channel inlet and outlet, respectively. Cell lysates of two chips were then 
pooled and RLT lysis buffer was added up to a volume of 350 µl. The extracted RNA 
was purified following the manufacturer’s protocol.
M-MLV Reverse Transcriptase (Promega, Madison, USA) was used to synthesize 
complementary DNA (cDNA) according the manufacturer’s protocol. Human kidney 
cortex material was used as reference. Tissues unsuitable for transplantation were 
obtained for research purposes from three donors, who gave permission and which was 
registered in the Dutch Donor registry. RNA isolation and cDNA synthesis were performed 
as previously described[20]. The expression levels of mRNA were quantified using gene-
specific primer-probe sets from Applied Biosystems (Bleiswijk, The Netherlands): 
GAPDH (hs99999905_m1), HPRT1 (hs02800695_m1), SLC22A6 (hs00537914_m1), 
ABCB (hs01067802_m1), ABCC2 (hs00166123_m1), ABCC4 (hs00195260_m1), SLC22A2 
(hs01010723_m1) and TaqMan Universal polymerase chain reaction (PCR) Master Mix. 
Quantitative PCR reactions were carried out using CFX96-Touch Real-Time PCR System 
(BioRad, Veenendaal, The Netherlands) and analyzed with BioRad CFX Manager (version 
3.1). Expression levels of GAPDH were used as reference gene. 
3D drug efflux assays in the OrganoPlate
Functionality of P-gp and MRP2/4 was assessed based upon accumulation of 
substrates, as previously described for ciPTEC in 2D (Figure 6.1C)[12]. Prior to measuring 
efflux activity of P-gp and MRP2/4 in the OrganoPlate, medium channel inlet and 
outlets were washed with 50 μl KHH at 37°C. Medium channels were then perfused 
two times. Then, cells were exposed to substrates with or without inhibitors or 
corresponding vehicle for one hour at 37°C.
For P-gp activity assessments, calcein-AM (2 μM, Life Technologies) was used as 
substrate and PSC833 (10 μM, Tocris, Bristol, UK) was used as inhibitor. Calcein-AM 
and PSC833 were dissolved in DMSO (Sigma-Aldrich). All dilutions were prepared in 
Krebs-Henseleit buffer (Sigma-Aldrich) supplemented with HEPES (10 mM, Sigma-
Aldrich) and adjusted to pH 7.4 (KHH).
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Chloromethylfluorescein-diacetate (CMFDA, 1.25 μM, Molecular Probes) was used 
to study MRP2/4 activity. A combination of PSC833 (10 μM), KO143 (10 μM, Sigma-
Aldrich) and MK571 (10 μM, Sigma-Aldrich) was used to inhibit efflux of CMFDA and 
GS-MF via P-gp, BCRP and MRP2/4, respectively. CMFDA and KO143 were dissolved 
in DMSO, while MK571 was dissolved in Milli-Q water, requiring appropriate vehicle 
controls. All dilutions were prepared in KHH. 
After substrate incubations, cell nuclei were stained with Hoechst33342 by first 
washing with KHH, followed by staining with Hoechst33342 (10 μg/ml, Molecular 
Probes) for 10 min at room temperature. Cells were co-incubated with PSC833 (10 
μM), KO143 (10 μM) and MK571 (10 μM) during staining with Hoechst33342 to inhibit 
all efflux transport processes. Subsequently, cells were washed and efflux of calcein-
AM and GS-MF was arrested by adding ice-cold KHH to medium channel. FSS in 
medium channel during experiment and washing was assured by adding 80 µl to the 
medium channel inlet and 20 µl to the medium channel outlet. 
Fluorescent imaging in the OrganoPlate
Fluorescence of intracellular accumulation of calcein or GS-MF and Hoechst33342 
in ciPTEC-OAT1 cultured in the OrganoPlate were imaged in situ using a Becton 
Dickinson (BD) Pathway 855 high-throughput microscope (BD Bioscience, Breda, The 
Netherlands) using a 10X objective (Figure 6.1C). The BD Pathway 855 microscope 
was compatible with the two-lane OrganoPlate and allowed to acquire images of 
the observation window of each chip using two different fluorescent dyes with 
wild-field microscopy and spinning disk confocal microscopy at room temperature. 
A macro was developed to acquire fluorescent and bright-field images using BD 
AttoVision (version 1.6, BD Bioscience). Z-height was determined per experiment by 
determining the top and bottom of multiple chips in the OrganoPlate visually. The 
average Z-height was used as starting point for acquiring five Z-planes with a 10 μm 
interval, covering 50 µm in Z-direction, generating focused images of cells cultured 
against ECM. First, calcein and GS-MF fluorescence images were acquired (488 nm 
excitation and 520 nm emission filters) with exposure time and gain set at 0.5 sec 
and 100, respectively. Hoechst33342 images were acquired subsequently (360 nm 
excitation filter and 435 nm emission filter), with exposure time and gain set at 0.01 
sec and 100, respectively. Afterwards, bright-field images of each chip were acquired 
using an exposure time of 0.02 sec. 
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Image processing
An image analysis method (Figure 6.1C) was set up to analyze the full data set using 
custom made macros in Fiji (version 1.51n). Initially, the region of interest (ROI) was 
selected from bright-field images in which the gel channel, medium channel and the 
phase guide were clearly visible, by focusing at the interface of ECM and medium. The 
same area size was used for all images. All raw fluorescence images (uncompressed 
12-bit TIFF) were cropped based upon the interface selection and converted from a 
pixel to μm scale. Then, the raw fluorescence images were corrected for background 
noise by subtracting images of chips with ECM without any cells exposed to either 
calcein-AM or CMFDA. Background corrected images were saved to an uncompressed 
16-bit TIFF file and the average intensity was calculated (see macro in Supplemental 
data). In parallel, a mask was created for each image using 17 threshold algorithms 
available in Fiji (Supplemental Table S6.1) to automatically determine localization 
of intracellular accumulated fluorescent calcein or GS-MF. Upon running a median 
image filter (radius size five pixels), a cell selection mask was created via the selected 
algorithm to create a binary image. Pixels from the edges of the cell selection mask in 
the binary image were removed using ‘erode’ in Fiji. The binary image represented a 
cell selection and was used to analyze fluorescence intensity of each Z-stack per chip. 
As part of the image quality control (QC), only in-focus images of cells cultured at 
the ECM and medium interface were selected and reviewed by three independent 
observers (Figure 6.1C). An image was defined as out-of-focus if no in-focus cell in the 
ROI were scored by at least two of the three observers. 
Manual interventions, such as determination of out-of-focus images are not compatible 
with HTS. Therefore, selected image QC metrics were established to automatically 
exclude out-of-focus images: focus score, image correlation and power log-log slope 
(PLLS), which all have been described in literature for image analysis[21-24]. An image QC 
method was set up using these image QC metrics in CellProfiler (version 2.2.0)[25, 26]. For 
the focus score, the deviation of pixel intensity was assessed upon normalization per 
image. The correlation of the gray scale value of neighboring pixel was evaluated for 
image correlation. Pixel size for image correlation and focus score was empirically based 
upon the area of the observed intracellular accumulation of calcein or GS-MF and set 
at 20, 50, 100, 200, 500 pixels. For the PLLS, the slope of power spectral density versus 
the spatial frequency, both on a log scale, was plotted. All images were automatically 
binned based upon the image QC metrics in GraphPad Prism (version 5.03). Multiple cut-
off values were compared per image QC metric. The efficiency of the automated image 
QC metrics was compared to visually reviewing of out-of-focus scoring as described 
earlier, which was defined as ground truth. For all image QC metrics, the precision and 
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recall rates were determined, as well as the harmonic mean of the precision and recall 
rates, also known as F-score. Precision, recall and F-score were calculated as follows: 
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And recall is: 
𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟 =	
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𝑡𝑡𝑠𝑠𝑡𝑡𝑠𝑠	𝑝𝑝𝑠𝑠𝑠𝑠𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠 + 𝑓𝑓𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠	𝑝𝑝𝑠𝑠𝑛𝑛𝑟𝑟𝑡𝑡𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠
 
 
Average intensities of visual observation in-focus images were calculated per chip (Figure 
6.1C). Two to eight chips were analyzed per condition and repeated in at least three 
independent experiments. All groups were checked for outliers using Grubbs’ test for 
outliers (using a significance level of α=0.05) and finally normalized to average 
fluorescence intensity in vehicle condition per experiment.  
 
The Z’-factor was used to index the thresholding algorithms and overall intensity per 
image and condition to assess quality and optimize the data analysis methods. The Z’-
factor has been described as statistical parameter in HTS assays taking in account the 
variation between a signal in maximum response, the positive control, and minimum 
response, the negative control [27]. Hence, the Z`-factor can be used as guideline to 
optimize semi-quantitative methods in order to improve discrimination between the 
Where precision is:
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Average intensities of visual observation in-focus images were calculated per chip (Figure 
6.1C). Two to eight chips were analyzed per condition and repeated in at least three 
independent experiments. All groups were checked for outliers using Grubbs’ test for 
outliers (using a significance level of α=0.05) and finally normalized to average 
fluorescence intensity in vehicle condition per experiment.  
 
The Z’-factor was used to index the thresholding algorithms and overall intensity per 
image and condition to assess quality and optimize the data analysis methods. The Z’-
factor has been described as statistical parameter in HTS assays taking in account the 
variation between a signal in maximum response, the positive control, and minimum 
response, the negative control [27]. Hence, the Z`-factor can be used as guideline to 
optimize semi-quantitative methods in order to improve discrimination between the 
And recall is:
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upon the area of e observed intracellular accumulation of calcein r GS-MF and s t at 
20, 50, 100, 200, 500 pixels. For the PLLS, the slop  of power spectral density versus the 
spatial frequency, both on a log scale, was plotted. All images were automatically binned 
ba ed upon the i age QC met ics in GraphPad Prism (versio  5.03). Multiple cut-off 
value w re compa ed per image QC metric. The efficiency of th  automated image QC 
metrics as compared to visually reviewi g of out- -focus s oring as described earlier, 
which w defined as ground truth. F r all i age QC metrics, the precision and c ll 
rates were determined, as well as the harmonic mean of the precision and recall rates, 
also known as F-score. Precision, recall and F-score were calculated as follows:  
𝐹𝐹 − 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 	
2 ∗ 𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑠𝑠𝑝𝑝𝑠𝑠𝑝𝑝 ∗ 𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟
𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑠𝑠𝑝𝑝𝑠𝑠𝑝𝑝 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟
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Average intens ties of visual observation in-focus images were calculated p r chip (Figure 
6.1C). Two to eight chips were analyzed per condition and rep ated in at l ast three 
independe t exper ments. All groups were checked for outliers using Grubbs’ test for 
outliers (using a significance level of α=0.05) and finally normalized to average 
fluorescence intensi y  vehicl conditi n per experiment.  
 
The Z’-factor was used to index the th esholding algorithms and overall intensity per 
image and condition to assess quality and optimize the data analysis methods. The Z’-
factor has b en des ribed as statistical parameter in HTS assay  takin  in account the 
variation between a signal in maximum esponse, the pos tive control, and minimum 
response, the negative control [27]. Hence, the Z`-factor can be used as guideline to 
optimize semi-quantitative methods in order to improve discrimination between the 
Average intensities of visual observation in-focus images were calculated per chip 
(Figure 6.1C). Two to eight chips were analyzed per condition and repeated in at least 
thr e independent experime ts. All groups wer  ch cked for outliers using Grubbs’ 
test for outliers (using a significance level of α=0.05) and finally normalized to average 
fluorescence intensity in vehicle condition per experiment. 
The Z’-factor was used to index the thresholding algorithms and overall intensity per 
image and condition to assess quality and optimize the data analysis methods. The 
Z’-factor h s been described as st tistical parameter in HTS assays taking in account 
the variation between a signal in maximum response, the positive control, and 
minimum response, the negative control[27]. Hence, the Z`-factor can be used as 
guideline to optimize semi-quantitative methods in order to improve discrimination 
between the positive and negative controls. Mean and standard deviation (SD) were 
determined for the positive control, inhibitor condition, and negative control, vehicle 
condition, to calculate the Z’-factor per experiment as follows:
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positive and negative controls. Me n and stand rd devia ion (SD) were de ermined for 
th  positive co trol, inhibit  condit on, and negative control, vehicle condition, to 
calculate the Z’-fact r per experiment as follows: 
𝑍𝑍8 − 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 = 1 −	
3(𝜎𝜎	𝑝𝑝𝑓𝑓𝑝𝑝𝑝𝑝𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝	𝑓𝑓𝑓𝑓𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜 + 	𝜎𝜎	𝑜𝑜𝑝𝑝𝑛𝑛𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝	𝑓𝑓𝑓𝑓𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜)	
|µ	𝑝𝑝𝑓𝑓𝑝𝑝𝑝𝑝𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝	𝑓𝑓𝑓𝑓𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜 − 	µ	𝑜𝑜𝑝𝑝𝑛𝑛𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝𝑝𝑝	𝑓𝑓𝑓𝑓𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑜𝑜|
 
 
Statistical data analysis 
All statistics were performed using GraphPad Prism (version 5.03). Data is presented as 
mean ± SEM of at least three independent experiments (n=3) and considered to be 
significantly different if p<0.05 using an unpaired two-tailed Student’s t-test, unless 
stated otherwise.  
 
6.3 Results 
PTEC’s formed a 3D tubular structure in the OrganoPlate 
Upon seeding ciPTEC-OAT1 against the ECM in the two-lane OrganoPlate, cells formed a 
monolayer that migrated towards the top and bottom of the medium channel, creating a 
tubule-like structure at day eight after seeding (Figure 6.2A, Supplemental Figure S6.1). 
PTEC tubules could be cultured up to 20 days in the OrganoPlate (Supplemental Figure 
S6.2). ZO-1, a tight-junction protein, was localized between the cells in the monolayer of 
the PTEC tubules (Figure 6.2B), indicative for polarization. Staining of the centrosome, or 
pericentrin, and acetylated-tubulin, showed apical expression of single cilia per cell 
(Figure 6.2C, Supplemental Figure S6.3). Some migration of ciPTEC-OAT1 from the 
medium channel into the ECM was observed, likely influencing the monolayer integrity. 
Although the majority of cilia were mainly expressed at the apical side of the tubules, 
some cilia were observed on single cells that migrated into the ECM (Supplemental Figure 
S6.3). 
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Statistical data analysis
All statistics were performed using GraphPad Prism (version 5.03). Data is presented 
as mean ± SEM of at least three independent experiments (n=3) and considered to be 
significantly different if p<0.05 using an unpaired two-tailed Student’s t-test, unless 
stated otherwise. 
Results
PTEC’s formed a 3D tubular structure in the OrganoPlate
Upon seeding ciPTEC-OAT1 against the ECM in the two-lane OrganoPlate, cells 
formed a monolayer that migrated towards the top and bottom of the medium 
channel, creating a tubule-like structure at day eight after seeding (Figure 6.2A, 
Supplemental Figure S6.1). PTEC tubules could be cultured up to 20 days in the 
OrganoPlate (Supplemental Figure S6.2). ZO-1, a tight-junction protein, was localized 
between the cells in the monolayer of the PTEC tubules (Figure 6.2B), indicative for 
polarization. Staining of the centrosome, or pericentrin, and acetylated-tubulin, 
showed apical expression of single cilia per cell (Figure 6.2C, Supplemental Figure 
S6.3). Some migration of ciPTEC-OAT1 from the medium channel into the ECM was 
observed, likely influencing the monolayer integrity. Although the majority of cilia 
were mainly expressed at the apical side of the tubules, some cilia were observed on 
single cells that migrated into the ECM (Supplemental Figure S6.3).
Drug transporter gene expression in ciPTEC-OAT1 cultured in the 
OrganoPlate
Drug transporter gene expression levels in ciPEC-OAT1 cultured in 2D static (6-well 
plate) and under FSS (OrganoPlate) were compared (Figure 6.3). Expression levels of SLC 
transporters OAT1 and OCT2 and ABC transporters P-gp, MRP2/4 were found to be similar 
in ciPTEC-OAT1 cultured in the OrganoPlate as compared to 2D cultures. This indicates 
a maintained phenotype of ciPTEC-OAT1 when cultured in the OrganoPlate. Only 
expression levels of HPRT1, here assessed to be used as a reference gene, were lower in 
ciPTEC-OAT1 cultured in the OrganoPlate and, consequently, not valid as reference gene. 
On the other hand, reference gene GAPDH was stably expressed in ciPTEC-OAT1 cultured 
both in 6-well plate and in the OrganoPlate with corresponding Ct values of 19.7 ± 0.1 
and 19.6 ± 0.1, respectively. It is important to note that drug transporter gene expression 
levels presented here were derived from cells both located in the perfused channels, 
as well as the medium channel inlet and outlets. As the latter cells are not exposed to 
laminar flow, nor were cultured in 3D, gene expression profiling was based on a hybrid 
population and should be regarded as qualitative measurement.
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Figure 6.1 Overview of two-lane OrganoPlate and cell culture, assay and image analysis protocol. 
(A) Schematic overview of a two-lane OrganoPlate consisting of a gel channel (red) and medium 
channel (blue) and covering four wells of a 384-wells plate. Four wells are named 1 = gel channel 
inlet, 2 = medium channel inlet, 3 = observation window. and 4 = medium channel outlet. Dotted 
line indicates position of cross-sectional overview. (B) Cross-sectional overview of culture protocol of 
ciPTEC-OAT1 in the OrganoPlate: 1 = addition of ECM to the gel channel creating two membrane-
free compartments because of the phase guide; 2 = seeding of ciPTEC-OAT1; 3 = by placing the 
plate vertically, cells are allowed to attach to ECM by gravity; 4 = ciPTEC-OAT1 is allowed to mature 
under FSS; 5 = two compartments are created per chip consisting of an extracellular matrix (ECM) 
and an apical channel (medium channel). (C) Culture conditions and assay details of 3D P-gp, MRP2/4 
drug efflux assay specified. Image analysis in Fiji contained background correction, image QC (visual 
observation) and normalization. Z stacks per chip were acquired using 10-μm intervals between each 
Z stack resulting in a total number of five Z stacks per chip. Cells on ECM and medium interface were 
selected for further analysis and calculation of the average intensity of Z stacks per chip.
A B
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Figure 6.2 Immunofluorescence staining of ciPTEC-OAT1 in OrganoPlate. (A) Three-dimensional 
(3D) view of ciPTEC-OAT1 in OrganoPlate with F-actin (red) and nuclei (DAPI, blue) showing the 
formation of tubule structures after 8 days of seeding. The phase guide is visible as blue bar at the 
left side of the image. The lumen at the apical side and the extracellular matrix (ECM) are indicated. 
Scale bar represents 100 μm. (B) Staining of nuclei (DAPI, blue) and zonula occludens (ZO-1, green). 
Expression of ZO-1 visible between cell monolayer on top of PTEC tubules. Scale bar represents 100 
μm. (C) Representative images of single cells attached to the extracellular matrix (ECM) selected from 
the tubular ciPTECOAT1 structures in the OrganoPlate, showing staining of nuclei (DAPI, blue) and 
primary cilia with pericentrin (magenta) and acetylated tubulin (green). Most cilia face towards the 
lumen (apical side), demonstrating polarization of the tubules. Scale bar represents 20 μm.
A
B
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Table 6.1 mRNA expression in human kidney cortex and ciPTEC-OAT1 cultured in 2D static or in 
the OrganoPlatea
dCt Relative expression 
ciPTEC-OAT1 vs. hKidneyhKidney ciPTEC-OAT1
6-well OrganoPlate 6-well OrganoPlate
HPRT1 4.2 ± 0.2 6.1 ± 0.1 6.9 ± 0.1 27.6% 15.8%
OAT1 -0.7 ± 0.5 2.2 ± 0.2 3.1 ± 0.7 11.5% 7.4%
OCT2 4.8 ± 0.3 17.5 ± 0.6 17.8 ± 0.3  0.017% 0.012%
P-gp 4.8 ± 0.5 7.6 ± 0.1 8.9 ± 0.7 12.9% 6.3%
MRP2 3.0 ± 0.6 14.18 ± 0.04 14.0 ± 0.1 0.037% 0.043%
MRP4 3.7 ± 0.1 6.3 ± 0.1 6.6 ± 0.4 17.0% 14.2%
a mRNA expression of drug transporters of three independent experiment performed at least in duplicate. Gene expression levels 
were normalized to GAPDH, used as reference gene. Ct values of GAPDH in human kidney (hKidney), ciPTEC-OAT1 in 6-well and in the 
OrganoPlate were 25.6 ± 0.7, 19.7 ± 0.1 and 19.6 ± 0.1, respectively. 
Figure 6.3 The HPRT1, OAT1, OCT2, P-gp, MRP2, and MRP4 expression levels in matured ciPTEC-
OAT1 cultured under FSS (OrganoPlate). Gene expression levels were normalized to GAPDH, used 
as reference gene, and here calculated a fold difference compared to gene expression levels in 2D 
static cell culture (6-well plate). **p < 0.01 compared to mRNA expression in ciPTEC-OAT1 cultured in 
a 6-well plate
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In addition, expression levels of ciPTEC-OAT1 cultured in 6-well plate or in 
the OrganoPlate were compared to expression levels in human kidney cortex 
samples (Table 6.1). In human kidney cortex, OAT1 is most abundantly expressed 
relative to expression levels of other drug transporters assessed here (rank order 
OAT1>MRP2>MRP4>OCT2> P-gp). Expression of OAT1 was also abundantly expressed 
in ciPTEC-OAT1 when cultured either in a 6-well plate or in the OrganoPlate, 
although a different relative expression was observed (rank order OAT1>MRP4>P-
gp>MRP2>OCT2).
Fluorescence-based drug efflux assays in 3D tubule structures
We set up 3D efflux assays for P-gp and MRP2/4 as proof-of-concept to demonstrate 
transport activity in 3D microfluidic PTEC model. The first step in our image analysis 
included the selection of the ROI per chip, which included cells at the ECM and 
medium interface. As shown in Figure 6.4A, the gel channel, medium channel and 
the phase guide were clearly visible. The bright-field images were used to objectively 
choose the ROI per chip. Cell layers formed at the ECM were demonstrated by the 
Hoechst staining (Figure 6.4A). 
P-gp shows the highest affinity for uncharged and positively charged compounds[28, 29]. 
Calcein-AM was used as substrate to study P-gp efflux activity in ciPTEC-OAT1 cultured 
in the OrganoPlate. Calcein-AM can freely diffuse through the cell membrane and 
is a substrate with high affinity for P-gp. Intracellularly, calcein-AM is metabolized 
through esterase activity into the fluorescent calcein. Slight accumulation of calcein 
was observed in the control and vehicle incubated tubules upon incubation with 
calcein-AM (Figure 6.4A), which was strongly enhanced upon co-incubation with 
PSC833, suggesting inhibition of P-gp (Figure 6.4A and Figure 6.5A).
MRP2/4 show highest affinity for negatively charged compounds in the kidney[30-33]. 
To study MRP2/4 activity, 5-chloromethylfluorescein-diacetate (CMFDA), which 
enters the cell via diffusion, was used. CMFDA is then metabolized to the fluorescent 
5-chloromethylfluorescein (CMF) via esterase activity and then further metabolized 
into carboxylfluorescein-glutathione (GS-MF) through direct interaction with 
glutathione (GSH) or via transferase activity. CMF is completely transferred into 
GS-MF during incubation time used here[12]. GS-MF is predominantly a substrate 
for MRP2/4, although some selectivity was demonstrated for BCRP and P-gp[12]. We 
therefore used a combination of inhibitors, as described in the materials and methods 
section. In the control and vehicle tubules, minor accumulation of GS-MF was visible. 
After co-incubation with an inhibitor cocktail of PSC833, KO143 and MK571, a higher 
fluorescence intensity was demonstrated as compared to vehicle control, indicating 
138
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active MRP2/4 in ciPTEC-OAT1 cultured in the OrganoPlate. Signal intensity was 
stable for at least 25 min for both calcein and GS-MF (data not shown).
Image QC and image analysis
Setting up a proper image QC could reduce the variation caused by factors such as 
out-of-focus images, signal-to-noise ratio and cell density. In-focus images of the cell 
layer between ECM and medium interfaces were acquired in the majority of chips. 
Available image QC metrics in CellProfiler were applied to obtain an automated and 
fast image QC of our data set. 
Each image was visually evaluated to be in-focus or out-of-focus. Of all images 
acquired for the 3D P-gp drug efflux assay (n=245, from four different experiments), 
14.3% (n=35) were assigned to be out-of-focus. For the 3D MRP2/4 drug efflux assay, 
21.7% (n=52) of all images (n=240, from four different experiments) were assigned 
to be out-of-focus. The visually evaluated in-focus and out-of-focus images were 
defined as ground truth.
Means of image QC metrics of in-focus and out-of-focus images were compared for 
the two transporter assays as defined for P-gp (Supplemental Table S6.2) and MRP2/4 
(Supplemental Table S6.3). By calculating the F-score per image QC metric, the 
false negatives, true and false positives were incorporated and compared with the 
ground truth. Focus score showed an F-score of 0.46, the highest F-score of all image 
QC metrics determined for the 3D P-gp drug efflux assay, the recall and precision 
score obtained were 0.33 and 0.77, respectively (Supplemental Table S6.2). For the 
3D MRP2/4 drug efflux assay, using focus score with a pixel size 200 resulted in an 
F-score of 0.53, the highest F-score for this assay, with corresponding precision and 
recall scores of 0.36 and 0.94, respectively (Supplemental Table S6.3). For both assays 
low precision scores were obtained, because of a high number of false positives 
compared to true positives, leading to low F-scores. 
To demonstrate proof-of-concept, further analysis was based on the visually 
determined out-of-focus images by three observers, since the image QC metrics 
determined here were less optimal to distinguish in-focus and out-of-focus images 
for our data set. Visually reviewed out-of-focus images were excluded from further 
calculations from this point. 
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Table 6.2 Fold difference in fluorescence intensity for the 3D P-gp drug efflux assay compared 
to vehicle using different threshold algorithm available in Fiji and corresponding calculated 
Z’-factors
CMFDAa CMFDA + vehiclea CMFDA + PSC833, 
KO143, MK571a
Z’-factorb
No threshold 1.0 ± 0.1 1.0 ± 0.1 4.4 ± 0.2*** 0.1 ± 0.3
Default 0.5 ± 0.1 1.0 ± 0.1 5.3 ± 0.6*** -2 ± 1
Huang 0.5 ± 0.1 1.0 ± 0.1 4.4 ± 0.5*** -0.5 ± 0.2
IJ_IsoData 0.5 ± 0.1 1.0 ± 0.1 4.8 ± 0.6*** -2 ± 1
Intermodes 0.6 ± 0.1 1.0 ± 0.1 4.7 ± 0.7*** -2 ± 1
IsoData 0.5 ± 0.1 1.0 ± 0.1 5.1 ± 0.6*** -2 ± 1
Li 0.6 ± 0.1 1.0 ± 0.1 4.4 ± 0.5*** -0.2 ± 0.3
MaxEntropy 0.6 ± 0.1 1.0 ± 0.1 4.1 ± 0.5*** -1 ± 1
Mean 0.8 ± 0.1 1.0 ± 0.1 5.0 ± 0.4*** -0.1 ± 0.3
MinError 0.5 ± 0.1 1.0 ± 0.1 4.8 ± 0.6*** -2 ± 1
Minimum 0.6 ± 0.1 1.0 ± 0.1 4.6 ± 0.7*** -2 ± 1
Moments 0.8 ± 0.1 1.0 ± 0.1 3.5 ± 0.6*** 3 ± 2
Otsu 0.5 ± 0.1 1.0 ± 0.1 5.0 ± 0.6*** -0.1 ± 0.4
Percentile 0.7 ± 0.1 1.0 ± 0.1 3.6 ± 0.5*** -0.5 ± 0.6
RenyiEntropy 0.6 ± 0.1 1.0 ± 0.1 4.0 ± 0.5*** -1 ± 1
Shanbhag 0.6 ± 0.1 1.0 ± 0.1 4.6 ± 0.7*** -2 ± 1
Triangle 0.7 ± 0.1 1.0 ± 0.1 4.0 ± 0.4*** -2 ± 1
aValues were normalized to vehicle per experiment. Significant differences of the means were compared to vehicle using one-way 
ANOVA followed by Dunnett’s multi comparison post-hoc test. ***p<0.01 compared to vehicle. bAverage Z’-factor as calculated in four 
independent experiments. 
Figure 6.5 Average intensity measured per condition and chip is shown for control, solvent-
treated and inhibitor-treated conditions. (A) Fold difference in calcein or in (B) GS-MF fluorescence. 
Values were normalized to vehicle per experiment. No threshold algorithm was used. Significant 
differences of the means were compared to vehicle using one-way ANOVA followed by Dunnett’s 
multi comparison post hoc test. ***p < 0.001 compared to vehicle.
A B
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Table 6.3 Fold difference in fluorescence intensity for the 3D MRP2/4 drug efflux assay compared 
to vehicle using different threshold algorithm available in Fiji and corresponding calculated Z’-
factors
CMFDAa CMFDA + vehiclea
CMFDA + PSC833, 
KO143, MK571a Z’-factorb
No threshold 1.3 ± 0.1 1.00 ± 0.05 3.0 ± 0.2*** 0.4 ± 0.1
Default 1.3 ± 0.2 1.0 ± 0.1 5.1 ± 0.7*** -0.4 ± 0.2
Huang 1.2 ± 0.2 1.0 ± 0.1 3.9 ± 0.5*** -0.6 ± 0.1
IJ_IsoData 1.3 ± 0.2 1.0 ± 0.1 4.2 ± 0.6*** -0.70 ± 0.05
Intermodes 1.2 ± 0.1 1.0 ± 0.1 3.7 ± 0.3*** -0.4 ± 0.2
IsoData 1.3 ± 0.2 1.0 ± 0.1 4.6 ± 0.6*** -0.5 ± 0.2
Li 1.3 ± 0.2 1.00 ± 0.05 4.0 ± 0.4*** -0.7 ± 0.2
MaxEntropy 1.2 ± 0.1 1.0 ± 0.1 3.7 ± 0.4*** -0.3 ± 0.3
Mean 1.4 ± 0.2 1.0 ± 0.1 3.4 ± 0.3*** -0.4 ± 0.4
MinError 1.3 ± 0.2 1.0 ± 0.1 4.2 ± 0.6*** -0.70 ± 0.05
Minimum 0.9 ± 0.2 1.0 ± 0.1 3.7 ± 0.3*** -0.2 ± 0.1
Moments 1.2 ± 0.2 1.0 ± 0.1 4.1 ± 0.5*** -0.3 ± 0.3
Otsu 1.3 ± 0.2 1.00 ± 0.04 4.5 ± 0.6*** -0.5 ± 0.1
Percentile 1.6 ± 0.3 1.0 ± 0.1 2.9 ± 0.3*** -1.4 ± 0.2
RenyiEntropy 1.2 ± 0.1 1.0 ± 0.1 3.6 ± 0.3*** -0.3 ± 0.2
Shanbhag 0.8 ± 0.2 1.0 ± 0.1 4.0 ± 0.7*** -5 ± 5
Triangle 1.4 ± 0.2 1.0 ± 0.04 3.2 ± 0.2*** -0.2 ± 0.1
aValues were normalized to vehicle per plate. Significant differences of the means were compared to vehicle using one-way ANOVA 
followed by Dunnett’s multi comparison post-hoc test. ***p<0.01 compared to vehicle. bAverage Z’-factor as calculated in four 
independent experiments. 
Fluorescence intensity in image and average per chip
Fluorescence intensities per image were determined in Fiji to perform semi-
quantitative analysis of P-gp and MRP2/4 drug efflux activities (Table 6.2 and 6.3). 
Masking using thresholding algorithms was applied to create a selection area 
incorporating the intracellular accumulation of calcein or GS-MF, and compared 
to the intensity of the entire image. A higher intensity after co-incubation with 
inhibitor(s) was observed for all semi-quantitative methods used in both drug efflux 
assays (Table 6.2 and 6.3). No differences between vehicle-treated and control were 
observed in the drug efflux assays. 
Z’-factor was calculated per experiment to compare and optimize the semi-
quantitative analysis methods. Thresholding algorithm and the intensity of the entire 
image were compared in Table 6.2 and 6.3. Z’-factors are only meaningful when they 
fall within a range of -1<Z’≤1, which is the case for the majority of the thresholding 
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algorithms[27]. Remarkably, when using algorithm threshold Moments for the 3D P-gp 
drug efflux assay, the mean of the negative control (vehicle treatment) was higher than 
the mean of positive control (PSC833) treatment the in two experiments, resulting 
in Z’>1. Without using a thresholding algorithm, this resulted in Z’-factor values of 
0.1 ± 0.3 and 0.4 ± 0.1 for the 3D P-gp and MRP2/4 drug efflux assays, respectively. 
For all analysis methods, a significant increase in fluorescence intensity was found 
upon transport inhibition for both assays, however, thresholding algorithms resulted 
in large standard deviations. In general, Z’-factor values were <0 when using a 
thresholding algorithm, because of an overlap in fluorescence intensity between 
the groups, indicating that image analysis using threshold algorithms as presented 
here is not suitable for HTS[27]. Thresholding algorithms included more steps in the 
semi-quantitative analysis macro in Fiji (see Supplemental data), which increased the 
processing time per image, and Z’-factors were lower compared to the intensity of 
the entire image. Therefore, measuring intensity in the entire image showed the most 
reliable results. 
Upon establishing a valid semi-quantitative image analysis method for both assays, 
the average fluorescence intensities per chip were calculated, as shown in Figure 6.5. 
PSC833-mediated inhibition of P-gp resulted in a 4.4 ± 0.2-fold increase fluorescence 
intensity compared to vehicle treated tubules (Figure 6.5A). For the 3D MRP2/4 drug 
efflux assay, in tubules co-incubated with PSC833, KO143 and MK571 led to a 3.0 ± 0.2-
fold increased compared to vehicle (Figure 6.5B). Both assays demonstrate function 
of P-gp and MRP2/4 and the possibility to semi-quantify renal drug interaction via 
increased fluorescence intensity. 
Discussion
In this study, we developed a 3D microfluidic PTEC model demonstrated to be suitable 
for the evaluation of renal drug interactions with efflux transporters. The system has 
high potential for early drug screening due to its medium to high-throughput features 
and compatibility with high-content imaging platforms as shown in the current study 
on 3D efflux assays as well as demonstrated by Vormann et al.[34] and Suter-Dick et 
al.[35]. We cultured the human conditionally immortalized cell line ciPTEC-OAT1 in the 
OrganoPlate exposed to FSS induced by leveling, creating a 3D microfluidic PTEC 
model. The OrganoPlate enabled the formation of polarized tubule-like structures in 
a 96-well format. 
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A polarized epithelium was obtained upon culturing of ciPTEC-OAT1 in the OrganoPlate 
and showed apical expression of cilia, in line with an earlier publication of a 
perfusable printed 3D PTEC[36]. Furthermore, gene expression levels of OAT1 (SLC22A6), 
OCT2 (SLC22A2), P-gp (ABCB1), MRP2 (ABCC2) and MRP4 (ABCC4) were confirmed. 
Representative monolayers were formed and functional activity and drug interactions 
for P-gp and MRP2/4 was demonstrated by means of fluorescence-based transport 
assays. Open source imaging software was used to analyze fluorescence to make this 
platform user friendly and suitable for screening of larger data sets. 
Basal PTEC characteristics were shown to be improved in kidney-on-a-chip platforms, 
likely because of inclusion of a physiological FSS and cell-ECM interaction[15, 36, 37]. 
Interestingly, enhanced P-gp efflux activity and transepithelial transport of para-
aminohippurate (PAH) was demonstrated[15, 38]. Microfluidic kidney models could advance 
lead optimization at early stages of drug development and are an emerging technology 
to study drug-transporter interactions and toxicity[39]. Future efforts demonstrating 
the improvements of such microfluidic 3D PTEC models as compared to regular 2D 
static culture should include a validation study with a compound library focusing 
on sensitivity and specificity using nephrotoxic and non-nephrotoxic compounds. 
Complexity and lack of compatibility with HTS of current kidney-on-a-chip models are 
a major drawback as opposed to 2D static cell culture in a multiwell setting required 
for drug screening purposes. Most published kidney-on-a-chip models use complex 
pump-driven single chip systems that frustrate experiments relying on multiple test 
conditions[15, 36, 38, 40-42]. The 3D microfluidic PTEC model presented here consisted of 96 
chips on one plate and physiological FSS that is induced by leveling, without the need 
for external components. Therefore, it has high potential for HTS settings and could 
relatively easily be implemented in current disposition studies in drug development.
In vitro toxicity screening at early phases of drug discovery benefits from its 
compatibility for HTS and low costs. Freshly isolated human primary PTEC are the 
golden standard for in vitro screenings when it comes to intact drug transporter 
functionality and resemblance to the human kidney. However, expression levels 
decrease within days after seeding and such studies are limited for their low 
reproducibility[43, 44]. Vesicles and over-expression of drug transporters in immortalized 
cell lines are powerful tools as well to evaluate such drug-transporter interactions, but 
often lack human PTEC characteristics that could link drug-transporter interactions 
to clinically relevant toxicological read-outs[45-49]. Human-derived immortalized renal 
cell models such as human embryonic kidney 293 (HEK 293) and human kidney 2 
(HK 2) cells have shown to be a valuable tool in screenings in drug development, but 
have low or no endogenous expression of relevant drug transporters[50, 51]. To overcome 
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these limitations, we have developed ciPTEC-OAT1 with proven suitability for 
nephrotoxicity and drug-transporter interactions studies[10-14]. The broad range of drug 
transporter expression in ciPTEC-OAT1 provides a strong basis for highly predictive 
renal drug interaction studies. The inter-complexity and overlap in substrates of renal 
drug transporters, rather than through one drug transporter, is incorporated because of 
this broad range of drug transporter expression. This resembles a more physiological, in 
vivo-like, mechanism of renal drug handling. Gene expression levels of drug transporters 
in ciPTEC-OAT1 assessed here were lower compared to levels observed in samples of 
the human renal cortex, in accordance with other renal cell lines[50]. Functionality of 
OAT1, OCT2, BCRP, P-gp and MRP2/4 in ciPTEC 2D cell culture has been demonstrated 
in multiple studies[9, 10, 12-14].
Establishing highly predictive renal in vitro models for nephrotoxicity and renal drug-
transporter interactions could refine and, ultimately, replace animal experiments. 
Besides the ethical issues, animal testing is expensive and not always translatable 
because of species differences. Following this study, future research should be 
directed to develop a method that allows in vitro-in vivo extrapolation of data, using 
experimental input from the 3D microfluidic PTEC model in accordance to Kunze et 
al.[52]. Such extrapolation could demonstrate the added value and potential of our 
model to replace current animal studies now used for renal drug handling screenings. 
Influx drug transporters should be evaluated in parallel to drug transporter efflux 
activity to obtain a reliable prediction on renal excretion. Uptake via OCT2 and 
OAT1/3 has been demonstrated in ciPTEC using uptake of fluorescent substrates[9, 10]. 
Using ciPTEC-OAT1, transepithelial transport of the uremic toxins indoxyl sulfate and 
kynurenic acid could be indirectly demonstrated when cells were cultured on hollow 
fiber membranes, thereby forming a renal epithelial tubule[13]. Expanding the platform 
with a third lane that includes a perfusable basolateral compartment together with 
a perfusable apical compartment in a 3D microfluidic platform could be used to 
study transepithelial transport or organic cations and anion in detail, as shown by 
Vormann et al.[34]. Other potential applications for the three-compartmental system are 
the incorporation of other segments of the renal tubules or co-culture with vascular 
endothelial cells, as recently was demonstrated[42, 53].
In the current study, accumulation of fluorescence in the chips was evaluated from 
five z-stacks with a 10 µm interval per chip. This approach resulted in a variation of 
image focus per chip and per experiment. To reduce variability per stack, an image 
QC was introduced. We used a visually determination of in-focus and out-of-focus 
images. In our study, image QC metrics tested, such as PLLS, resulted in low precision 
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and corresponding F-scores because of overlapping means of image QC metric 
between in-focus and out-of-focus images assessed. Optimizing imaging in the 
OrganoPlate by using autofocus could reduce the number of out-of-focus images 
and improve image QC metric outcome. In addition, by acquiring more Z-stacks per 
chip, chances of obtaining in-focus images increase. A proper image QC is key in 
reliably screening larger data sets typical for HTS, and should therefore be optimized 
for each setting. Measuring fluorescence intensity in the entire image as compared 
to using thresholding algorithms provided the most optimal semi-quantification of 
efflux activity. Corresponding Z’-scores where within an acceptable range (0.5>Z>0) 
where standard deviation bands of positive and negative controls were separated[27]. 
Aforementioned improvements in confocal imaging could further increase separation 
of standard deviations from controls. 
Conclusion
To conclude, we present a 3D microfluidic PTEC model including most important 
renal drug transporters in a platform consisting of 96 chips. Multiplexing of different 
endpoint read-outs and testing multiple conditions in one plate allows this platform 
to be suitable for medium to high-throughput screenings and compatible with most 
high-content imaging platforms.
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Supplemental data
Supplemental Figure S6.1 Rotation of 360° of tubules at day 8 after seeding. Immunofluorescence 
staining with F-actin (red) and nuclei (DAPI, blue) in ciPTEC-OAT1 in the OrganoPlate. Available 
online[54].
Supplemental Figure S6.2 Long-term culture of 20 days of ciPTEC-OAT1. Immunofluorescence 
staining of F-actin (red), tight-junction protein zonula occludens (ZO-1, green), nuclei (DRAQ5, blue) 
in ciPTEC-OAT1 in the OrganoPlate, stained at day 20 after seeding. Scale bar represents 100 μm.
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Supplemental Figure S6.3 Cilia staining in ciPTEC-OAT1 demonstrates polarized tubular 
structures. Immunofluorescence staining of nuclei (DAPI, blue) and cilia by means of staining 
pericentrin (magenta) and acetylated-tubulin (green) in ciPTEC-OAT1 in the OrganoPlate at day 
8 after seeding. Z stacks displayed as volume and 360° rotation of cell monolayer attached to the 
extracellular matrix (ECM). Rotation starts viewing from lumen (apical side) and rotates to viewing 
point from ECM (basolateral side) and back with the viewing point from lumen. Clearly visible is that 
cilia were mainly demonstrated on apical side, facing the lumen of the tubules. Cilia are also observed 
on few cells that migrated into the ECM. Available online[54].
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Supplemental Table S6.1 Thresholding algorithms available in Fiji (version 1.51n) and used in 
image analysis described in this paper
Default IsoData MinError Percentile
Huang Li Minimum RenyiEntropy
IJ_IsoData MaxEntropy Moments Shanbhag
Intermodes Mean Otsu Triangle
Supplemental Table S6.2 Image QC metrics focus score, image correlation and PLSS of 3D P-gp 
drug efflux assaya
Metrics Pixel size In focus Out of focus Cut-off Precision Recall F-score
Focus score - 3.0×10-3 ± 0.3×10-3 4.2×10-4 ± 0.8×10-4*** 0 0.33 0.77 0.46
500 3.8×10-4 ± 0.8×10-4 2×10-5 ±  1×10-5 0 0.18 0.97 0.30
200 2.8×10-3 ± 0.5×10-3 7×10-4 ± 5×10-4 0 0.17 0.94 0.29
100 5.8×10-3 ± 0.7×10-3 2×10-3 ± 1×10-3* 0 0.23 0.94 0.36
50 7.7×10-3 ± 0.9×10-3 7×10-4 ± 4×10-4** 0 0.23 0.94 0.37
20 5.0×10-3 ± 0.8×10-3 3×10-4 ± 2×10-4* 0 0.22 0.91 0.36
Image correlation 500 0.20 ± 0.01 0.23 ± 0.03 0.55 0.15 1.00 0.25
200 0.27 ± 0.01 0.27 ± 0.03 0.60 0.15 1.00 0.26
100 0.35 ± 0.01 0.33 ± 0.04 0.20 0.20 0.43 0.27
50 0.45 ± 0.01 0.41 ± 0.04 0.20 0.25 0.43 0.32
20 0.63 ± 0.01 0.51 ± 0.04*** 0.3 0.45 0.40 0.42
PLLS - -1.90 ± 0.02 -1.94 ± 0.09 -2.2 0.23 0.43 0.30
aData is of spinning disk confocal microscopy images of calcein (n=245) from four independent experiments. In-focus and out-of-focus 
images were determined visually, using criteria as described in the methods section, and defined as ground truth. Per image QC metric, 
cut-off values and its corresponding F-scores were calculated. The best achievable F-score is displayed in this table. *p<0.05 compared to 
in-focus, **p<0.01 compared to in-focus, ***p<0.001 compared to in focus images.
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Supplemental Table S6.3 Image QC metrics focus score, image correlation and PLSS of 3D 
MRP2/4 drug efflux assaya
Metrics Pixel size In focus Out of focus Cut-off Precision Recall F-score
Focus score - 7.2×10-4 ± 0.5×10-4 2.2×10-4 ± 0.2×10-4** 2×10-4 0.39 0.73 0.51
500 8×10-5 ± 1×10-5 1.1×10-5 ± 0.3×10-5** 0 0.30 0.83 0.44
200 5.7×10-4 ± 0.7× 10-4 6×10-5 ± 2×10-5*** 0 0.38 0.87 0.53
100 1.4×10-3 ± 0.2×10-3 8×10-5 ± 3×10-5** 0 0.30 0.92 0.46
50 9×10-4 ± 1×10-4 4×10-5 ± 1×10-5*** 0 0.33 0.92 0.48
20 2.7×10-4 ± 0.4×10-4 9×10-6 ± 3×10-6*** 0 0.36 0.94 0.52
Image correlation 500 0.19 ± 0.01 0.15 ± 0.02 0.1 0.33 0.62 0.43
200 0.25 ± 0.01 0.18 ± 0.02** 0.15 0.31 0.65 0.42
100 0.33 ± 0.01 0.24 ± 0.03** 0.15 0.38 0.48 0.43
50 0.43 ± 0.01 0.32 ± 0.03*** 0.3 0.36 0.62 0.45
20 0.60 ± 0.01 0.43 ± 0.03*** 0.4 0.45 0.56 0.50
PLLS - -1.89 ± 0.02 -1.87 ± 0.06 -2.3 0.53 0.31 0.39
aData is of spinning disk confocal microscopy images of GS-MF (n=240) from four independent experiments. In-focus and out-of-focus 
images were determined visually, using criteria as described in the methods section, and defined as ground truth. Per image QC metric, 
cut-off values and its corresponding F-scores were calculated. The best achievable F-score is displayed in this table. *p<0.05 compared to 
in-focus, **p<0.01 compared to in-focus, ***p<0.001 compared to in focus images.
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Macro to measure fluorescence intensity
Note: different algorithm thresholds can be used to measure intensity
macro “Measure intensity Alexa488, no thresholding algorithm” {
nameImg=getTitle();
setOption(“BlackBackground”, true);
run(“Set Measurements...”, “area mean standard modal min centroid center perimeter 
bounding fit shape feret’s integrated median skewness kurtosis area_fraction stack 
display redirect=None decimal=3”);
selectWindow(nameImg);
run(“Measure”); 
selectWindow(nameImg);
close(); 
}
macro “Measure intensity Alexa488 with thresholding algorithm” {
nameImg=getTitle();
setOption(“BlackBackground”, true);
run(“Duplicate...”, “title=Mask”);
selectWindow(“Mask”);
run(“Median...”, “radius=5”);
algorithm = “[add name threshold here]”;
run(“Auto Threshold”, “method=” + algorithm + “ dark”);
run(“Convert to Mask”);
run(“Erode”);
run(“Create Selection”);
roiManager(“Add”);
roiManager(“select”, 0);
selectWindow(“Mask”);
close();
run(“Set Measurements...”, “area mean standard modal min centroid center perimeter 
bounding fit shape feret’s integrated median skewness kurtosis area_fraction stack 
display redirect=None decimal=3”);
selectWindow(nameImg);
roiManager(“Select”, 0);
roiManager(“Measure”);
selectWindow(nameImg);
close(); 
}
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Introduction
The first phase in drug development often concerns the identification of a lead 
compound for the biological target of interest, using high-throughput screening of 
large chemical libraries. Adverse effects of candidate drugs are commonly evaluated 
only in late pre-clinical stages, following optimization of pharmacokinetics and 
pharmacodynamics, and are traditionally regarded as the ‘final hurdles’ before 
clinical trials can be initiated. At this point, the remaining drug candidates are 
tested using rodent and non-rodent animal models, while 2D cell culture models 
are applied in screening for specific organ toxicity. These current preclinical models 
are, however, insufficiently capable of predicting drug-induced kidney injury, 
resulting in undesirably high clinical attrition of potential drugs[1]. Laboratory animals 
and humans intrinsically differ in physiology and therefore responses in animal 
toxicological studies are not always applicable to human drug toxicity. The reason 
why existing in vitro models perform suboptimal, may be reflected in the use of 
oversimplified and insufficiently differentiated cell lines and the neglect of renal 
micro environmental cues[2-4]. The lack of predictive value results in approximately 
50% of drug candidates having unknown harmful effects while entering clinical trials 
with harmful effects, leading to costly and ethically compromised late-stage drug 
withdrawals[1]. To improve the success rate of drug development, harmful compounds 
need to be eliminated at early phases, without the risk of excluding false-positives. To 
this end, in vitro toxicity studies and drug-drug interaction (DDI) evaluations should 
be implemented at earlier stages of the drug development pipeline, employing 
models with high predictive value for humans.
In vitro models for drug-induced renal proximal 
tubule toxicity screening
The most important and ongoing challenge for in vitro disease modeling in general, 
including drug-induced toxicity research, is to find a reliable and sustainable source 
of human-derived cells that phenotypically represent their in vivo counterpart[5]. 
Drug-induced renal toxicity commonly affects the proximal tubule epithelium. 
Therefore, the phenotype of cultured proximal tubule epithelial cells (PTEC) is 
decisive for drug sensitivity and faithful replication of the mechanisms responsible 
for toxicity induction. Renal models generally consist of either freshly isolated or 
cryopreserved primary renal cortex cells, immortalized proximal tubule cell lines or 
induced pluripotent stem cell (iPSC)-derived renal cells. Each of these models has 
unique advantages and disadvantages, which are summarized below. 
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Primary renal tubule cells phenotypically resemble their in vivo counterpart best 
in terms of morphology, polarization, drug transporter function and biomarkers. 
As such, primary cells demonstrate the best replication of drug-induced toxicity 
mechanisms[6, 7]. While they can be cryopreserved to be readily available, their 
expansion capacity in culture is low, resulting in the need for multiple donors. While 
the observed differences between donors lead the way for personalized medicine, 
this does not contribute to experimental reproducibility. 
Induced pluripotent stem cell (iPSC), on the other hand, can be cultured for extended 
passages and are capable of differentiation into renal cells, theoretically generating an 
unlimited cell source[8]. Usually skin fibroblasts are the source of these cells but they 
can be generated from any nucleated cell type, and can consecutively be differentiated 
into tissues relevant for drug-induced toxicity evaluation, including proximal tubule-
like cells[9, 10]. Accumulating evidence in literature underlines the influence of inter-
individual genetic differences on drug responses and drug-induced toxicity, giving 
rise to a personalized medicine approach[11, 12]. Most adverse effects only occur in a 
subset of treated individuals, which are most likely underrepresented in clinical trials. 
Experimental models representing subgroups of the general population may identify 
individuals at increased risk for developing adverse effects, including children, elderly 
and patients for which the drug is intended, but also individuals suffering from chronic 
kidney disease or diabetes mellitus. Being able to generate renal proximal tubule cell 
models derived from any individual will pave the way towards personalized medicine. 
At present, these cell models have been successfully applied in kidney organoid cultures 
for toxicity evaluation, suggesting intact function including drug transporter activity, 
but it remains to be elucidated how the in vitro phenotypes of individual iPSC-derived 
cells compare to their in vivo counterparts[10]. In addition, modeling subpopulations or 
disease states in vitro likely requires reproducing affected physiological parameters. 
While further progress is needed to fully mature the techniques involved, iPSC-derived 
tissues are likely to be implemented in the evaluation of drug-induced toxicity and 
DDIs in a personalized approach.
Immortalized cell lines can overcome some of the limitations mentioned above and 
therefore have been adapted for industrial screening applications. The phenotypes 
of human-derived renal cell lines are well-characterized and include retained PTEC 
morphology, in some cases polarization, and demonstrate enhanced proliferative 
capacity compared to primary PTEC. However, reduced drug transporter function 
and renal biomarker expression may cause these cells to be hampered by low 
predictivity[13, 14]. Several suitable human-derived proximal tubule cell lines were 
established that have retained proximal tubule characteristics rather well, including 
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ciPTEC and RPTEC/TERT1. Recently, the genome of both cell lines has been edited to 
over-express transport proteins that were initially lost in the immortalization process, 
like OAT1 and OAT3 for ciPTEC[15], and OAT1 and OCT2 for RPTEC/TERT1[ATCC-LGC Standards, 
Wesel, Germany].
As we demonstrated in Chapter 2 for ciPTEC, expression of OATs results in regained 
sensitivity for clinically relevant nephrotoxic antiretroviral agents, such as adefovir 
and tenofovir. Compared to earlier studies employing OAT over-expressing cell lines 
of non-renal origin, ciPTEC-OAT1 remarkably demonstrated reduced sensitivity to the 
antiretroviral drugs tested. Although we used a relatively insensitive endpoint, the 
main reason for this observation is most likely the presence of active ABC (efflux) 
transporters, including MRP4. The in vitro capacity of MRP4 to transport adefovir 
and tenofovir has been known for several years[16, 17], while evidence for the clinical 
implications of MRP4-mediated transport of antiretrovirals was only reported recently. 
For example, several single nucleotide polymorphisms in ABCC4 have been identified 
that predispose for tenofovir-induced nephrotoxicity[18, 19]. In the clinical setting, DDIs 
with MRP4 could have the same effect, but this has not been observed consistently[20, 
21]. Expression of MRP4 is retained in ciPTEC, which provides a good platform to study 
modulation of proximal tubule efflux as approach to reduce antiretroviral-induced 
acute kidney injury (AKI). Mitochondria are the primary target of renal toxicity by 
antiretrovirals. Impairment of these organelles especially affects the PTEC as they are 
rich in mitochondria and dependent on aerobic, OXPHOS-mediated ATP production 
to supply the energy required for active transport processes and metabolism[22]. The 
mechanism of adefovir toxicity involves inhibition of mitochondrial DNA polymerase-γ 
leading to a decrease in mitochondrial DNA (mtDNA) replication and expression of 
mitochondrial OXPHOS proteins, ultimately resulting in reduced ATP production[23]. 
The mechanism for tenofovir may be different as in vitro studies suggested that 
depletion of mtDNA and cytotoxicity is lower compared to similar antiretroviral 
drugs[24, 25], while it caused severe AKI in the clinic, associated with morphological 
aberrations and swollen mitochondria[26]. Unknown additional mitochondrial targets 
may be responsible for the observed tenofovir-induced adverse effects in PTEC. 
OAT1-overexpressing ciPTEC may be a suitable model to study these mechanisms in 
more detail.
Expression of OATs in PTEC models also offers the opportunity to investigate the indirect 
contribution of OAT-mediated transport to drug-induced toxicity. In Chapter 3, we 
showed that expression of OAT1 and OAT3 reduced ciPTEC sensitivity to cisplatin, a 
cytostatic drug that is handled by organic cation transporters. The observation could 
be explained by reduced activity of the influx transporter OCT2, although we can only 
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speculate about the involved regulatory pathways. OAT transport function is closely 
related to energy metabolism since these transporters exchange dicarboxylates, 
preferentially the citric acid cycle intermediates α-ketoglutarate, glutarate, succinate 
and fumarate[27]. Therefore, metabolic changes due to loss of OAT expression in PTEC 
models may affect in vitro prediction of drug-induced toxicity. Using metabolomics 
and microarray data from OAT1 and OAT3 knockout mice, it was possible to 
generate an extended metabolic network focused on these transporters, indicating 
their importance in glycolysis, citric acid cycle, fatty acid and lipid, pyruvate, NAD, 
flavonoid, amino acid, vitamin, and (cyclic) nucleotide metabolism[28-31]. In line with 
these observations, drug transporters are postulated to be involved in the regulation 
of endogenous metabolism and metabolic homeostasis[32]. Considering drug-induced 
toxicity, DDIs with OATs may affect energy metabolism and could contribute to 
adverse drug effects, especially in tissues with high OAT expression, such as the 
kidney proximal tubule epithelium. A better understanding of the endogenous roles 
of drug transporters will shed light on their influence on physiological and disease 
metabolism, and possibly on adverse drug effects and predisposing factors we do 
not yet understand.
Biomarkers for drug-induced renal proximal tubule 
toxicity screening
To enable in vitro to in vivo extrapolation of renal adverse effects, human-derived 
cell culture models should allow analysis of clinically relevant biomarkers. Classical 
readouts of toxicity used in regular 2D assays as evaluated in Chapters 2 and 3 focus 
on acute toxicity and reflect membrane integrity, like lactate dehydrogenase (LDH) 
and propidium iodide (PI), or metabolic activity, like reduction of MTT and intracellular 
ATP concentration. Biochemical markers for membrane integrity and energy 
metabolism are widely applied, but are not specific to the kidney and, therefore, 
have limited translational value[33, 34]. In addition, evaluating general cytotoxicity by 
studying membrane integrity and ATP metabolism may underestimate renal injury 
in the clinic, which involves more subtle, functional changes, such as proteinuria. 
This was illustrated in Chapter 4, as uptake of antisense oligonucleotides (AON’s) 
in ciPTEC resulted in competition with low-molecular weight proteins for receptor-
mediated endocytosis, mimicking proteinuria in vitro, while cytotoxicity for AON’s was 
not observed. Quantification of kidney-specific proteins like kidney injury molecule 1 
(KIM-1) and their gene expression profiles allows for in vitro to in vivo extrapolation. 
KIM-1 is a transmembrane glycoprotein involved in tubular regeneration and is 
increasingly expressed in dedifferentiated proximal tubule epithelial cells after 
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ischemic or toxic injury[35, 36]. Upon tubule cell damage, the ectodomain of KIM-1 is shed 
into the urine and abundance increases over 100-fold, significantly outperforming 
serum creatinine as biomarker in rat models of kidney injury[36]. This response has 
been validated for tubular toxicity induced by well-established nephrotoxicants, 
such as cisplatin and aminoglycoside antibiotics in rodents[36, 37], although additional 
clinical evaluation is required[34]. Biomarkers with similar in vitro to in vivo translation 
potential include the cytosolic protein NGAL (neutrophil gelatinase-associated 
lipocalin), cystatin C, cytokines involved in renal immune responses, such as IL-6 
and IL-8; and possibly heme oxygenase 1 (HO-1)[33, 38]. In addition, several miRNAs, 
including miR-21, miR-155 and miR-18a, may see future application as renal-specific 
biomarkers, as these are released into the urine upon drug-induced tubule epithelial 
injury, similar to KIM-1[39]. Implementation of renal-specific biomarkers will improve 
our mechanistic understanding of drug-induced kidney injury and will be crucial for 
translation of renal adverse effects to the clinic.
Fluid shear stress in renal proximal tubule function
A growing body of evidence in literature shows that increased reproduction of the 
physiological microenvironment, including luminal flow, improves in vitro renal 
proximal tubule characteristics and, therefore, may enhance predictive value of these 
models, as discussed in Chapter 5. Replicating the characteristic microenvironment 
of kidneys improves the differentiation of human primary PTEC as evaluated by 
epithelial polarization, indicated by increased cell height, basolateral expression of 
Na+/K+-ATPase and apical expression of AQP1[2, 40, 41]. Regarding evaluation of drug-
induced toxicity and DDIs, fluid shear stress (FSS) has been shown to enhance Pgp 
and MATE2-k transport function and receptor-mediated endocytosis in proximal 
tubule cells[2, 4, 42].
Primary cilia have been postulated to regulate the activity of drug transporters and 
endocytosis receptors in response to FSS, but conclusive evidence for this relation has 
not been produced. Primary cilia are immotile, microtubule-based organelles that are 
responsible for transduction of flow-mediated signaling in epithelial cells. This role is 
supported in in vitro tubule models by an increased number of ciliated cells and length 
of primary cilia after exposure to FSS[2, 43-45]. Hence, to investigate the role of primary 
cilia in flow-mediated regulation of drug transporters, a deciliated clone of ciPTEC was 
generated by CRISPR/Cas9 genome editing technology. The target sequence selected 
was located in the KIF3A gene (Figure 7.1A, underlined), because its disruption should 
prevent the formation of the primary cilia cellular membrane[46, 47]. The KIF3A gene in 
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cilia-depleted and parent ciPTEC was sequenced, confirming the introduction of a 
genomic frame shift mutation (Figure 7.1A), resulting in knock-out of KIF3A protein 
in ciPTECKIF3A-/-, while it was clearly expressed in ciPTEC parent in both proliferating 
(33°C) and maturating (37°C) cultures (Figure 7.1B). Finally, cilia-depleted and parent 
ciPTEC were stained for acetylated tubulin and peri-centrin to confirm the presence 
of primary cilia in ciPTEC-parent (indicated by the white arrows) and the successful 
inhibition of ciliogenesis in ciPTECKIF3A-/- (Figure 7.1C). While cilia formation was 
prevented in ciPTECKIF3A-/-, the downstream signaling pathways should be preserved, in 
contrast to methods using chemically removal of cilia by chloral hydrate that possibly 
compromises pathways and metabolic processes[45, 48]. In addition to flow regulation, 
primary cilia are known to be involved in cell differentiation and proliferation through 
Wnt and Hedgehog signaling pathways[49]. Therefore, cilia are also postulated to play 
a role in epithelial repair mechanisms following drug-induced insults[50]. Together, the 
ciPTEC model and its cilia-depleted counterpart are currently available as tools to 
investigate the mechanism of cilia-mediated signaling in the human proximal tubule.
Kidney-on-a-chip for drug-induced renal proximal 
tubule toxicity and DDI screening
A luminal flow that is regulated, equally distributed (laminar) and pulsatile within the 
physiological range will better mimic the renal tubule physiological microenvironment 
in vitro. The most promising technique to generate proximal tubule cultures with 
increased physiological relevance and investigate the effect of FSS is a microfluidic 
device, also called kidney-on-a-chip, as discussed in Chapter 5. Microfluidic devices 
enable the in vitro culture of cells in a perfused channel with micrometer dimensions, 
in order to recreate the physiologically relevant niche of the cell type in question, 
hence, potentially increasing differentiation status and function. The force of FSS that 
is applied in current in vitro models ranges from 0.2 to 1 dyne•cm-2, and most likely 
resembles the force as experienced in vivo by a normal human PTEC[51]. In addition to 
flow, microfluidic models support replication of the extracellular matrix (ECM), eg. by 
coating with collagen type IV. Furthermore, it may include multiple compartments 
that stimulate polarization of PTEC with formation of distinct apical and basolateral 
membranes and access to their bounding compartments[2, 40, 41, 44, 52]. Combining these 
technologies with a human-derived PTEC model provides a promising basis for 
developing advanced renal drug-induced toxicity testing models. In Chapter 6 we 
demonstrated proof-of-principle for ciPTEC using fluorescent-based assays to evaluate 
transport activity of Pgp and MRP2/4 in a microfluidic device. The microtiterplate 
OrganoPlate® used in our study allows culturing of ciPTEC-OAT1 on collagen type I in 
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a perfused channel with a tubule-like structure. Additional studies should point out 
if the increased physiological relevance of this novel model translates into a higher 
predictive value for drug-induced renal toxicity in humans.
The future position and complexity of renal microfluidic devices in drug development 
will be reflected by their need as pre-clinical evaluation tools that partly replace 
animal testing and reduce adverse events during clinical trials. Current examples 
of kidney-on-a-chip systems that demonstrate high complexity and physiological 
resemblance can easily be applied in mechanistic studies[53-55]. Such studies are most 
likely to be performed in late-phase pre-clinical studies, if the number of compounds 
to be tested is relatively low (less than 10), and clinically more relevant models are 
required[54]. This application may benefit from the experimental designs of current 
microfluidic devices, which allows a fit-for-purpose solution[55]. Additional advantages 
of current systems include the optical transparency, which allows for real-time and 
high-resolution analysis; a reduction in expensive cell culture reagents and drug 
compounds due to small volumes; and the possibility to culture multiple cell types, 
representing interacting tissues or even organs[53]. Microfluidic devices are, moreover, 
a suitable approach to comply with the principles of 3Rs, being reduction, refinement 
and replacement of animals in research. Despite the promising and tempting leap 
forward in physiological relevance and drug sensitivity of in vitro cultures of proximal 
tubule cells, several challenges remain to be solved before microfluidic devices can be 
implemented in pharmaceutical industry. The ongoing challenges will be discussed 
point-by-point in the following paragraphs and are summarized in Figure 7.2.
Kidney models that demonstrate an increased complexity and physiological 
resemblance are generally not compatible with automated screening. High content 
screening (HCS) employs automated imaging and analysis to ideally evaluate multiple 
toxicological endpoints, which increases throughput and improves mechanistic 
insight at the same time[56]. An essential requirement is multiplexing of fluorescent 
dyes probing cellular functions like membrane integrity and mitochondrial membrane 
potential, to enable analysis by algorithms and automation compatibility. Such an 
approach was used previously in the liver-derived HepG2 cell line, which resulted 
in a sensitivity of around 50% and less than 10% false positives in drug-induced 
hepatotoxicity screening[57]. Similar predictive values were found in a study evaluating 
drug-induced toxicity in cultured primary human PTEC in which 129 phenotypic 
parameters were derived from 4 combined fluorescent probes using machine-
learning algorithms[58]. The combination of HCS and microfluidic devices might 
further improve drug-induced nephrotoxicity screening. Consequently, designing 
microfluidic devices with HCS and automation will be an essential asset for future 
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Figure 7.1 Absence of KIF3A protein and cilia in ciPTECKIF3A‑/‑ confirms the successful knock-out 
of KIF3A in ciPTEC. (A) Sequenced genomic DNA of ciPTEC-parent and ciPTECKIF3A-/- demonstrating 
the loss of 2 base pairs, demonstrating a successful frame shift mutation in the KIF3A gene. KIF3A 
genomic RNA target sequence used to guide CRISPR/Cas9 to the KIF3A gene is underlined. (B) KIF3A 
protein (80 kDa) expression is present in ciPTEC-parent and is lacking in ciPTECKIF3A-/-, suggesting 
successful knock-out of KIF3A at both 33°C and 37°C using β-actin (42 kDa) as loading control (n=3, 
representative images are used) (C) Confocal immunofluorescent images confirm the presence of 
primary cilia (indicated by the white arrows) specific acetylated tubulin (green) in ciPTEC-parent and 
the absence in ciPTECKIF3A-/-, while the basal body specific peri-centrin (red) is present in both cell lines 
(n=1, scale bar indicates 20 μm).
A
B
C
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drug screening devices. In Chapter 6 we have shown compatibility of a semi high-
throughput microfluidic device with automated image capture and analysis, suitable 
for screening purposes. The future of renal toxicity screening will probably consist 
of a tiered approach with increasing complexity and physiological resemblance as 
compounds progress through the phases of development, reducing the throughput 
capacity along the way. An overview of in vitro approaches in order of increasing 
complexity was presented in Chapter 5, including the most important advantages 
and disadvantages of each system. Regular 2D cell culture of immortalized PTEC 
are suitable to identify overtly toxic compounds, while microfluidic-based proximal 
tubule tissue provides the cell physiological cues to mechanistically study adverse 
effects of drug candidates, which is required at more advanced stages of drug 
development[55].  
Another important limitation of in vitro safety evaluation models is the diversity of 
toxicological mechanisms and cellular targets that need to be represented. Animal 
models inherently demonstrate a higher integrative physiological value than any in 
vitro system currently available, illustrated by the role of hepatic metabolism in the 
uptake and nephrotoxicity of cisplatin[59]. Combining a liver-on-a-chip and a kidney-
on-a-chip in one model would include the toxic effects of drug metabolites to be 
investigated, as was shown for ifosfamide, and could be part of the solution for 
modeling the processes involved in cisplatin-induced nephrotoxicity[60]. Multi-organ 
cultures are promising tools for toxicity studies that involve drugs administered as 
prodrugs and/or undergo extensive metabolism that could account for toxicity. It 
is, however, important to implement the correct scaling between the different 
organotypic cultures incorporated, and developing a common culture medium is an 
ongoing challenge in this field[53, 54]. For now, we should be aware that even in models 
demonstrating the highest degree of physiological resemblance technically possible, 
only a subset of the entire variation of cell types, tissues and organs of a human 
body is represented, which may still be insufficient to account for many of the toxic 
mechanisms that we do not yet understand. Nevertheless, better identification and 
recapitulation of off-target toxicities with in vitro models will be a necessary step in 
improving the drug safety evaluation process.
The materials used to produce microfluidic devices, such as polydimethylsiloxane 
(PDMS), polycarbonate and polyester have several advantages. They allow a flexible 
design, are not expensive and are optically clear, enabling real-time analysis 
by microscopy. On the other hand, these synthetic materials do not resemble 
the in vivo ECM, requiring coatings to enable cell adhesion[53]. Moreover, PDMS 
absorb hydrophobic drug molecules, which leads to a reduction in their effective 
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concentration and thereby underestimation of the toxic potential[61]. Oxidizing a thin 
layer of PDMS on the inside of the device, creates a layer of silicon dioxide on the 
surface, that limits binding[62]. Future and more standardized microfluidic devices will 
most likely be developed with more inert materials, such as the OrganoPlate® that is 
composed of glass[63, 64]. Cell adherence can be improved by coating the inner surface 
of microfluidic channels with ECM components that resemble the physiological 
environment, such as collagen type I and IV, laminin and fibronectin[65]. As this 
increases costs, reduces manufacturing capacity and implies the persistent need 
for animal-derived materials, successful industrial application may see the use of 
biocompatible synthetic hydrogels in the near future. They can be modified to closely 
mimic the ECM surrounding the cell type of interest, including ciPTEC[66], enhancing 
attachment and possibly study toxic responses or kidney regeneration in vitro[67].
Figure 7.2 Overview of the inherent characteristics of microfluidic devices, the advantages and 
opportunities these devices offer and the challenges and future applications of this advanced 
culture method. The lines at the center of this figure represent microfluidic channels in general and 
are for illustrative purposes only.
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Finally, microfluidic-based tissue technology can only achieve its full potential for 
drug safety evaluation upon proper validation and full implementation in the drug 
development processes[53-55]. Validation of drug-induced responses can be achieved 
best by using a well-defined set of nephrotoxic and non-nephrotoxic agents, for 
which both in vitro and in vivo data are readily available. Comparing the responses 
to known nephrotoxic drugs and drug candidates that failed because of toxicity 
observed with available animal data and regular culture systems, will be crucial to 
demonstrate the additional predictive capability of the newly developed in vitro 
model. To accommodate this process, organ-on-a-chip developers, and partners from 
pharmaceutical industry and regulatory agencies should team up to form consortia 
that provide an integrated testing platform for novel microfluidic devices. An 
international network that is already in place is the Crack-it NephroTube Challenge, 
initiated by the National Centre for the Replacement, Refinement and Reduction 
of Animals in Research (NC3Rs), in which pharmaceutical industry, academia and 
companies developing microfluidic devices are brought together. The first results of 
this effort are described in Chapter 6 of this thesis, in which the proximal tubule 
model ciPTEC-OAT1 and the microfluidic OrganoPlate® were combined for renal DDI 
studies. Currently, this international consortium performs a screen of 12 nephrotoxic 
compounds and 15 different biomarkers, as the first step towards validating this 
renal microfluidic culture device and its compatibility with industrial high content 
equipment. Another example is the National Centre for Advancing Translation 
Sciences (NCATS) at the National Institutes of Health, which has recently started 
to evaluate intra- and inter-laboratory reproducibility, robustness and shipping of 
microfluidic-based tissue culture devices[54]. Continuous dialog with the international 
regulatory agencies, such as EMA and FDA, is needed to develop guidelines for 
the use of novel organ-on-a-chip systems in early safety toxicology. In turn, this 
enables a discussion to ultimately reduce and refine animal studies in drug-induced 
toxicity evaluation of candidate therapeutic drugs. It is important to note here that 
culture models usually require animal-derived serum, which may compromise their 
promise to reduce animal burden. Some culture models, including selected proximal 
tubule cell lines, are readily compatible with serum-free media. As formulations are 
improving, it may soon be possible to extend these towards cultures that have not 
yet made this transition. In order for microfluidic devices to become commercially 
interesting, the feasibility of technical implementation into the currently existing 
drug development process will play a key role and needs a focus on the end-users[68]. 
Therefore, kidney-on-a-chip devices should ideally be packaged into off-the-shelf 
applications, accompanied by reliable and reproducible assays, and be compatible 
to some degree with conventional culture methodologies, that will ease automated 
handling, analysis and data extraction[53].
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In silico models for drug-drug interaction screening
In silico modeling of DDIs has gained much interest over recent years and has been 
applied to identify, predict and explain DDIs with higher capacity as compared to in 
vitro experiments[69, 70]. Computational approaches like protein-based pharmacophore 
modeling, combines structural information of the target protein and drug molecule and 
uses molecular docking methods to predict in silico ligand–protein interactions. This type 
of computational modeling is hampered however, as this method requires determination 
of the crystal structure of renal drug transporters in a useful conformation, binding to 
each substrate or inhibitor involved, with sufficient resolution. This is available for several 
mammalian drug transporters, including Pgp[71] and MRP2[72]. Chemical pharmacophore 
modeling, on the other hand, evaluates molecular descriptors related to binding 
affinity and substrate specificity and identifies features common among substrates 
and inhibitors. This strategy was first used to identify aromatic, ether and amine 
functional groups shared among Pgp substrates[73]. In addition, substrates for the 
SLC transporters have been investigated, elucidating that OATs seem to have higher 
preference for planar molecules, while OCTs tend to transport compounds with 
more 3D-shaped structures[74]. Further, substrates of OAT3 are usually more cationic 
or zwitterionic in character compared to substrates for OAT1[74]. For MATE1, chemical 
pharmacophore models suggested that the presence of an aromatic ring and sufficient 
hydrophobicity are important features of inhibitors[75]. Chemical pharmacophore 
modeling is currently applied for predicting the substrate or inhibition capacity 
of new chemical entities in drug discovery. However, a vast database containing 
chemical structures of substrates, inhibitors and non-interacting compounds of the 
target of interest is required to feed the algorithm[76]. Recent validation of chemical-
based pharmacophore modeling has indicated that its predictions are as of yet only 
valid for extrapolation between compounds with very similar structures, although 3D 
pharmacophore modeling can enhance its performance[77]. Therefore, in vitro models 
are still required to evaluate DDIs, such as those developed in Chapters 2 and 6. 
Finally, physiologically-based pharmacokinetic (PBPK) modeling forms a separate 
class of in silico prediction methods, as it estimates the concentration of drugs in 
plasma and tissues over time under varying physiological and pharmacological 
conditions, including co-medication[70]. PBPK software platforms such as SimCYP may 
be used to predict organ and tissue exposure to the drug of interest, which can serve 
as a starting point for in vitro toxicity studies. A slowly growing amount of information 
on drug-protein interactions may increase the application of computational DDI 
screening in early phases of the drug development process in the future. Similar to 
DDIs, it might be possible in the future to understand how toxicity arises from certain 
chemical features using in silico methods, which would allow chemical adjustment 
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of lead molecules into safer alternatives[78]. Early attempts are made for the liver as 
target organ, modelling crucial pathways involved in toxicity induction, including 
glutathione status, mitochondrial (dys)function, energy balance, cellular life cycle, 
cell death and parts of the innate immune system[79]. Due to the complexity of the 
biology involved, future validation will demonstrate to what extent computational 
models will be able to predict drug-induced nephrotoxicity.
Conclusions
In conclusion, the high incidence of renal adverse effects observed in the final stages of 
drug development underlines the limitations of current pre-clinical models for drug-
induced toxicity testing. PTEC cultures demonstrating relevant drug transporters and 
metabolism, combined with analysis of renal specific biomarkers, have the potential 
to improve the predictive value of in vitro drug-induced toxicity testing and reduce 
safety-related drug attrition in the clinic. Microfluidic devices can further increase 
the physiological relevance, possibly aided by in silico predictions in the future. 
Depending on the research question, models with different degrees of complexity 
are available that range from those suitable for relatively simple screening purposes 
to detailed mechanistic investigations. Organ-on-a-chip models have, therefore, the 
capacity to shift the paradigm of toxicology from the traditional ‘final hurdle’ before 
clinical evaluation is initiated, to a continuous process that aims to reduce the toxic 
potential of novel drugs in every step of the of drug development pipeline.
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Summary
This thesis describes the development of advanced renal proximal tubule epithelial 
cell (PTEC) culture models to study the mechanisms of drug-induced toxicity and 
drug-drug interactions (DDIs), and to evaluate their potential for in vitro drug-
induced toxicity screenings. 
The excretory function of the kidney is vital to human health. In addition to glomerular 
filtration, PTEC express multiple drug transporters and endocytosis receptors that 
mediate the selective excretion of waste products and reabsorption of nutrients. 
Drug transporters facilitate influx and efflux of drug compounds and are major 
determinants of PTEC drug sensitivity. In fact, one in five cases of acute kidney injury 
(AKI) is caused by nephrotoxicity of therapeutic drugs, indicating that evaluation 
of renal adverse effects in drug development lacks predictive value for humans. 
Chapter 1 describes that animal models and most PTEC models have poor 
translational value for clinical drug studies because of species differences in 
transporter expression and lack of functional differentiation in the cell models. 
The conditionally immortalized proximal tubule epithelial cell line (ciPTEC) is an 
exception, since it demonstrates endogenous expression of drug transporters and 
endocytosis receptors. This thesis aimed to develop advanced in vitro cell culture 
models based on ciPTEC, that reflect differentiated human renal PTEC enabling the 
investigation of the mechanisms by which drugs induce nephrotoxicity, with a focus 
on renal drug handling and drug-drug interactions (DDIs). 
Expression of physiologically relevant drug transporters in in vitro models is crucial 
for sensitive drug-induced toxicity evaluation. Primary proximal tubule cells rapidly 
lose their epithelial phenotype upon culturing, including loss of expression of OAT 
transporters, as is the case for ciPTEC. Therefore, developed ciPTEC constitutively 
expressing OAT1 (ciPTEC-OAT1) or OAT3 (ciPTEC-OAT3) as is described in 
Chapter 2. Lentiviral transfection of vectors containing either OAT-gene coupled to 
a cytomegalovirus promoter, resulted in successful expression that was confirmed 
by qPCR. Organic anion transport function was demonstrated by the active uptake 
of the fluorescent OAT1/3 model substrate fluorescein, and competitive inhibition 
by the OAT1/3 substrates para-aminohippuric acid, estrone sulfate, probenecid and 
diclofenac. In addition, OAT1 DDIs could be confirmed for the antiretroviral agents 
adefovir, cidofovir, tenofovir and zidovudine. For the first three compounds, the 
crucial role of OAT transport function in antiretroviral-induced toxicity was shown 
by the renal proximal tubule models ciPTEC-OAT1 and ciPTEC-OAT3, which exhibited 
increased sensitivity to these substrates.
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Renal toxicity induced by the chemotherapeutic cisplatin is mainly mediated by 
OCT2 influx activity, which is endogenously expressed in ciPTEC. In Chapter 3, we 
showed that overexpression of OAT1 or OAT3 in ciPTEC reduced PTEC sensitivity to 
cisplatin, which was associated with reduced intracellular cisplatin accumulation. 
This observation was explained further by decreased gene expression and transport 
capacity of OCT2, demonstrated by reduced accumulation of the fluorescent OCT2 
model substrate ASP+. Despite a profound increase in MATE1 gene expression in 
ciPTEC-OAT1 and ciPTEC-OAT3, known to mediate cisplatin efflux, no functional 
contribution to cisplatin accumulation, ASP+ accumulation, or cisplatin-induced 
toxicity was found. Together, the results suggest that expression of OATs is also 
important for the evaluation of toxicity induced by drugs that are typically cleared 
by organic cation transporters, underlining the need for in vitro models that express 
both organic anion and cation drug transporters for the evaluation of drug-induced 
renal toxicity.
Receptor-mediated endocytosis is important for the proximal tubule reabsorption 
of low-molecular weight proteins and is the major uptake pathway of nucleotides, 
peptides, proteins but also (nephrotoxic) aminoglycoside antibiotics, such as 
gentamicin. In Chapter 4, we demonstrated that antisense oligonucleotides (AONs) 
competitively inhibit receptor-mediated endocytosis of α1-microglobulin and 
albumin in ciPTEC, which can explain transient low-molecular weight proteinuria 
at pharmacologically relevant concentrations. Uptake of AONs was visualized 
using fluorescent tags, showing accumulation in vesicular-like structures over 
time. Interestingly, prolonged treatment with AONs at pharmacologically relevant 
concentrations did not affect ciPTEC viability or albumin uptake capacity. This shows 
that uptake of AONs in PTEC is facilitated by receptor-mediated endocytosis and 
compromises protein reabsorption, but does not induce direct toxic responses.
Monolayer cultures of proximal tubule cells may benefit from renal microenviron-
mental cues to help retain, or even regain, their epithelial differentiation status. 
Chapter 5 reviews the use of 3D renal proximal tubule tissue reconstruction as 
advanced models for drug-induced toxicity screening, including kidney-on-a-chip. 
Culturing proximal tubule cells in a 3D microfluidic device allows for recapitulation 
of a tubule structure, multi-compartmentalization and exposure to fluid shear stress 
(FSS), which increases the physiological relevance of the model. Recent examples of 
kidney-on-a-chip models suggest that signals from the microenvironment increase 
proximal tubule transport functionality, which improves the sensitivity and response 
of PTEC to drug-induced injury and their predictive capacity. Future applications 
of kidney-on-a-chip devices include drug development and investigating the 
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contribution of FSS to renal epithelial cell differentiation and epithelial repair 
mechanisms.
While microfluidic devices are capable of increasing the physiological relevance 
of renal tubule cultures, this implicitly increases the complexity of the systems 
involved, which is accompanied by a lack of automation compatibility and reduced 
throughput. Chapter 6 describes the development of a novel kidney-on-a-chip 
system that is suitable for high-throughput in vitro screening of DDIs. The platform 
combines the ciPTEC-OAT1 model with the 3D microfluidic system OrganoPlate®. 
This device is derived from the regular culture plate format and allows independent 
gravitational-based perfusion of its culture channels, allowing simultaneous culturing 
and automated fluorescent imaging of renal chips in parallel, while maintaining high-
throughput compatibility. Gene expression and function of the efflux transporters Pgp 
and MRP2/4 was demonstrated in this device for ciPTEC-OAT1, using fluorescence-
based assays coupled to automated image analysis and data extraction. This suggests 
that major limitations of microfluidic devices can be overcome, including lack of 
automation and throughput, paving the way for application of kidney-on-a-chip 
systems in industry. 
Finally, Chapter 7 provides a general discussion on the findings in this thesis and 
describes the role of advanced renal in vitro models in current and future drug-
induced toxicity and DDI screening. In the future, induced pluripotent stem cell-
derived renal cultures may replace immortalized cell lines as cell source, paving 
the way for personalized medicine in which clinically-relevant biomarkers will play 
a pivotal role. Apical fluid flow is an emerging microenvironmental factor that can 
increase PTEC differentiation. A ciPTEC model lacking its flow-sensing organelle, the 
primary cilium, is proposed as a tool to evaluate the contribution of flow-induced 
cilia-mediated signaling to drug transporter activity and drug sensitivity of in vitro 
PTEC models. 
In conclusion, the in vitro models and techniques described in this thesis have 
increased the mechanistic insight into drug-induced adverse effects to the renal 
proximal tubule. Future applications of these advanced models in drug-induced 
toxicity and DDI screening have the potential to improve pre-clinical safety of 
candidate drugs in drug development and reduce animal experimentation.
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Dit proefschrift beschrijft de in vitro-ontwikkeling van geavanceerde proximale 
tubulusepitheelcelkweken (PTEC). Met deze modellen kunnen bijwerkingen van 
medicijnen op de nier mechanistisch worden onderzocht. Ook kunnen de modellen 
worden ingezet om bijwerkingen die de nierfunctie aantasten al vroeg tijdens de 
ontwikkeling van potentiële geneesmiddelen op te sporen. 
De uitscheiding van afvalstoffen via de nieren is essentieel om gezond te blijven. 
De PTEC hebben verschillende transporteiwitten die zorgen voor de actieve 
uitscheiding van afvalstoffen vanuit het bloed naar de urine. Daarnaast hebben de 
PTEC receptoren op hun celmembraan, die gefiltreerde stoffen uit de glomerulus 
kunnen binden en recyclen. Al deze transporteiwitten faciliteren ook de opname en 
afgifte van medicijnen in de nier, en spelen daarom een belangrijke rol bij de hoge 
gevoeligheid van PTEC voor geneesmiddeltoxiciteit. 
Eén op de vijf gevallen van acuut nierfalen wordt veroorzaakt door medicijnen. De 
huidige wijze om bijwerkingen op de nieren in medicijnontwikkeling te onderzoeken 
moet dus worden verbeterd. Hoofstuk 1 beschrijft de beperkte waarde van 
dierproeven en de huidige PTEC-kweekmodellen om de klinische bijwerkingen te 
voorspellen. Voor de kweekmodellen geldt dat de activiteit van de transporteiwitten 
vaak is afgenomen of specifieke transporters zelfs afwezig zijn, waarmee de 
gevoeligheid van de cellen in kweek voor geneesmiddeltoxiciteit is verminderd. 
De aanwezigheid van fysiologisch relevante transporteiwitten in kweekmodellen 
is van cruciaal belang gebleken voor het bepalen van nierschade veroorzaakt door 
medicijnen. Het conditioneel-geïmmortaliseerde humane PTEC (ciPTEC) model 
heeft een reeks endogene transporteiwitten en receptoren die wel actief zijn. 
Echter, ciPTEC heeft net als veel andere humane niercellijnen een verminderde 
expressie van organisch-anion transporteiwitten (OAT). Daarom hebben we een 
ciPTEC ontwikkeld, die OAT1 (ciPTEC-OAT1) of OAT3 (ciPTEC-OAT3) tot expressie 
brengen, zoals beschreven in Hoofdstuk 2. Hiervoor hebben we gebruik gemaakt 
van een lentivirale transfectie met vectoren waarin elk van deze genen is gekoppeld 
aan de cytomegalovirus promotor. De succesvolle expressie van OAT1 en OAT3 kon 
worden bevestigd door middel van qPCR. Door opname van het fluorescerende OAT-
modelsubstraat fluorescein, in combinatie met competitieve remming door de OAT-
substraten para-aminohippuurzuur, estronsulfaat, probenecide en diclofenac konden 
we de functionele activiteit bepalen. Daarnaast kon een geneesmiddelinteractie 
met OAT1 en OAT3 worden aangetoond voor de antiretrovirale middelen adefovir, 
cidofovir, tenofovir en zidovudine. Voor de eerste drie geneesmiddelen hebben we 
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tevens laten zien dat de OAT-transportfunctie direct verantwoordelijk is voor de 
nierschade veroorzaakt door deze medicijnen. 
Bij nierschade veroorzaakt door het chemotherapeuticum cisplatina speelt opname 
door het organisch-kationtransporteiwit 2 (OCT2) een grote rol. In Hoofdstuk 3 
laten we zien dat de aanwezigheid van OAT1 of OAT3 in ciPTEC resulteert in een 
verminderde gevoeligheid voor cisplatina, doordat het geneesmiddel minder stapelt 
in de cel. Dit effect kan deels worden verklaard door een verminderde aanwezigheid 
en transportcapaciteit van OCT2, zoals aangetoond door een verminderde stapeling 
van het fluorescerende OCT2-modelsubstraat ASP+ in ciPTEC-OAT1 en ciPTEC-OAT3. 
Ondanks een duidelijke verhoging in een van de effluxpompen, multidrug en toxine 
extrusietransporteiwit 1 (MATE1) in ciPTEC-OAT1 en ciPTEC-OAT3. Hieruit hebben we 
geconcludeerd dat MATE1 in ons humane model hoogstwaarschijnlijk geen effect 
heeft op cisplatina stapeling, in tegenstelling tot datgene wat in diermodellen is 
aangetoond. Bij elkaar laten deze resultaten zien dat expressie van OATs belangrijk is bij 
het onderzoek naar nierschade, zelfs voor medicijnen die worden uitgescheiden door 
organisch-kationtransporteiwitten. Het is daarom van belang dat celkweekmodellen 
die worden gebruikt voor het testen van bijwerkingen van medicijnen zowel organisch-
anion- als organisch-kationtransporteiwitten hebben, zoals ciPTEC-OAT1.
De reabsorptie van nucleotiden, peptiden en eiwitten met laagmoleculaire massa 
uit het glomerulaire ultrafiltraat in PTEC vindt plaats door receptorgemedieerde 
endocytose. Dezelfde receptoren zijn echter ook verantwoordelijk voor de opname 
van nierschadelijke substraten, waaronder aminoglycoside antibiotica zoals 
gentamicine. Dit leidt uiteindelijk tot schade aan de PTEC en verlies van eiwitten, 
suikers en aminozuren via de urine. Antisense oligonucleotiden (AON) zijn in staat 
om de cellulaire eiwitexpressie te moduleren en hebben daarom een toepassing als 
geneesmiddel. In Hoofdstuk 4 laten we zien dat de endocytose receptoren op de PTEC 
verantwoordelijk zijn voor opname van AON. Farmacologisch relevante concentraties 
van AON remmen de opname van α1-microglobuline en albumine competitief in 
ciPTEC. Dit kan verklaren waarom (pre-) klinische behandeling met AON, die onder 
andere ontwikkeld worden voor de behandeling van de ziekte van Duchenne, tijdelijk 
eiwitverlies in de urine veroorzaakt. In ciPTEC kon de opname van AON worden 
aangetoond met stapeling in endosomen, intracellulaire blaasjes. Langdurige 
behandeling van AON had echter geen invloed op de viabiliteit en functionaliteit van 
de cellen, zoals aangetoond voor albumineopname in ons celmodel. Deze resultaten 
laten zien dat receptorgemedieerde endocytose verantwoordelijk is voor opname 
van AONs in PTEC en dat blootstelling aan deze geneesmiddelen de reabsorptie van 
andere eiwitten remt, zonder direct schadelijke effecten op de tubuluscellen.
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Eén hypothese die kan verklaren waarom de activiteit van transporteiwitten in 
de huidige PTEC-kweekmodellen is afgenomen, is het gebrek aan natuurlijke 
omgevingsfactoren van de nier in reguliere 2D celkweek. Celkweken van PTEC zouden 
daarom een verbeterde gevoeligheid voor geneesmiddeltoxiciteit kunnen verkrijgen 
door de microfysiologie van de niertubulus na te bootsen. Hiermee kunnen de cellen 
in kweek mogelijk hun differentiatie behouden of zelfs terugwinnen die verloren 
is in reguliere 2D celkweek. Hoofdstuk 5 geeft een overzicht hoe 3-dimensionale 
(3D) reconstructies van PTEC gebruikt kunnen worden als model om nierschade 
door medicijnen te onderzoeken. Wanneer PTEC in een geperfuseerd buizensysteem 
met heel lage volumes (microliters) worden gekweekt, ontstaan zogenaamde 
nierchips, die door eigenschappen als de buisstructuur, de aanwezigheid van 
verschillende compartimenten en de blootstelling aan een vloeistofstroom de 
fysiologische gelijkenis van het in vitro model verhogen. Recente voorbeelden van 
nierchips laten zien dat het nabootsen van de microfysiologie op deze manier de 
transportfunctie van PTEC in kweek verhogen, en daarmee ook de gevoeligheid voor 
geneesmiddelen waarvan bekend is dat ze nierschade veroorzaken. In de toekomst 
kunnen nierchipmodellen toegepast worden bij de ontwikkeling van medicijnen of 
in fundamentele studies waar bijvoorbeeld de invloed van vloeistofstroom op het 
epitheliale karakter van PTEC of herstel na weefselschade kunnen worden onderzocht. 
Alhoewel kweeksystemen met vloeistofstromen in de orde van microliters in staat 
zijn om de fysiologische gelijkenis van PTEC-kweekmodellen te verhogen, maken 
zij het system inherent complexer, wat automatisering door middel van pipeteer-
robots en een verminderde studiecapaciteit tot gevolg heeft. Om dit probleem 
aan te pakken, beschrijven wij in Hoofdstuk 6 de ontwikkeling van een nieuw 
nierchipmodel dat geschikt is voor in vitro onderzoek naar geneesmiddelinteracties. 
Het door ons ontwikkelde platvorm combineert het celmodel ciPTEC-OAT1 met het 
3D microvloeistofsysteem OrganoPlate®. Dit systeem is gebaseerd op een reguliere 
celkweekplaat en maakt gebruik van zwaartekracht-gedreven perfusie van de 
kweekkanalen. Hierdoor kunnen 40 tot 96 nierchips in parallel worden gekweekt en 
geanalyseerd met hoge capaciteit door gebruik te maken van fluorescentiemicroscopie. 
Wanneer ciPTEC-OAT1 gekweekt wordt in de OrganoPlate® bleken de effluxpompen, 
P-glycoproteine en multidrug-resistentieeiwtten 2 en 4 functioneel intact. Dit kon 
worden aangetoond door gebruik te maken van fluorescerende modelsubstraten 
en geautomatiseerde microscopieanalyse. Dit model toont aan dat de limiterende 
beperkingen van nierchips, hoofdzakelijk een gebrek aan automatisering en 
studiecapaciteit, overwonnen kunnen worden. Nierchips zijn dan ook op termijn 
geschikt voor toepassing op industriële schaal waardoor het gebruik van dierproeven 
voor studies naar geneesmiddeltoxiciteit mogelijk beperkt kan worden.
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Tenslotte bevat Hoofdstuk 7 een algemene discussie over de bevindingen in dit 
proefschrift en beschrijft het de rol van geavanceerde nierkweekmodellen in huidige 
en toekomstige studies naar geneesmiddeltoxiciteit en geneesmiddelinteracties. 
Geïnduceerde pluripotente stamcellen (iPSC) zijn gededifferentieerde cellen, 
potentieel afkomstig van vrijwel elk weefsel in het lichaam, die door middel van strikte 
kweekprotocollen naar een ander celtype kunnen differentiëren. In de toekomst 
zouden nierkweken die gegenereerd zijn vanuit iPSC de rol van geïmmortaiiseerde 
cellijnen over kunnen nemen, aangezien deze bron onuitputtelijk is en de differentiatie 
van deze cellen is af te stellen, met mogelijk een verhoogde aanwezigheid van 
bijvoorbeeld transporteiwitten. Deze techniek maakt het mogelijk om celmodellen 
te gebruiken die afkomstig zijn van patiënten, waardoor geneesmiddeltoxiciteit 
ook voor deze risicogroepen beter voorspeld zou kunnen worden, resulterend 
in persoonlijk afgestelde therapie: personalized medicine. Om bevindingen in 
kweekmodellen goed te kunnen vertalen naar mensen speelt de ontwikkeling van 
klinisch-relevante biomarkers, stoffen in bloed of urine die aangeven of en wanneer 
nierschade optreedt, een belangrijke rol. Het belang van vloeistofstromen in complexe 
kweeksystemen, zoals nierchips, wordt in toenemende mate onderzocht. Nabootsen 
van de microfysiologische nier kenmerken kan bijdragen aan de voorspellende 
waarde van dergelijk systemen bij het testen van medicijnen. Het primaire cilium is 
een organel aanwezig op vrijwel alle epitheelcellen, waaronder PTEC, en detecteert 
de vloeistofstroom over de cellen met een intracellulaire reactie als gevolg. Om de rol 
van cilia op de nierfunctie te kunnen onderzoeken, wordt in dit hoofdstuk een ciPTEC 
model gepresenteerd waarbij het primaire cilium ontbreekt. Hiermee kan de bijdrage 
van vloeistofstroom en signaaltransductie door het primaire cilium op de functie en 
differentiatie van PTEC-kweekmodellen verder worden onderzocht. 
De kweekmodellen en technieken die in dit proefschrift staan beschreven dragen 
bij aan het inzicht in de mechanismen waarop geneesmiddelen bijwerkingen 
veroorzaken op de niertubulus. Toekomstige toepassing van zulke geavanceerde 
modellen in een vroeg stadium van de ontwikkeling van nieuwe medicijnen zal de 
veiligheid van deze middelen in de preklinische ontwikkelingsfase kunnen verbeteren 
en mogelijk het aantal proefdieren dat nu voor geneesmiddelontwikkeling wordt 
gebruikt kunnen verminderen.
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Dankwoord
Wetenschap is mensenwerk en de voortgang van onze kennis en kunde is afhankelijk 
van gebundelde krachten, zowel van spieren als grijze massa. Nu het wetenschappelijk 
inhoudelijke gedeelte van dit proefschrift is afgesloten, wil ik de tijd en ruimte nemen 
om iedereen die op welke manier dan ook heeft bijgedragen aan mijn onderzoek, 
mijn proefschrift en mijn ontwikkeling, wetenschappelijk of niet, van harte te 
bedanken. Een aantal mensen wil ik in de komende alinea’s in het bijzonder noemen.
Beste Martijn. Jouw aandeel in mijn ontwikkeling als onderzoeker is van onschatbare 
waarde. Als begeleider van mijn masterstage leerde je mij tal van labvaardigheden 
die ik nu nog bijna dagelijks toepas. Je enthousiasme voor en toewijding aan de 
wetenschap werkten aanstekelijk en samen ontdekten we de potentie om de door 
jou ontwikkelde ciPTEC te gebruiken voor toxiciteitsstudies. Toen je eind 2013 een 
subsidie verkreeg voor het NephroTube-project zat ik met één telefoontje weer 
tegenover je. Het vertrouwen dat je hierdoor in mij uitsprak is fenomenaal en stelde 
me in staat mijn PhD-traject te starten. Iets meer dan 6 maanden hadden we om 
de resultaten van vervolgstudies te laten zien. Met succes, zo bleek, en het project 
was verzekerd van de nodige liquide middelen. In de jaren die volgden verschoof je 
rol van dagelijkse begeleider naar projectleider en bleef je betrokkenheid bij mijn 
wetenschappelijke ontwikkeling onverminderd groot. Terwijl ik in allerlei details 
verzeild raakte, bleef jij altijd het grote plaatje van het project zien en legde ons soms 
deadlines voor waarvan ik nooit had gedacht ze te halen. Tijdens de vele discussies 
over onze onderzoeksplannen, methodes en resultaten kwam je kennis en ervaring 
van het onderzoeksveld altijd bovendrijven. Je directe stijl helpt om problemen 
te analyseren en hielp mij om mijn argumentatie te allen tijde op orde te hebben. 
Je stelde mij in staat om mijn werk op verschillende nationale en internationale 
congressen te presenteren waar ik telkens weer dankbaar gebruik maakte van jouw 
netwerk. Je bent een bedreven onderhandelaar en goed in organiseren en beide 
vaardigheden bleken uiterst nuttig tijdens de teleconferenties en vergaderingen met 
onze sponsoren. Naast alle professionele kennis en vaardigenheden, praat je heel 
makkelijk. Daardoor konden we open van gedachten wisselen over wat ons bezig 
hield, zowel wanneer het goed ging als wanneer het iets minder ging. Je bent een 
leider met oog voor mensen; dat had ik nodig en dat is unieker dan je misschien 
denkt. Dankzij jou heb ik het beste uit mezelf kunnen halen en daar kan ik je niet 
genoeg voor bedanken!
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Beste Roos. Jouw deskundigheid was van cruciaal belang bij de totstandkoming van 
dit proefschrift. De manier waarop jij tijdens een vergadering kennis naar boven haalt 
voorzien van de juiste referentie en ook nog treffende schatting van het publicatiejaar 
is ongekend. Van deze kennis en kunde heb ik ontelbare malen gebruik gemaakt, 
bij situaties die uiteenlopen van de juiste experimentele condities tot strategische 
projectkeuzes. Je zeer ruime ervaring met het schrijven van wetenschappelijke 
teksten kwam veelvuldig van pas en was zeker nodig om mij op het juiste schrijfpad 
te houden. Dat liet je mij uiteraard weten op je eigen, humoristische manier door 
mijn eerste artikel volledig terecht ‘een hele bevalling’ te noemen. Ik heb heel veel 
respect voor de manier waarop jij succesvol je drukke gezinsleven combineert met 
een ontzettend veeleisende baan en toch altijd tijd kunt vinden voor die ene vraag 
in een mailtje laat op donderdagavond. Ongeveer halverwege mijn PhD werd jij 
welverdiend benoemd tot professor Experimentele Farmacologie bij de Universiteit 
Utrecht en daar ben je met hernieuwde energie begonnen. Om dat te vieren nodigde 
je ons na een rondleiding spontaan uit voor een etentje bij je thuis. Ondanks je 
fysieke verhuizing ben ik blij dat jij als professor betrokken bent gebleven bij het 
NephroTube-project en bij mijn ontwikkeling als wetenschapper. Daarbij dekken 
deze woorden van dank helaas nóg steeds de lading niet. 
Beste Frans. Jouw kritische blik en onuitputtelijke farmacologische kennis hebben 
een belangrijke bijdrage geleverd aan de kwaliteit van mijn werk en mijn proefschrift. 
Ik waardeer je revisies van de vele manuscripten waar je onafhankelijk van het 
stadium, opmerkingen aanbracht die ik al lang over het hoofd was gaan zien. Ondanks 
je drukke schema vond je gelukkig vaak tijd om onze vergaderingen bij te wonen. Ik 
heb veel bewondering voor de bevlogenheid die jij als afdelingsleider dag in dag uit 
weet op te brengen om het onderzoek en onderwijs binnen de afdeling farmacologie 
en toxicologie naar een nog hoger niveau te tillen. Mijn dank dat je het NephroTube-
project als onderdeel daarvan hebt gesteund. 
De financiële zekerheid die het Nephrotube-project met zich meebracht, stelde 
de afdeling in staat om nóg een PhD-student aan te stellen. Jelle, al bij de eerste 
kennismaking toonde je aan over een vlotte stijl en een wetenschappelijk 
onderbouwde vragenmachine te beschikken. Met volle overgave stortte jij je op het 
project en dat is van cruciaal belang gebleken voor het uiteindelijke succes daarvan. 
Ik wil je bedanken voor ontelbare discussies, zowel tijdens vergaderingen als 
daarbuiten, je meningen over experimentele opzetten, het uitwisselen van gedachten 
over resultaten, alle suggesties voor artikelen die ik dankzij jou wél gelezen heb en 
alle andere zaken die ik me nu simpelweg niet meer herinner. Ik heb er heel veel van 
opgestoken. Ik heb bewondering voor de efficiënte manier waarop je werkt en de 
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eerlijke, directe manier waarop je mensen benadert. Dat maakt je niet alleen tot een 
fijne collega, maar ook buiten het lab konden we het goed vinden. Je enthousiaste 
verhalen over vliegreizen, Macbooks en hardlopen hebben een positieve impact 
gehad. Mijn inschrijving voor de halve marathon van Göteborg staat. Dankzij jouw 
Noord-Hollandse accent weet ik ook hoe een André Hazes-karaoke hoort te klinken; 
een stuk authentieker. Het afscheidsetentje bij jou thuis is memorabel en ik nodig 
je hierbij graag uit voor de return. Ik vind het geweldig dat je mijn paranimf wil zijn. 
Janny, ik wil je eerst bedanken voor alle bergen werk die je voor mij hebt verzet. De 
nauwkeurigheid en grondige wijze waarmee jij niet alleen experimenteel werk, maar 
ook de meer administratieve taken vervult, zijn ongekend. Je stond altijd klaar om mij 
en anderen te voorzien van advies over zo’n beetje alles dat op het lab relevant is. Van 
gedetailleerde protocollen en trainingen tot organisatie van aankopen en zelfs IT. 
Door het netwerk dat je door de jaren heen bij het Radboud hebt opgebouwd, weet 
je precies bij wie je moet aankloppen om zaken te regelen en daar maakt iedereen 
op het lab dankbaar gebruik van. Jij bent voor mij de constante factor geweest die 
zoeken overbodig maakte en mij veel organisatie uit handen heeft genomen. Na 
werktijd bleven we regelmatig hangen op het lab om al dan niet werk-gerelateerde 
zaken te bespreken. Ik kwam erachter dat we beide een voorliefde hebben voor 
sport en iPhones en ik zal je hilarische verhalen over Nomi niet snel meer vergeten. 
Samenwerken met jou vond ik bijzonder aangenaam. Ik vind het super om je aan 
mijn zijde te hebben als paranimf. 
Als PhD-student spendeer je heel wat uren op de afdeling en leer je je collega’s goed 
kennen. Ik wil jullie allemaal hartelijk bedanken voor je interesse, enthousiasme en 
gezelligheid. Jitske, de efficiënte manier waarop jij bergen werk verzet is fenomenaal 
en daar heb ik veel respect voor. Bedankt dat je me als student wegwijs hebt gemaakt 
op het lab en me voortdurend liet zien wat je met ciPTEC kunt bereiken. Je eerlijkheid 
en openheid zorgde altijd wel voor hilariteit tijdens de pauzes. Manoe, het was fijn om 
met jou samen te werken en in die relatief korte tijd heb jij het AON-artikel naar een 
hoger niveau getild. Die publicatie komt er nu (hopelijk) echt aan. Marieke (H), dank 
voor al het kweekwerk dat je mij uit handen nam en voor de gezelligheid tijdens onze 
treintripjes terug naar het zuiden. Milos, thank you for being an oasis of calm in a world 
that does not seem to stop talking. I admire the choices you made to build your career 
and to do what you like best, science. Michele, thanks for all the coffee break talks 
and adding some Italian flair to the lab. The coffee you made is still the best. Period. 
Pedro, thanks for all the discussions we had about our work and on the fluorescence-
based transporter assays in particular; I learned a lot from it. Thanks as well for joining 
me countless times to the local pub and giving me an inspiring peek into developing 
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one’s career in an international world. As it turns out, even the global market is not all 
that big and I was quite surprised when you showed up as part of the evaluation panel 
during my job interview. I’m delighted to work with you again. Tom (S), mijn dank voor 
je hulp met de BD Pathway en voor je motiverende kijk op onderzoek, al was het nog 
zo laat op de avond. Mijn dank is ook op zijn plaats voor al het werk dat je hebt gehad 
met inrichten van de IT-faciliteiten van de afdeling. Op het moment dat ik jouw taak 
overnam realiseerde ik me pas hoe complex dat systeem in elkaar zit. Dank aan Laurens 
voor het overnemen van diezelfde IT-taak van mij. Sanne, jij bent een harde werker 
en kunt echt doorzetten. Daar heb ik bewondering voor en dat heb ik ook aan den 
lijve ondervonden. Toen jij me vroeg of ik de Elfstedentocht wilde fietsen, realiseerde 
ik me niet hoe ver het eigenlijk was. Dankzij jouw haast professionele coaching waren 
onze trainingstochten die volgden een goede en vooral gezellige voorbereiding. Deze 
meer dan 230 kilometer lange tocht bleek een ware banden- en kuitensloper, maar we 
hielden vol en konden hem toevoegen aan onze palmaressen. Dank je wel voor deze 
prachtige ervaring. Jan en Jeroen, ik heb zeer veel bewondering voor de haast ultieme 
balans die jullie beiden gevonden lijken te hebben tussen werk en privé. Jullie zijn 
enthousiaste en bedreven collega’s en ik dank jullie voor de vele verhelderende ‘Maybe 
I missed it’ vragen en ideeën voor vervolgexperimenten. Carlijn, dankzij jou weet ik 
nu meer van E-bikes dan ooit en was Limburg nooit verder weg dan één u’tje. Bedankt 
voor je gezelligheid. Gaby, als koorzanger was het fantastisch om een uitvoering van 
je theatergroep bij te wonen. Zoveel enthousiasme werkt altijd aanstekelijk. Jolien, 
als sportfanaat begreep jij gelukkig dat er ook gezonde verslavingen bestaan en 
daar geven we dan ook beiden graag aan toe. Gaby en jij zijn heel begaan met het 
placentaonderzoek en jullie hebben mijn fascinatie gewekt voor ex vivo-werk door de 
door jullie opgezette perfusie-opstelling eens live te demonstreren. Al kan ik nu nooit 
meer gewetenloos BBQ-en. Ik dank jullie voor alle suggesties en vragen die tijdens 
mijn presentaties naar boven kwamen, jullie interesse en gezelligheid. Rick, ik heb 
veel bewondering voor de manier waarop jij studenten bij je colleges en werkgroepen 
betrekt, geholpen door je enorme kennis van de farmacologie. Ik dank je voor je 
kritische blik en voor het mede organiseren van het afdelingsuitje naar Den Bosch. Dat 
was een daverend succes. Lindsey en Maarten, bedankt voor alle discussies die we 
hebben gehad en voor de goede sfeer die jullie altijd meebrachten. Saskia, Gerard, 
Daniëlle en Stan wil ik graag bedanken voor hun klinische blik op mijn werk. Jullie 
herinnerden mij er op de juiste momenten aan dat mijn in vitro-werk uiteindelijk aan de 
patiënt ten goede komt. Petra, bedankt voor alle hulp en flexibiliteit bij het opzetten 
en meten van mijn metformine-experimenten. Petra, Ab en Jeanne, bedankt voor 
jullie gezelligheid bij de borrels. Tenslotte wil ik Wendy, Lilibeth, Robert en Nicolai 
bedanken voor alle organisatie en ondersteuning tijdens mijn jaren bij de afdeling. 
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Ik wil graag Marieke (W) en Huib bedanken voor het beschikbaar stellen van jullie 
microscopen, alle introducties en cursussen die jullie hebben gegeven en voor het 
beantwoorden van talloze vragen over microscopen en image-analyse.
Ger, mijn dank dat je af en toe tijd vrij maakte om samen een kop thee te drinken 
zodat ik de voortgang van mijn project kon delen met een kundig persoon buiten de 
farmacologie. Je blik als mentor werkte elke keer weer verhelderend. 
Ik heb het geluk gehad om aan het NephroTube-project te mogen werken binnen 
een internationaal consortium samen met een groep betrokken en bekwame 
wetenschappers. Mijn dank gaat uit naar Marianne, Henriëtte en Bas van Mimetas 
voor alle discussies en het beantwoorden van talloze vragen over OrganoPlates. 
Dankzij jullie inzet konden we snel aan de slag en zijn jullie producten en protocollen 
door de jaren heen voortdurend geoptimaliseerd, wat een flink aandeel heeft gehad 
in het slagen van het project. Paul en Jos wil ik bedanken voor hun scherpe blik op 
het project vanuit een commercieel perspectief. Laura, despite your busy schedule 
as professor at the Fachhochschule Nordwest Schweiz you luckily managed to join 
many meetings and teleconferences. As toxicologist, your continuous contributions 
to the project turned out to be invaluable for its success. I would like to thank our 
collaborators at Pfizer, Roche and GlaxoSmithKline for their discussions and 
support. I thank the National Centre for the Replacement, Refinement and Reduction 
of animals in Research (NC3Rs) for financially supporting this project.
It’s clear from the extended author lists on all experimental papers in this thesis 
that collaborations are important contributors to research and science. Therefore, I 
would like to thank Niels (S) for producing the OAT-constructs and Rob (W) for his 
FACS analyses that made the generation of the ciPTEC-OAT models possible. Many 
thanks in particular to Constanze (H) from AstraZeneca for her contributions and 
for supporting this project. Thanks as well to Neslihan (T) and Thomas (F) from the 
Technical University of Berlin for their help with setting up and measuring my cisplatin 
samples. Our work on antisense oligonucleotides was performed in collaboration 
with Biomarin Netherlands and I would like to thank Cathaline (B), Tessa (S) and 
Melissa (M) for their continuing discussions and help with analysis of samples.
De afdeling deelt de 7de verdieping van het RIMLS-gebouw met de afdelingen 
Biochemie en Fysiologie. Ik wil alle huidige en oud-medewerkers bedanken voor 
het delen van apparatuur en voorraden en voor alle gezelligheid tijdens pauzes, 
spelletjesavonden en PhD-retreats. Sander, dankzij jouw inzet heeft het cisplatina-
werk een enorme boost gekregen. Uiteindelijk heeft dat zelfs een artikel opgeleverd, 
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waar jouw bijdrage in zit verwerkt; mijn dank. Lisanne, ik wil je bedanken voor je 
gesprekjes over de voortgang van onze projecten en alle andere zaken die de revue 
passeerden tijdens pauzes en dinertjes. Wanneer ik weer in Nijmegen ben, kom ik 
graag nog eens langs. Elianne, je maakt er geen geheim van dat muziek maken 
een van je vele passies is en dat is er eentje die we delen. Ik vond het geweldig 
om een uitvoering van het studentenorkest bij te wonen en te zien met hoeveel 
enthousiasme jij je hobby beoefend. Estel, onze gezamenlijk interesse voor sport 
heeft ervoor gezorgd dat ik jou een echt sportmaatje mag noemen. Ik wil ik je 
bedanken voor alle gezellige uren die we samen hardgelopen hebben en op de 
spinningfiets hebben doorgebracht. Bovendien heeft je internationale kijk op de 
wereld mijn interesse gewekt. Sanne en Anke, dankzij jullie ben ik bekend geraakt 
met heerlijke glutenvrije biertjes en ook dat heeft bijgedragen aan mijn PhD. Dank 
voor jullie interesse, gezelligheid en de lach en een traan bij de cursus ‘Management 
voor promovendi’.
Part of my development as a PhD student was to learn how to train, educate and 
supervise students from both the medical and science faculties. I would like to give 
many thanks to Katja, Thom, Melanie, Ritchie, Milou, Dina, Daphne and Nina 
for choosing my project for a Bachelor’s or Master’s traineeship. I appreciate your 
enthusiasm, commitment, tricky questions, refreshing views and hard work. The 
best way to check if you’re into a subject is by explaining it to someone else and 
thanks to you I was able to do just that. I learned a great deal about teamwork and 
your feedback taught me how to become a (better) supervisor. Some of you have 
seen your work ending up in my thesis, but I realize that this does not apply to all 
of you, which is a real pity. I hope you find comfort in the fact that all the work you 
did contributed to our understanding of the models we worked with. By now, you 
know that adding knowledge usually takes a million small steps, not one giant leap. I 
have seen all of you grow tremendously in your practical skills and scientific attitude 
during the months in the lab. Some of you already have committed themselves to 
the next step on the scientific ladder and I’m proud to have played a part in that, if 
only a tiny bit. Thanks, I thoroughly enjoyed working with you. Although technically 
not supervised by me, I would also like to thank Tom (van H), Tijmen and Renata for 
all your help with my work, genuine interest and the thoughts and drinks we shared 
after work. 
I realize I was extremely lucky to find a new job while my PhD project was still 
ongoing. As my Tour-de-Writing was, however, not yet finished, this meant that I had 
to double-job for a while. I would like to give many thanks to Anna-Karin, Jorrit, 
Mikael, and all other colleagues at the Department of Discovery Safety for the time 
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and space they allowed me to fulfil the tasks I was required to do. I’m looking forward 
to all the science and the years ahead!
Life is not only about work and I would like to thank all the members of the 
international Campus Choir ‘Veelstemmig’ for all the hours we indulged in our shared 
hobby. Singing in a choir is teamwork above else and I thoroughly enjoyed the official 
rehearsals and the unofficial ones. The fact that it required my undivided attention 
allowed me to completely immerse myself in a world of musical mindfulness for one 
evening a week. I liked the diversity and ever-changing dynamics of the group. I 
would like to give special thanks to Willibrord for his never-ending energy to drive 
the choir and to my fellow bases Hendrik-Jan and Paul for correcting all my mistakes 
and all the fun we had. 
Marjolein, Samantha en Luc, als studievrienden hebben we samen vele uren college 
en ontelbare zelfstudieopdrachten en verslagen geproduceerd. Ik wil jullie bedanken 
voor jullie inzet; onze studie is immers de opmaat geweest voor dit proefschrift. Jullie 
zijn intelligente en gezellige mensen met een heel groot hart, waarbij ik me altijd 
thuis gevoeld heb. We zijn een heel eind gekomen; van ons eerste goede gesprek 
op de trap van (het oude) Doornroosje tijdens de introductieweek en een tuinfeest 
voor wat wel de halve opleiding leek, tot aan verhuizingen, promoties en zelfs een 
(aankomend) trouwfeest. Ook toen we later allemaal in een andere stad woonden, 
bleven jullie de moeite nemen om mij periodiek uit het verre oosten te plukken en tijd 
vrij te maken voor een dinertje, terrasje, potje midgetgolf of simpelweg een middagje 
aan zee. Ik waardeer jullie gesprekken, humor, enthousiasme en eerlijkheid. Ik heb 
veel van jullie geleerd, niet op zijn minst een aantal nodige sociale skills. Ondanks 
dat het voor mij allemaal iets meer logistieke planning vereist, hoop ik dat we die 
periodiek erin houden. Laten we samen nog heel wat hoogtepunten vieren!
Bart, een juiste mix van overeenkomsten en tegenstellingen bleken de basis van 
onze jarenlange vriendschap te zijn. Je bent als professional in de IT opgeleid in een 
heel ander vakgebied dan ik. Je interesse heeft mij aangezet tot nadenken over het 
grotere doel van het werk dat ik verricht en dat werkt op zijn beurt weer motiverend. 
Ik heb grote bewondering voor het ogenschijnlijke gemak waarmee je met mensen 
omgaat, je uitgebreide autodidactische kennis van de menselijke psychologie en 
voor je niet-te-stillen honger naar nieuwe ervaringen. Ik wil je graag bedanken voor 
alle ontspannen uren die we samen hebben zitten praten, lachen en gamen, alle 
drankjes die we gewijd hebben aan de toekomst en die ontelbare keren dat jij me 
de comfortabele zone uit hielp op weg naar een nieuwe ervaring. Onze filosofische 
overpeinzingen waarbij wereldproblemen keurig verpakt en opgelost worden in 
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het tijdsbestek van één avond, werken voor mij heel relativerend en ontnuchterend. 
Bedankt ook voor alle heerlijke zonvakanties die mij in staat stelden om even bij te 
komen van alle beslommeringen en de batterij weer op te laden. Ik kijk alvast uit naar 
onze volgende reis en alle jaren die we van terrasjes mogen genieten! 
Marco, wat ooit begon als huisgenoten die simpelweg geen zin hadden om (in hun 
eentje) te koken, groeide door onze gemeenschappelijke interesses al snel uit tot een 
hechte vriendschap. Je bent een echte denker, kunt helemaal opgaan in een ervaring 
of verhaal en voelt mensen goed aan; daar heb ik veel bewondering voor. Of het nu 
gaat om politiek, reizen, boeken, het klimaat of dopinggebruik in de sportwereld, 
ik dank je voor al die keren dat we samen ontspannen van gedachten wisselden 
en natuurlijk alles beter weten dan de échte experts. Onze gemeenschappelijke 
interesse in sport uit zich het beste in alle middagen die we doorgebracht hebben 
voor de tv, kijkend naar de Tour de France die we vervolgens van ons eigen hilarische 
commentaar voorzien. Als uitvoerend idealist voeg je de daad bij het woord en onze 
uitputtende, maar totaal ecologisch verantwoorde fietsvakanties en treinreizen 
naar alle uithoeken van respectievelijk Nederland en Europa, zijn daar het meest 
memorabele voorbeeld van. Het zijn geweldige ervaringen. Ik kan je ook niet genoeg 
bedanken voor alle keren die je mij hebt gemaand om het eens iets rustiger aan te 
doen. Mijn natuurlijke neiging om altijd alles uit alles te willen halen is niet altijd 
goed en jij begrijpt dat als geen ander. Ik kom snel nog eens langs in Utrecht voor een 
aangename avond in een versnellinkje lager!
Oma, ondanks dat de details van mijn werk meestal aan u voorbijgaan, blijft u toch 
altijd geïnteresseerd in waar ik mee bezig ben en daar wil ik u graag voor bedanken. 
Uw verhalen over opa, de enige andere bioloog binnen onze familie, zijn ontroerend 
en inspirerend en zullen mij altijd bijblijven. Mijn dank voor alle middagen die we 
samen thee hebben gedronken en ik hoop dat we dat nog een hele tijd kunnen 
blijven doen!
Mieke, de band die wij als broer en zus hebben opgebouwd is uniek. Jij kent me 
zo goed dat je vaak al weet wat ik ga zeggen, nog voordat ik het bedacht heb. Het 
maakte niet uit hoe lang ik van huis was geweest, dankzij jou kon ik altijd weer op 
een warm welkom rekenen en dat waardeer ik heel erg. En als het te lang duurde, dan 
reisde je mij samen met mam gewoon achterna. Dank je voor alle uren die we samen 
hebben zitten vertellen, lachen, lunchen, Netflixen en gamen en voor al die keren 
dat we samen broer-zusdag gevierd hebben. De Efteling heeft flink wat geld aan ons 
verdiend. Laten we snel nog maar eens een dagje uit plannen!
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Pap en mam, jullie kan ik niet genoeg bedanken voor alle vrijheid en steun die ik de 
afgelopen jaren van jullie heb ontvangen. Jullie hebben mij altijd vrijgelaten om mijn 
eigen keuzes te maken, hoe ogenschijnlijk bizar mijn toekomstplannen ook werden. 
Van mijn aankondiging dat ik van plan was om in Nijmegen te gaan studeren tot 
aan mijn vertrek naar Zweden, jullie mening was altijd dat ik mijn hart diende te 
volgen waar dat ook toe zou leiden. Ik realiseer me dat ik door mijn drukke baan en 
volle reisschema het er de afgelopen jaren voor jullie niet altijd gemakkelijker op 
heb gemaakt om bereikbaar te zijn. Toch zijn jullie mij altijd blijven steunen door 
ervoor te zorgen dat ik écht thuiskwam wanneer ik er dan een keertje wél bij was. De 
weekendjes in Limburg voelen nog altijd alsof ik even op minivakantie ga, waardoor ik 
weer even energie kan tanken voor de weken die gaan komen. Ik hoop dat we samen 
nog van heel wat gezellige wandeltochten en familiedinertjes mogen genieten!
Tack så mycket mina vänner! Det var jätteroligt att jobba med er J 
Vänliga hälsningar,
Tom
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Curriculum vitae
Tom Theodurs Gerarda Nieskens werd geboren op 21 juni 1990 te Roermond. In 2008 
behaalde hij daar cum laude zijn atheneumdiploma, profiel Natuur en Gezondheid, 
aan het Bisschoppelijk College Broekhin. Later dat jaar begon hij de bacheloropleiding 
Moleculaire Levenswetenschappen aan de Radboud Universiteit in Nijmegen. Hij 
deed hier kennis op van moleculaire celbiologie, biochemie, organische chemie en 
trainde hier zijn basislaboratoriumvaardigheden. Zijn bachelor werd vervolgd door 
de masteropleiding Molecular Life Sciences, tevens aan de Radboud Universiteit, 
waarbij hij twee onderzoeksstages doorliep. Zijn eerste masterstage volgde hij bij 
de afdeling Farmacologie-Toxicologie van het (toenmalig) Nijmegen Centre for 
Molecular Life Sciences, Nijmegen. Onder leiding van Dr. Martijn Wilmer, Prof. Dr. 
Roos Masereeuw en Prof. Dr. Frans Russel bestudeerde hij gedurende een periode 
van 8 maanden de mechanismen van nierschade veroorzaakt door cisplatina, 
alsmede mogelijke strategieën om deze effecten te voorkomen, gebruikmakend van 
een humaan kweekmodel van de proximale tubulus. Deze stage werd vervolgd door 
een onderzoeksproject van een maand, waarin de opname en mogelijk bijwerkingen 
van antisense-oligonucleotiden in de nieren met hetzelfde kweekmodel werden 
bestudeerd, in samenwerking met (het toenmalige) Prosensa in Leiden. Zijn tweede 
masterstage liep Tom bij de onderzoeksgroep van Prof. Jamie Davies aan de Universiteit 
van Edinburgh. Gedurende 7 maanden bestudeerde hij de mogelijkheden om Turing-
patronen synthetisch te genereren, wat een bijdrage leverde aan het begrip van 
de autonome embryologische ontwikkeling van de nieren en het weefselherstel 
na acute nierschade. In 2013 studeerde hij cum laude af. Verder bouwend op zijn 
ervaring en kennis van de niertoxicologie, begon hij in januari 2014 aan zijn 
promotieonderzoek, met dit proefschrift als eindresultaat. Het doel was om met 
behulp van nierchips een model met een hoge screeningscapaciteit te ontwikkelen 
om hiermee nierschade veroorzaakt door medicijnen te kunnen onderzoeken, met 
een mogelijke industriële toepassing en beperking van dierproeven. Dit project is 
uitgevoerd in een internationaal consortium met verschillende partners van zowel 
de academie als het bedrijfsleven, waaronder MIMETAS in Leiden, de Fachhochschule 
Nordwest Schweiz (FHNW) in Basel en drie marktleidende farmaceutische bedrijven. 
Zijn onderzoek maakte deel uit van de Nephrotube CRACKIT Challenge, gefinancierd 
door het National Centre for Replacement, Reduction and Refinement of Animals in 
Research (NCR3s). Tom heeft meerdere bachelor- en masterstudenten begeleid en 
heeft zijn werk gepresenteerd op diverse nationale en internationale congressen. Hij 
zet zijn carrière voort als postdoctoraal onderzoeker binnen de niertoxicologie en is 
op dit moment werkzaam bij de Discovery Safety-Cardiovascular, Renal and Metabolic 
groep van de afdeling Drug Safety and Metabolism bij AstraZeneca in Gotenburg, 
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Zweden, onder leiding van Dr. Anna-Karin Sjögren en Dr. Mikael Persson. Zijn project 
heeft als doel om een geavanceerd kweekmodel van de proximale tubulus met een 
hoge fysiologische gelijkenis te ontwikkelen, zodat de moleculaire en cellulaire 
bijwerkingen van medicijnen op de nier in detail kunnen worden onderzocht en 
veiligere geneesmiddelen kunnen worden ontwikkeld.
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PhD PORTFOLIO
Name PhD student:  Tom T. G. Nieskens
Department:  Pharmacology and Toxicology
Graduate school:   Radboud Institute for Molecular 
Life Sciences
PhD period:         01-01-2014 until 31-12-2017
Promotors:           Prof. Dr. R. Masereeuw 
Prof. Dr. F. G. M. Russel
Co-promotor:     Dr. M. J. Wilmer
TRAINING ACTIVITIES Year(s) ECTS
Courses & Workshops
RIMLS Graduate Course
Radboud Orientation Program for PhD Students
Winterschool Dutch Kidney Foundation 2015
Course: Management voor Promovendi
Course: Fiji Microscopy Analysis
Course: Scientific Integrity
Course: Scientific Writing for PhD Candidates
Workshop: InDesign, PhD Organization Nijmegen
2014
2014
2015
2015
2015
2015
2016
2016
1.75
0.2
1.75 
1.75
1.0
1.0
3.0
0.2
Seminars & Lectures
Raymond Vanholder: An update on the Cinderella of protein bound uremic toxins
Robert Walker: Mechanisms of Drug Nephrotoxicity
Vishva Dixit: Role of Ubiquitin Modifìcation in Cancer Pathogenesis
Technical forum: Career Development
Laurens van der Meer: CRISPR Cas 9 Genome editing
Mike Murphy: Mitochondrial Reactive Oxygen Species in health and disease
Dirk Schübeler: The genetics of epigenetics
Kidney Theme Meeting (5x)
Technical Forum: Statistics
Technical Forum: lmaging
Technical Forum: Nanoscience and Nanomedicine
Technical Forum: From Bench to Bedside
Technical Forum: Bioinformatics
Technical Forum: Statistics
Kidney Theme Meeting (8x)
Technical Forum: Gene Expression/Repression Tools
Technical Forum: Grant Writing
Orson Moe: A Klotho-Centric View of Kidney Disease
Organization of and presenting at Technical Forum: Organ-on-a-Chipb
Kidney Theme Meeting (8x)b
2014
2014
2014
2014
2014
2014
2014
2015
2015
2015
2015
2015
2015
2016
2016
2016
2016
2016
2016
2017
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.5
0.1
0.1
0.1
0.1
0.1
0.1
0.8
0.1
0.1
0.1
0.85
0.8
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(Inter)national Symposia & Congresses
RIMLS PhD Retreat 2014a
Symposium ESTIV 2014: Making sense of in vitro methodsa
Figon Dutch Medicines Days 2014a
Najaarsvergadering van de Nederlandse Federatie voor Nefrologiea*
New Frontiers Symposium 2014: Regenerative Medicine
Spring Meeting Dutch Society of Pharmacologya
RIMLS PhD Retreat 2015a
Nephrotools Conference: The Kidney, Development, Disease and Regenerationa
New Frontiers Symposium 2015: Cilia Medicinea
Dutch Society for Toxicology, PhD Days 2016
Figon Dutch Medicines Days 2016b
New Frontiers Symposium 2016: Cancer Research
RIMLS PhD Retreat 2017b
Figon Dutch Medicines Days 2017
Symposium: Transporttage 2017, Munster, Germanyb
2014
2014
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2014
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2015
2015
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2016
2016
2017
2017
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0.75
1.5
0.75
0.5
0.5
0.5
0.75
1.25
0.75
0.5
0.75
0.5
0.75
0.5
1.0
Other
Publieksavond ‘Nier op maat’ - Demo experimental setup
World Kidney Day 2016
2014
2016
0.2
0.2
TEACHING ACTIVITIES Year(s) ECTS
Lecturing
Capita Selecta: De biologische kunstnier
Capita Selecta: De biologische kunstnier
Computer practical: Cellular, Organs and Systems Toxicology, Biomedical Sciences
2014
2014
2015
0.3
0.4
0.8
Other
Supervision Katja Jansen, Bachelor internship
Supervision Melanie Röring, Master internship
Supervision Ritchie Timmermans, Bachelor internship
Supervision Dina Dabaghie, Master internship
Supervision Milou Smits, Bachelor internship
Supervision student Biomedical Sciences 5AM08
Supervision Daphne Korte, Master internship
Supervision Nina Blaimschein, Master internship
2014
2015
2015
2016
2016
2016
2016
2017
1.0
2.0
1.0
2.0
1.0
0.4
2.0
2.0
TOTAL 39.5
a poster presentation, b oral presentation, * awarded

